0001342958 false --12-31 Q2 P2Y P3Y P3Y P2Y P3Y P54M P16M P25M P9M P6M P36M P55M 0001342958 2022-01-01 2022-06-30 0001342958 2022-08-15 0001342958 2022-06-30 0001342958 2021-12-31 0001342958 2022-04-01 2022-06-30 0001342958 2021-04-01 2021-06-30 0001342958 2021-01-01 2021-06-30 0001342958 us-gaap:ProductMember 2022-04-01 2022-06-30 0001342958 us-gaap:ProductMember 2021-04-01 2021-06-30 0001342958 us-gaap:ProductMember 2022-01-01 2022-06-30 0001342958 us-gaap:ProductMember 2021-01-01 2021-06-30 0001342958 us-gaap:ServiceOtherMember 2022-04-01 2022-06-30 0001342958 us-gaap:ServiceOtherMember 2021-04-01 2021-06-30 0001342958 us-gaap:ServiceOtherMember 2022-01-01 2022-06-30 0001342958 us-gaap:ServiceOtherMember 2021-01-01 2021-06-30 0001342958 us-gaap:CommonStockMember 2020-12-31 0001342958 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001342958 us-gaap:TreasuryStockMember 2020-12-31 0001342958 us-gaap:NoncontrollingInterestMember 2020-12-31 0001342958 us-gaap:RetainedEarningsMember 2020-12-31 0001342958 2020-12-31 0001342958 us-gaap:CommonStockMember 2021-03-31 0001342958 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001342958 us-gaap:TreasuryStockMember 2021-03-31 0001342958 us-gaap:NoncontrollingInterestMember 2021-03-31 0001342958 us-gaap:RetainedEarningsMember 2021-03-31 0001342958 2021-03-31 0001342958 us-gaap:CommonStockMember 2021-12-31 0001342958 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001342958 us-gaap:TreasuryStockMember 2021-12-31 0001342958 us-gaap:NoncontrollingInterestMember 2021-12-31 0001342958 us-gaap:RetainedEarningsMember 2021-12-31 0001342958 us-gaap:CommonStockMember 2022-03-31 0001342958 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001342958 us-gaap:TreasuryStockMember 2022-03-31 0001342958 us-gaap:NoncontrollingInterestMember 2022-03-31 0001342958 us-gaap:RetainedEarningsMember 2022-03-31 0001342958 2022-03-31 0001342958 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001342958 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001342958 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001342958 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001342958 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001342958 2021-01-01 2021-03-31 0001342958 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001342958 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001342958 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001342958 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001342958 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001342958 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001342958 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001342958 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001342958 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001342958 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001342958 2022-01-01 2022-03-31 0001342958 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001342958 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001342958 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001342958 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001342958 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001342958 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001342958 us-gaap:CommonStockMember 2021-06-30 0001342958 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001342958 us-gaap:TreasuryStockMember 2021-06-30 0001342958 us-gaap:NoncontrollingInterestMember 2021-06-30 0001342958 us-gaap:RetainedEarningsMember 2021-06-30 0001342958 2021-06-30 0001342958 us-gaap:CommonStockMember 2022-06-30 0001342958 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001342958 us-gaap:TreasuryStockMember 2022-06-30 0001342958 us-gaap:NoncontrollingInterestMember 2022-06-30 0001342958 us-gaap:RetainedEarningsMember 2022-06-30 0001342958 us-gaap:IPOMember us-gaap:WarrantMember 2021-03-31 0001342958 DGLY:IPOOneMember us-gaap:WarrantMember 2021-03-31 0001342958 us-gaap:WarrantMember 2021-03-31 0001342958 DGLY:WarrantOneMember 2021-03-31 0001342958 2021-01-01 2021-12-31 0001342958 us-gaap:CashMember 2022-06-30 0001342958 us-gaap:CashMember 2022-01-01 2022-06-30 0001342958 us-gaap:MoneyMarketFundsMember 2022-06-30 0001342958 us-gaap:MoneyMarketFundsMember 2022-01-01 2022-06-30 0001342958 us-gaap:CashMember 2021-12-31 0001342958 us-gaap:CashMember 2021-01-01 2021-12-31 0001342958 us-gaap:MoneyMarketFundsMember 2021-12-31 0001342958 us-gaap:MoneyMarketFundsMember 2021-01-01 2021-12-31 0001342958 DGLY:MutualFundsMember 2021-12-31 0001342958 DGLY:MutualFundsMember 2021-01-01 2021-12-31 0001342958 DGLY:PaycheckProtectionProgramMember DGLY:TwoThousandTwentySmallBusinessAdministrationNotesMember 2020-05-04 0001342958 DGLY:PaycheckProtectionProgramMember DGLY:TwoThousandTwentySmallBusinessAdministrationNotesMember 2020-05-04 2020-05-04 0001342958 DGLY:PaycheckProtectionProgramMember DGLY:TwoThousandTwentySmallBusinessAdministrationNotesMember 2020-12-09 2020-12-10 0001342958 DGLY:PaycheckProtectionProgramMember DGLY:TwoThousandTwentySmallBusinessAdministrationNotesMember 2021-04-01 2021-06-30 0001342958 DGLY:TwoThousandTwentySmallBusinessAdministrationNotesMember 2020-05-10 2020-05-12 0001342958 DGLY:TwoThousandTwentySmallBusinessAdministrationNotesMember 2020-05-12 0001342958 DGLY:JuneContingentNoteMember 2021-06-30 0001342958 DGLY:JuneContingentNoteMember 2021-06-28 2021-06-30 0001342958 DGLY:JuneContingentNoteMember 2022-01-01 2022-06-30 0001342958 DGLY:JuneContingentNoteMember 2022-06-30 0001342958 DGLY:JuneContingentNoteMember 2022-03-31 0001342958 DGLY:JuneContingentNoteMember 2022-04-01 2022-06-30 0001342958 DGLY:AugustContingentPaymentNoteMember 2021-08-31 0001342958 DGLY:AugustContingentPaymentNoteMember 2021-08-31 2021-08-31 0001342958 DGLY:AugustContingentPaymentNoteMember 2022-01-01 2022-06-30 0001342958 DGLY:AugustContingentPaymentNoteMember 2022-06-30 0001342958 DGLY:AugustContingentPaymentNoteMember 2021-12-31 0001342958 DGLY:AugustContingentPaymentNoteMember 2022-04-01 2022-06-30 0001342958 DGLY:JanuaryContingentPaymentNoteMember 2022-01-01 0001342958 DGLY:JanuaryContingentPaymentNoteMember 2022-01-01 2022-01-01 0001342958 DGLY:JanuaryContingentPaymentNoteMember 2022-06-30 0001342958 DGLY:JanuaryContingentPaymentNoteMember 2022-03-31 0001342958 DGLY:JanuaryContingentPaymentNoteMember 2022-04-01 2022-06-30 0001342958 DGLY:FebruaryContingentPaymentNoteMember 2022-02-01 0001342958 DGLY:FebruaryContingentPaymentNoteMember 2022-02-01 2022-02-01 0001342958 DGLY:FebruaryContingentPaymentNoteMember 2022-06-30 0001342958 DGLY:FebruaryContingentPaymentNoteMember 2022-03-31 0001342958 DGLY:FebruaryContingentPaymentNoteMember 2022-04-01 2022-06-30 0001342958 DGLY:FebruaryContingentPaymentNoteMember 2022-01-01 2022-06-30 0001342958 us-gaap:FairValueInputsLevel1Member DGLY:WarrantLiabilityMember 2022-06-30 0001342958 us-gaap:FairValueInputsLevel2Member DGLY:WarrantLiabilityMember 2022-06-30 0001342958 us-gaap:FairValueInputsLevel3Member DGLY:WarrantLiabilityMember 2022-06-30 0001342958 DGLY:WarrantLiabilityMember 2022-06-30 0001342958 us-gaap:FairValueInputsLevel1Member DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2022-06-30 0001342958 us-gaap:FairValueInputsLevel2Member DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2022-06-30 0001342958 us-gaap:FairValueInputsLevel3Member DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2022-06-30 0001342958 DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2022-06-30 0001342958 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001342958 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001342958 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001342958 us-gaap:FairValueInputsLevel1Member DGLY:WarrantLiabilityMember 2021-12-31 0001342958 us-gaap:FairValueInputsLevel2Member DGLY:WarrantLiabilityMember 2021-12-31 0001342958 us-gaap:FairValueInputsLevel3Member DGLY:WarrantLiabilityMember 2021-12-31 0001342958 DGLY:WarrantLiabilityMember 2021-12-31 0001342958 us-gaap:FairValueInputsLevel1Member DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2021-12-31 0001342958 us-gaap:FairValueInputsLevel2Member DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2021-12-31 0001342958 us-gaap:FairValueInputsLevel3Member DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2021-12-31 0001342958 DGLY:ContingentConsiderationPromissoryNotesAndContingentConsiderationEarnOutMember 2021-12-31 0001342958 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001342958 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001342958 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001342958 DGLY:ContingentConsiderationPromissoryNoteMember 2021-12-31 0001342958 DGLY:WarrantLiabilityMember 2021-12-31 0001342958 DGLY:ContingentConsiderationPromissoryNoteMember DGLY:RevenueCycleManagementSegmentAcquisitionMember 2022-01-01 2022-03-31 0001342958 DGLY:WarrantLiabilityMember DGLY:RevenueCycleManagementSegmentAcquisitionMember 2022-01-01 2022-03-31 0001342958 DGLY:ContingentConsiderationPromissoryNoteMember 2022-01-01 2022-03-31 0001342958 DGLY:WarrantLiabilityMember 2022-01-01 2022-03-31 0001342958 DGLY:ContingentConsiderationPromissoryNoteMember 2022-03-31 0001342958 DGLY:WarrantLiabilityMember 2022-03-31 0001342958 DGLY:ContingentConsiderationPromissoryNoteMember DGLY:RevenueCycleManagementSegmentAcquisitionMember 2022-04-01 2022-06-30 0001342958 DGLY:WarrantLiabilityMember DGLY:RevenueCycleManagementSegmentAcquisitionMember 2022-04-01 2022-06-30 0001342958 DGLY:WarrantLiabilityMember 2022-04-01 2022-06-30 0001342958 DGLY:ContingentConsiderationPromissoryNoteMember 2022-06-30 0001342958 DGLY:WarrantLiabilityMember 2022-06-30 0001342958 us-gaap:BuildingMember 2022-01-01 2022-06-30 0001342958 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2022-01-01 2022-06-30 0001342958 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2022-01-01 2022-06-30 0001342958 srt:WarehouseMember srt:MinimumMember 2022-01-01 2022-06-30 0001342958 srt:WarehouseMember srt:MaximumMember 2022-01-01 2022-06-30 0001342958 DGLY:DemonstrationAndTradeshowEquipmentMember srt:MinimumMember 2022-01-01 2022-06-30 0001342958 DGLY:DemonstrationAndTradeshowEquipmentMember srt:MaximumMember 2022-01-01 2022-06-30 0001342958 us-gaap:BuildingImprovementsMember srt:MinimumMember 2022-01-01 2022-06-30 0001342958 us-gaap:BuildingImprovementsMember srt:MaximumMember 2022-01-01 2022-06-30 0001342958 DGLY:RentalEquipmentMember srt:MinimumMember 2022-01-01 2022-06-30 0001342958 DGLY:RentalEquipmentMember srt:MaximumMember 2022-01-01 2022-06-30 0001342958 DGLY:SeptemberTwoThousandAndTwelveForOfficeAndWarehouseSpaceMember srt:MinimumMember 2020-05-10 2020-05-13 0001342958 DGLY:SeptemberTwoThousandAndTwelveForOfficeAndWarehouseSpaceMember srt:MaximumMember 2020-05-10 2020-05-13 0001342958 DGLY:SeptemberTwoThousandAndTwelveForOfficeAndWarehouseSpaceMember 2020-05-10 2020-05-13 0001342958 DGLY:SeptemberTwoThousandAndTwelveForOfficeAndWarehouseSpaceMember 2022-06-30 0001342958 DGLY:OctoberTwoThousandAndNineteenForCopiersMember 2019-10-31 0001342958 DGLY:OctoberTwoThousandAndNineteenForCopiersMember 2019-10-01 2019-10-31 0001342958 DGLY:OctoberTwoThousandAndNineteenForCopiersMember 2022-06-30 0001342958 DGLY:EliteMedicalBillingSpecialistsMember srt:MinimumMember 2021-06-30 2021-06-30 0001342958 DGLY:EliteMedicalBillingSpecialistsMember srt:MaximumMember 2021-06-30 2021-06-30 0001342958 DGLY:EliteMedicalBillingSpecialistsMember 2021-06-30 2021-06-30 0001342958 DGLY:EliteMedicalBillingSpecialistsMember 2022-06-30 0001342958 srt:MinimumMember DGLY:CCCAcquisitionMember 2021-08-31 2021-08-31 0001342958 DGLY:CCCAcquisitionMember srt:MaximumMember 2021-08-31 2021-08-31 0001342958 DGLY:CCCAcquisitionMember 2021-08-31 2021-08-31 0001342958 DGLY:CCCAcquisitionMember 2022-06-30 0001342958 srt:MinimumMember DGLY:TicketSmarterAcquisitionMember 2021-09-01 2021-09-01 0001342958 srt:MaximumMember DGLY:TicketSmarterAcquisitionMember 2021-09-01 2021-09-01 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-09-01 2021-09-01 0001342958 DGLY:TicketSmarterAcquisitionMember 2022-06-30 0001342958 DGLY:PrivateMedicalBillingCompanyMember srt:MinimumMember 2022-01-01 2022-01-01 0001342958 DGLY:PrivateMedicalBillingCompanyMember srt:MaximumMember 2022-01-01 2022-01-01 0001342958 DGLY:PrivateMedicalBillingCompanyMember 2022-01-01 2022-01-01 0001342958 DGLY:PrivateMedicalBillingCompanyMember 2022-06-30 0001342958 DGLY:OfficeSpaceAndCopierMember 2022-04-01 2022-06-30 0001342958 DGLY:OfficeSpaceAndCopierMember 2022-01-01 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:LicensesMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:LicensesMember 2021-12-31 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:PatentsAndTrademarksMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:PatentsAndTrademarksMember 2021-12-31 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:SponsorshipAgreementNetworkMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:SponsorshipAgreementNetworkMember 2021-12-31 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:SEOContentMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:SEOContentMember 2021-12-31 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:PersonalSearLicensesMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:PersonalSearLicensesMember 2021-12-31 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:ClientAgreementRevenueCycleMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember DGLY:ClientAgreementRevenueCycleMember 2021-12-31 0001342958 DGLY:AmortizedIntangibleAssetsMember 2022-06-30 0001342958 DGLY:AmortizedIntangibleAssetsMember 2021-12-31 0001342958 DGLY:UnAmortizedIntangibleAssetsMember us-gaap:GoodwillMember 2022-06-30 0001342958 DGLY:UnAmortizedIntangibleAssetsMember us-gaap:GoodwillMember 2021-12-31 0001342958 DGLY:UnAmortizedIntangibleAssetsMember DGLY:TradeNameMember 2022-06-30 0001342958 DGLY:UnAmortizedIntangibleAssetsMember DGLY:TradeNameMember 2021-12-31 0001342958 DGLY:UnAmortizedIntangibleAssetsMember DGLY:PatentsAndTrademarksPendingMember 2022-06-30 0001342958 DGLY:UnAmortizedIntangibleAssetsMember DGLY:PatentsAndTrademarksPendingMember 2021-12-31 0001342958 DGLY:TwoThousandAndFivePlanMember DGLY:DuringTwoThousandFifteenMember 2022-06-30 0001342958 DGLY:TwoThousandAndSixPlanMember DGLY:DuringTwoThousandSixteenMember 2022-06-30 0001342958 DGLY:TwoThousandAndFivePlanMember DGLY:DuringTwoThousandSixteenMember 2022-06-30 0001342958 DGLY:TwoThousandAndSevenPlanMember DGLY:DuringTwoThousandSevenTeenMember 2022-06-30 0001342958 DGLY:TwoThousandAndFivePlanMember DGLY:DuringTwoThousandSevenTeenMember 2022-06-30 0001342958 DGLY:TwoThousandAndEightPlanMember DGLY:DuringTwoThousandEighteenMember 2022-06-30 0001342958 DGLY:TwoThousandAndFivePlanMember DGLY:DuringTwoThousandEighteenMember 2022-06-30 0001342958 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001342958 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001342958 DGLY:StockOptionsMember 2021-12-31 0001342958 DGLY:StockOptionsMember 2022-01-01 2022-06-30 0001342958 DGLY:StockOptionsMember 2022-06-30 0001342958 DGLY:RangeOneMember 2022-01-01 2022-06-30 0001342958 DGLY:RangeOneMember 2022-06-30 0001342958 DGLY:RangeTwoMember 2022-01-01 2022-06-30 0001342958 DGLY:RangeTwoMember 2022-06-30 0001342958 DGLY:RangeThreeMember 2022-01-01 2022-06-30 0001342958 DGLY:RangeThreeMember 2022-06-30 0001342958 us-gaap:RestrictedStockMember 2021-12-31 0001342958 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001342958 us-gaap:RestrictedStockMember 2022-06-30 0001342958 DGLY:CommonStockPurchaseWarrantsMember 2022-06-30 0001342958 DGLY:CommonStockPurchaseWarrantsMember srt:MinimumMember 2022-06-30 0001342958 DGLY:CommonStockPurchaseWarrantsMember srt:MaximumMember 2022-06-30 0001342958 DGLY:CommonStockPurchaseWarrantsMember 2022-01-01 2022-06-30 0001342958 2021-01-14 0001342958 DGLY:PreFundedWarrantsMember us-gaap:CommonStockMember 2021-01-14 0001342958 us-gaap:CommonStockMember 2021-01-14 0001342958 DGLY:PreFundedWarrantsMember us-gaap:CommonStockMember 2021-02-01 0001342958 us-gaap:CommonStockMember 2021-02-01 0001342958 2021-08-19 0001342958 DGLY:ExchangeWarrantsMember 2021-08-19 0001342958 DGLY:ReplacementOriginalWarrantsMember 2021-08-19 0001342958 2021-08-18 2021-08-19 0001342958 us-gaap:FairValueInputsLevel3Member 2021-08-18 2021-08-19 0001342958 us-gaap:WarrantMember 2022-06-30 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember DGLY:OriginalTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember DGLY:ModifiedTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember DGLY:OriginalTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember DGLY:ModifiedTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember DGLY:OriginalTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember DGLY:ModifiedTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember DGLY:OriginalTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember DGLY:ModifiedTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember DGLY:OriginalTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember DGLY:ModifiedTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember DGLY:OriginalTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember DGLY:ModifiedTermsMember 2021-08-19 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2022-06-30 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-06-30 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-01-13 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-01-13 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2021-01-14 0001342958 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001342958 DGLY:WarrantLiabilityMember 2021-01-14 0001342958 DGLY:WarrantLiabilityMember 2022-06-30 0001342958 us-gaap:WarrantMember 2021-12-31 0001342958 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeOneMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeOneMember 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeTwoMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeTwoMember 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeThreeMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeThreeMember 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeFourMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeFourMember 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeFiveMember 2022-01-01 2022-06-30 0001342958 us-gaap:WarrantMember DGLY:RangeFiveMember 2022-06-30 0001342958 DGLY:StockRepurchaseProgramMember srt:MaximumMember 2021-12-06 0001342958 DGLY:StockRepurchaseProgramMember 2022-04-01 2022-06-30 0001342958 DGLY:StockRepurchaseProgramMember 2022-01-01 2022-06-30 0001342958 DGLY:StockRepurchaseProgramMember 2021-12-01 2022-06-30 0001342958 DGLY:NobilityHealthcareLLCMember 2022-06-30 0001342958 DGLY:NobilityHealthcareLLCMember 2022-06-30 0001342958 DGLY:DecemberTwoThousandTwentyOneMember 2022-06-30 0001342958 DGLY:JanuaryTwoThousandTwentyTwoMember 2022-06-30 0001342958 DGLY:FebruaryTwoThousandTwentyTwoMember 2022-06-30 0001342958 DGLY:MarchTwoThousandTwentyTwoMember 2022-06-30 0001342958 DGLY:AprilTwoThousandTwentyTwoMember 2022-06-30 0001342958 DGLY:MayTwoThousandTwentyTwoMember 2022-06-30 0001342958 DGLY:JuneTwoThousandTwentyTwoMember 2022-06-30 0001342958 DGLY:NobilityLLCMember 2021-06-04 0001342958 DGLY:NobilityLLCMember 2021-06-03 2021-06-04 0001342958 DGLY:NobilityLLCMember DGLY:HealthcareAcquisitionMember 2021-06-30 2021-06-30 0001342958 DGLY:NobilityLLCMember DGLY:HealthcareAcquisitionMember DGLY:PromissoryNoteMember 2021-06-30 0001342958 DGLY:NobilityLLCMember DGLY:HealthcareAcquisitionMember 2021-12-31 0001342958 DGLY:NobilityLLCMember DGLY:HealthcareAcquisitionMember DGLY:PromissoryNoteMember 2021-06-30 2021-06-30 0001342958 DGLY:NobilityLLCMember DGLY:HealthcareAcquisitionMember 2021-06-30 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionMember 2021-08-31 2021-08-31 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionMember DGLY:PromissoryNoteMember 2021-08-31 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionMember 2021-08-31 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionOneMember 2022-01-01 2022-01-01 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionOneMember DGLY:PromissoryNoteMember 2022-01-01 0001342958 DGLY:NobilityLLCMember DGLY:HealthcareAcquisitionMember 2022-01-01 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionTwoMember 2022-02-01 2022-02-01 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionTwoMember DGLY:PromissoryNoteMember 2022-02-01 0001342958 DGLY:NobilityLLCMember DGLY:MedicalBillingAcquisitionTwoMember 2022-02-01 0001342958 DGLY:HealthcareAcquisitionMember 2022-01-01 2022-06-30 0001342958 DGLY:MedicalBillingAcquisitionMember 2022-01-01 2022-06-30 0001342958 DGLY:MedicalBillingAcquisitionOneMember 2022-01-01 2022-06-30 0001342958 DGLY:MedicalBillingAcquisitionTwoMember 2022-01-01 2022-06-30 0001342958 DGLY:HealthcareAcquisitionMember 2021-06-30 0001342958 DGLY:HealthcareAcquisitionMember 2022-06-30 0001342958 DGLY:HealthcareAcquisitionMember 2022-06-30 2022-06-30 0001342958 DGLY:HealthcareAcquisitionMember 2021-06-30 2021-06-30 0001342958 DGLY:MedicalBillingAcquisitionMember 2021-08-31 0001342958 DGLY:MedicalBillingAcquisitionMember 2021-08-31 2021-08-31 0001342958 DGLY:MedicalBillingAcquisitionOneMember 2022-01-01 0001342958 DGLY:MedicalBillingAcquisitionOneMember 2022-01-01 2022-01-01 0001342958 DGLY:MedicalBillingAcquisitionTwoMember 2022-02-01 0001342958 DGLY:MedicalBillingAcquisitionTwoMember 2022-02-01 2022-02-01 0001342958 DGLY:TicketSmarterAcquisitionMember DGLY:PromissoryNoteMember 2021-12-31 0001342958 DGLY:TicketSmarterAcquisitionMember DGLY:PromissoryNoteMember 2021-09-01 2021-09-01 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-09-01 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-01-01 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-01-01 2021-01-01 0001342958 DGLY:TicketSmarterAcquisitionMember 2022-01-01 2022-06-30 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-09-30 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-12-31 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-09-01 2021-09-30 0001342958 DGLY:TicketSmarterAcquisitionMember 2021-12-31 2021-12-31 0001342958 2021-09-30 2021-09-30 0001342958 us-gaap:TrademarksAndTradeNamesMember 2021-09-01 2021-09-01 0001342958 us-gaap:TrademarksAndTradeNamesMember 2021-09-01 2022-06-30 0001342958 DGLY:SponsorshipAgreementNetworkMember 2021-09-01 2021-09-01 0001342958 DGLY:SponsorshipAgreementNetworkMember 2021-09-01 2022-06-30 0001342958 DGLY:SearchEngineOptimizationMember 2021-09-01 2021-09-01 0001342958 DGLY:SearchEngineOptimizationMember 2021-09-01 2022-06-30 0001342958 2021-09-01 2021-09-01 0001342958 2021-09-01 2022-06-30 0001342958 DGLY:VideoSolutionsMember 2022-04-01 2022-06-30 0001342958 DGLY:VideoSolutionsMember 2021-04-01 2021-06-30 0001342958 DGLY:VideoSolutionsMember 2022-01-01 2022-06-30 0001342958 DGLY:VideoSolutionsMember 2021-01-01 2021-06-30 0001342958 DGLY:RevenueCycleManagementMember 2022-04-01 2022-06-30 0001342958 DGLY:RevenueCycleManagementMember 2021-04-01 2021-06-30 0001342958 DGLY:RevenueCycleManagementMember 2022-01-01 2022-06-30 0001342958 DGLY:RevenueCycleManagementMember 2021-01-01 2021-06-30 0001342958 DGLY:TicketingMember 2022-04-01 2022-06-30 0001342958 DGLY:TicketingMember 2021-04-01 2021-06-30 0001342958 DGLY:TicketingMember 2022-01-01 2022-06-30 0001342958 DGLY:TicketingMember 2021-01-01 2021-06-30 0001342958 us-gaap:CorporateMember 2022-04-01 2022-06-30 0001342958 us-gaap:CorporateMember 2021-04-01 2021-06-30 0001342958 us-gaap:CorporateMember 2022-01-01 2022-06-30 0001342958 us-gaap:CorporateMember 2021-01-01 2021-06-30 0001342958 DGLY:VideoSolutionsMember 2022-06-30 0001342958 DGLY:VideoSolutionsMember 2021-12-31 0001342958 DGLY:RevenueCycleManagementMember 2022-06-30 0001342958 DGLY:RevenueCycleManagementMember 2021-12-31 0001342958 DGLY:TicketingMember 2022-06-30 0001342958 DGLY:TicketingMember 2021-12-31 0001342958 us-gaap:CorporateMember 2022-06-30 0001342958 us-gaap:CorporateMember 2021-12-31 0001342958 DGLY:NobilityLLCMember 2021-12-31 0001342958 DGLY:NobilityLLCMember 2022-06-30 0001342958 us-gaap:SubsequentEventMember 2022-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft DGLY:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022.

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to __________.

Commission File Number: 001-33899

Digital Ally, Inc.

(Exact name of registrant as specified in its charter)

Nevada |  | 20-0064269
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

14001 Marshall Drive, Lenexa, KS 66215

(Address of principal executive offices) (Zip Code)

(913) 814-7774

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of exchange on which registered
Common stock, $0.001 par value per share |  | DGLY |  | The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐
Non-accelerated filer ☒ | Smaller reporting company ☒
Emerging growth company ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class |  | Outstanding at August 15, 2022
Common Stock, $0.001 par value per share |  | 47,828,405

FORM 10-Q

DIGITAL ALLY, INC.

June 30, 2022

TABLE OF CONTENTS |  | Page(s)
PART I – FINANCIAL INFORMATION |  |
Item 1. Financial Statements. |  |
Condensed Consolidated Balance Sheets – June 30, 2022 (Unaudited) and December 31, 2021 |  | 3
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited) |  | 4
Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited) |  | 5
Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited) |  | 6
Notes to the Condensed Consolidated Financial Statements (Unaudited) |  | 7-36
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. |  | 37-63
Item 3. Quantitative and Qualitative Disclosures About Market Risk. |  | 63
Item 4. Controls and Procedures. |  | 63
PART II - OTHER INFORMATION |  |
Item 1. Legal Proceedings. |  | 63
Item 1A. Risk Factors. |  | 63
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. |  | 64
Item 3. Defaults Upon Senior Securities |  | 64
Item 4. Mine Safety Disclosures |  | 64
Item 5. Other Information. |  | 64
Item 6. Exhibits. |  | 64
SIGNATURES |  | 65

2

PART I – FINANCIAL INFORMATION

Item 1 – Financial Statements.

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, 2022 AND DECEMBER 31, 2021

|  | June 30, 2022 (Unaudited) |  |  | December 31, 2021 |
Assets |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 13,454,246 |  |  | $ | 32,007,792 |
Accounts receivable – trade, net |  |  | 2,167,280 |  |  |  | 2,727,052 |
Other receivables (including $138,384 due from related parties – June 30, 2022 and $158,384 – December 31, 2021, refer to Note 20) |  |  | 2,798,029 |  |  |  | 2,021,813 |
Inventories, net |  |  | 9,405,954 |  |  |  | 9,659,536 |
Prepaid expenses |  |  | 7,911,435 |  |  |  | 9,728,782 |
Total current assets |  |  | 35,736,944 |  |  |  | 56,144,975 |
Property, plant, and equipment, net |  |  | 8,457,199 |  |  |  | 6,841,026 |
Goodwill and other intangible assets, net |  |  | 18,675,469 |  |  |  | 16,902,513 |
Operating lease right of use assets, net |  |  | 951,928 |  |  |  | 993,384 |
Other assets |  |  | 6,907,281 |  |  |  | 2,107,299 |
Total assets |  | $ | 70,728,821 |  |  | $ | 82,989,197 |
Liabilities and Stockholders’ Equity |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 6,762,924 |  |  | $ | 4,569,106 |
Accrued expenses |  |  | 1,130,737 |  |  |  | 1,175,998 |
Current portion of operating lease obligations |  |  | 353,646 |  |  |  | 373,371 |
Contract liabilities – current portion |  |  | 1,944,382 |  |  |  | 1,665,519 |
Debt obligations – current portion |  |  | 514,664 |  |  |  | 389,934 |
Warrant derivative liabilities |  |  | 9,285,143 |  |  |  | 14,846,932 |
Income taxes payable |  |  | 11,796 |  |  |  | 1,827 |
Total current liabilities |  |  | 20,003,292 |  |  |  | 23,022,687 |
Long-term liabilities: |  |  |  |  |  |  |  |
Debt obligations – long term |  |  | 754,680 |  |  |  | 727,278 |
Operating lease obligation – long term |  |  | 666,477 |  |  |  | 688,207 |
Contract liabilities – long term |  |  | 4,087,426 |  |  |  | 2,687,786 |
Total liabilities |  |  | 25,511,875 |  |  |  | 27,125,958 |
Commitments and contingencies |  |  | - |  |  |  | - |
Stockholders’ Equity: |  |  |  |  |  |  |  |
Common stock, $0.001 par value per share; 100,000,000 shares authorized; shares issued: 47,828,405 shares issued – June 30, 2022 and 50,904,391 shares issued – December 31, 2021 |  |  | 47,828 |  |  |  | 50,904 |
Additional paid in capital |  |  | 125,202,080 |  |  |  | 124,426,379 |
Noncontrolling interest in consolidated subsidiary |  |  | 325,993 |  |  |  | 56,453 |
Accumulated deficit |  |  | (80,358,955 | ) |  |  | (68,670,497 | )
Total stockholders’ equity |  |  | 45,216,946 |  |  |  | 55,863,239 |
Total liabilities and stockholders’ equity |  | $ | 70,728,821 |  |  | $ | 82,989,197 |

See Notes to the Unaudited Condensed Consolidated Financial Statements.

3

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED

JUNE 30, 2022 AND 2021

(unaudited)

|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product |  | $ | 2,210,181 |  |  | $ | 1,719,332 |  |  | $ | 4,620,241 |  |  | $ | 3,631,910 |
Service and other |  |  | 7,141,276 |  |  |  | 774,339 |  |  |  | 15,025,997 |  |  |  | 1,397,591 |
Total revenue |  |  | 9,351,457 |  |  |  | 2,493,671 |  |  |  | 19,646,238 |  |  |  | 5,029,501 |
Cost of revenue: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product |  |  | 2,070,476 |  |  |  | 1,017,659 |  |  |  | 4,892,527 |  |  |  | 2,578,969 |
Service and other |  |  | 5,561,903 |  |  |  | 215,212 |  |  |  | 11,095,015 |  |  |  | 377,849 |
Total cost of revenue |  |  | 7,632,379 |  |  |  | 1,232,871 |  |  |  | 15,987,542 |  |  |  | 2,956,818 |
Gross profit |  |  | 1,719,078 |  |  |  | 1,260,800 |  |  |  | 3,658,696 |  |  |  | 2,072,683 |
Selling, general and administrative expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  | 540,222 |  |  |  | 460,999 |  |  |  | 1,038,222 |  |  |  | 909,964 |
Selling, advertising and promotional expense |  |  | 2,763,045 |  |  |  | 870,183 |  |  |  | 5,542,448 |  |  |  | 1,466,938 |
General and administrative expense |  |  | 5,077,063 |  |  |  | 2,546,502 |  |  |  | 10,542,616 |  |  |  | 5,178,359 |
Total selling, general and administrative expenses |  |  | 8,380,330 |  |  |  | 3,877,684 |  |  |  | 17,123,286 |  |  |  | 7,555,261 |
Operating loss |  |  | (6,661,252 | ) |  |  | (2,616,884 | ) |  |  | (13,464,590 | ) |  |  | (5,482,578 | )
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 32,233 |  |  |  | 90,774 |  |  |  | 103,595 |  |  |  | 132,461 |
Interest expense |  |  | (8,501 | ) |  |  | (1,365 | ) |  |  | (25,511 | ) |  |  | (2,793 | )
Other income (loss) |  |  | (381 | ) |  |  | — |  |  |  | 43,059 |  |  |  | — |
Gain on extinguishment of debt |  |  | — |  |  |  | 10,000 |  |  |  | — |  |  |  | 10,000 |
Change in fair value of contingent consideration promissory notes |  |  | 542,096 |  |  |  | — |  |  |  | 486,046 |  |  |  | — |
Change in fair value of short-term investments |  |  | — |  |  |  | (1,590 | ) |  |  | (84,818 | ) |  |  | (6,554 | )
Change in fair value of warrant derivative liabilities |  |  | 5,413,618 |  |  |  | (2,863,422 | ) |  |  | 5,561,789 |  |  |  | 21,688,835 |
Total other income (expense) |  |  | 5,979,065 |  |  |  | (2,765,603 | ) |  |  | 6,084,160 |  |  |  | 21,821,949 |
Income (loss) before income tax benefit |  |  | (682,187 | ) |  |  | (5,382,487 | ) |  |  | (7,380,430 | ) |  |  | 16,339,371 |
Income tax benefit |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Net income (loss) |  |  | (682,187 | ) |  |  | (5,382,487 | ) |  |  | (7,380,430 | ) |  |  | 16,339,371 |
Net income attributable to noncontrolling interests of consolidated subsidiary |  |  | (383,326 | ) |  |  | — |  |  |  | (285,232 | ) |  |  | — |
Net income (loss) attributable to common stockholders |  | $ | (1,065,513 | ) |  | $ | (5,382,487 | ) |  | $ | (7,665,662 | ) |  | $ | 16,339,371 |
Net loss per share information: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.02 | ) |  | $ | (0.10 | ) |  | $ | (0.15 | ) |  | $ | 0.34 |
Diluted |  | $ | (0.02 | ) |  | $ | (0.10 | ) |  | $ | (0.15 | ) |  | $ | 0.34 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 48,657,440 |  |  |  | 51,513,691 |  |  |  | 49,787,562 |  |  |  | 48,177,399 |
Diluted |  |  | 48,657,440 |  |  |  | 51,513,691 |  |  |  | 49,787,562 |  |  |  | 48,177,399 |

See Notes to the Unaudited Condensed Consolidated Financial Statements.

4

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021

(Unaudited)

|  | Shares |  |  | Amount |  |  | Capital |  |  | stock |  |  | subsidiary |  |  | deficit |  |  | Total |
|  | Common Stock |  |  | Additional Paid In |  |  | Treasury |  |  | Noncontrolling interest in consolidated |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | stock |  |  | subsidiary |  |  | deficit |  |  | Total |
Balance, December 31, 2020 |  |  | 26,834,709 |  |  | $ | 26,835 |  |  | $ | 106,501,396 |  |  | $ | (2,157,226 | ) |  |  | — |  |  | $ | (90,014,500 | ) |  | $ | 14,356,505 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 326,164 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 326,164 |
Restricted common stock grant |  |  | 450,000 |  |  |  | 450 |  |  |  | (450 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Restricted common stock forfeitures |  |  | (7,500 | ) |  |  | (8 | ) |  |  | 8 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Issuance of common stock through registered direct offering at $3.095 per share and accompanying warrants (net of offering expenses and placement agent discount) |  |  | 2,800,000 |  |  |  | 2,800 |  |  |  | 6,726,200 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6,729,000 |
Issuance of common stock through registered direct offering at $2.80 per share and accompanying warrants (net of offering expenses and placement agent discount) |  |  | 3,250,000 |  |  |  | 3,250 |  |  |  | 6,614,350 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6,617,600 |
Exercise of pre-funded common stock purchase warrants at $3.095 per share |  |  | 7,200,000 |  |  |  | 7,200 |  |  |  | 22,276,800 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 22,284,000 |
Exercise of pre-funded common stock purchase warrants at $2.80 per share |  |  | 11,050,000 |  |  |  | 11,050 |  |  |  | 30,928,950 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 30,940,000 |
Issuance of pre-funded common stock purchase warrants in connection with the registered direct offerings |  |  | — |  |  |  | — |  |  |  | (1,817,548 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,817,548 | )
Issuance of common stock purchase warrants at exercise price of $3.25 per share in connection with the registered direct offerings |  |  | — |  |  |  | — |  |  |  | (49,398,510 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (49,398,510 | )
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 21,721,858 |  |  |  | 21,721,858 |
Balance, March 31, 2021 |  |  | 51,577,209 |  |  |  | 51,577 |  |  |  | 122,157,360 |  |  |  | (2,157,226 | ) |  |  | — |  |  |  | (68,292,642 | ) |  |  | 51,759,069 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 330,213 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 330,213 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5,382,487 | ) |  |  | (5,382,487 | )
Balance, June 30, 2021 |  |  | 51,577,209 |  |  | $ | 51,577 |  |  | $ | 122,487,573 |  |  | $ | (2,157,226 | ) |  | $ | — |  |  | $ | (73,675,129 | ) |  | $ | 46,706,795 |
Balance, December 31, 2021 |  |  | 50,904,391 |  |  | $ | 50,904 |  |  | $ | 124,426,379 |  |  | $ | — |  |  | $ | 56,453 |  |  | $ | (68,670,497 | ) |  | $ | 55,863,239 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 394,749 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 394,749 |
Restricted common stock grant |  |  | 715,000 |  |  |  | 715 |  |  |  | (715 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Restricted common stock forfeitures |  |  | (15,000 | ) |  |  | (15 | ) |  |  | 15 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Repurchase and cancellation of common stock |  |  | (1,876,034 | ) |  |  | (1,876 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,061,892 | ) |  |  | (2,063,768 | )
Distribution to noncontrolling interest in consolidated subsidiary |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (15,692 | ) |  |  | — |  |  |  | (15,692 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (98,094 | ) |  |  | (6,600,148 | ) |  |  | (6,698,242 | )
Balance, March 31, 2022 |  |  | 49,728,357 |  |  |  | 49,728 |  |  |  | 124,820,428 |  |  |  | — |  |  |  | (57,333 | ) |  |  | (77,332,537 | ) |  |  | 47,480,286 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 381,602 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 381,602 |
Restricted common stock forfeitures |  |  | (50,000 | ) |  |  | (50 | ) |  |  | 50 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Repurchase and cancellation of common stock |  |  | (1,849,952 | ) |  |  | (1,850 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,960,905 | ) |  |  | (1,962,755 | )
Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 383,326 |  |  |  | (1,065,513 | ) |  |  | (682,187 | )
Balance, June 30, 2022 |  |  | 47,828,405 |  |  | $ | 47,828 |  |  | $ | 125,202,080 |  |  | $ | — |  |  | $ | 325,993 |  |  | $ | (80,358,955 | ) |  | $ | 45,216,946 |

See Notes to the Unaudited Condensed Consolidated Financial Statements.

5

DIGITAL ALLY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021

(Unaudited)

|  | Six months ended June 30, |
|  | 2022 |  |  | 2021 |
Cash Flows From Operating Activities: |  |  |  |  |  |  |  |
Net income (loss) |  | $ | (7,380,430 | ) |  | $ | 16,339,371 |
Adjustments to reconcile net income (loss) to net cash flows used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 1,024,238 |  |  |  | 145,459 |
Stock-based compensation |  |  | 776,350 |  |  |  | 656,378 |
Change in fair value of warrant derivative liabilities |  |  | (5,561,789 | ) |  |  | (21,688,835 | )
Provision for inventory obsolescence |  |  | 192,622 |  |  |  | 361,437 |
Provision for doubtful accounts receivable |  |  | (161,768 | ) |  |  | — |
Gain on extinguishment of debt |  |  | — |  |  |  | (10,000 | )
Change in fair value of contingent consideration promissory note |  |  | (486,046 | ) |  |  | — |
Change in operating assets and liabilities: |  |  |  |  |  |  |  |
(Increase) decrease in: |  |  |  |  |  |  |  |
Accounts receivable – trade |  |  | 721,540 |  |  |  | 817,077 |
Accounts receivable – other |  |  | (776,216 | ) |  |  | (265,627 | )
Inventories |  |  | 60,960 |  |  |  | (1,774,922 | )
Prepaid expenses |  |  | 1,848,058 |  |  |  | (391,084 | )
Operating lease right of use assets |  |  | 201,376 |  |  |  | 30,332 |
Other assets |  |  | (4,799,982 | ) |  |  | (616,005 | )
Increase (decrease) in: |  |  |  |  |  |  |  |
Accounts payable |  |  | 1,994,602 |  |  |  | (307,744 | )
Accrued expenses |  |  | (73,127 | ) |  |  | 79,290 |
Income taxes payable |  |  | 9,969 |  |  |  | (7,231 | )
Operating lease obligations |  |  | (201,375 | ) |  |  | (41,185 | )
Contract liabilities |  |  | 1,678,503 |  |  |  | 523,516 |
Net cash used in operating activities |  |  | (10,932,515 | ) |  |  | (6,149,773 | )
Cash Flows from Investing Activities: |  |  |  |  |  |  |  |
Purchases of property, plant and equipment |  |  | (1,923,501 | ) |  |  | (5,452,729 | )
Additions to intangible assets |  |  | (54,866 | ) |  |  | (41,126 | )
Cash paid for acquisition, net of cash acquired |  |  | — |  |  |  | (1,012,552 | )
Cash paid for acquisition of Medical Billing Company |  |  | (1,153,627 | ) |  |  | — |
Cash paid for asset acquisition of Medical Billing Company |  |  | (230,000 | ) |  |  | — |
Net cash used in investing activities |  |  | (3,361,994 | ) |  |  | (6,506,407 | )
Cash Flows from Financing Activities: |  |  |  |  |  |  |  |
Repurchase and cancellation of common stock |  |  | (4,026,523 | ) |  |  | — |
Distribution to noncontrolling interest in consolidated subsidiary |  |  | (15,692 | ) |  |  | — |
Net proceeds from sale of common stock in registered direct offerings |  |  | — |  |  |  | 13,346,600 |
Proceeds from issuance of common stock upon exercise of pre-funded warrants |  |  | — |  |  |  | 53,224,000 |
Principal payment on contingent consideration promissory notes |  |  | (216,822 | ) |  |  | — |
Net cash (used in) provided by financing activities |  |  | (4,259,037 | ) |  |  | 66,570,600 |
Net increase (decrease) in cash and cash equivalents |  |  | (18,553,546 | ) |  |  | 53,914,420 |
Cash, cash equivalents, beginning of period |  |  | 32,007,792 |  |  |  | 4,361,758 |
Cash, cash equivalents, end of period |  | $ | 13,454,246 |  |  | $ | 58,276,178 |
Supplemental disclosures of cash flow information: |  |  |  |  |  |  |  |
Cash payments for interest |  | $ | 27,059 |  |  | $ | — |
Cash payments for income taxes |  | $ | 9,969 |  |  | $ | 7,231 |
Supplemental disclosures of non-cash investing and financing activities: |  |  |  |  |  |  |  |
Issuance of contingent consideration promissory note for business acquired |  | $ | 855,000 |  |  | $ | 350,000 |
Assets acquired in business acquisitions |  | $ | 190,631 |  |  | $ | — |
Liabilities assumed in the business acquisition |  | $ | 387,005 |  |  | $ | 162,552 |
Goodwill acquired in business acquisitions |  | $ | 2,100,000 |  |  | $ | — |
Restricted common stock grant |  | $ | 715 |  |  | $ | 450 |
Restricted common stock forfeitures |  | $ | 65 |  |  | $ | 8 |
Amounts allocated to initial measurement of warrant derivative liabilities in connection with the warrants and pre-funded warrants |  | $ | — |  |  | $ | 51,216,058 |

See Notes to the Unaudited Condensed Consolidated Financial Statements.

6

DIGITAL ALLY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations:

Digital Ally, Inc. was originally incorporated in Nevada on December 13, 2000 as Vegas Petra, Inc. and had no operations until 2004. On November 30, 2004, Vegas Petra, Inc. entered into a Plan of Merger with Digital Ally, Inc., at which time the merged entity was renamed Digital Ally, Inc.

The business of Digital Ally, Inc. (with its wholly-owned subsidiaries, Digital Ally International, Inc., Shield Products, LLC, Digital Ally Healthcare, LLC, TicketSmarter, Inc., Worldwide Reinsurance, Ltd., Digital Connect, Inc., Kustom 440, Inc., and its majority-owned subsidiary Nobility Healthcare, LLC, collectively, “Digital Ally,” “Digital,” and the “Company”) is divided into three reportable operating segments: 1) the Video Solutions Segment, 2) the Revenue Cycle Management Segment and 3) the Ticketing Segment. The Video Solutions Segment is our legacy business that produces digital video imaging, storage products, disinfectant and related safety products for use in law enforcement, security and commercial applications. This segment includes both service and product revenues through our subscription models offering cloud and warranty solutions, and hardware sales for video and health safety solutions. The Revenue Cycle Management Segment provides working capital and back-office services to a variety of healthcare organizations throughout the country, as a monthly service fee. The Ticketing Segment acts as an intermediary between ticket buyers and sellers within our secondary ticketing platform, ticketsmarter.com, and we also acquire tickets from primary sellers to then sell through various platforms. The accounting guidance on Segment Reporting establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information of those segments to be presented in financial statements. Such required segment information is included in Note 18.

Basis of Presentation:

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

The balance sheet at December 31, 2021 has been derived from the audited financial statements at that date, but does not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

For further information, refer to the audited financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2021.

COVID-19 pandemic/Supply Chain:

The COVID-19 pandemic continues to represent an evolving and fluid situation that presents a wide range of potential impacts of varying durations for different global geographies, including locations where the Company has offices, employees, customers, vendors and other suppliers and business partners.

Like most U.S.-based businesses, the COVID-19 pandemic and efforts to mitigate the same began to have impacts on our business in March 2020. Since that time, although the original effect of the COVID-19 pandemic has eased, we have continued to operate in an uncertain economic environment that is characterized by, business slowdowns or shutdowns, labor shortages, supply chain challenges, changes in government spending and requirements, regulatory challenges, inflationary pressures and market volatility.

We continue to experience operational challenges as a result of worldwide events including the Russia-Ukraine conflict, continued uncertainty associated with the pandemic, and volatility in global markets, which are compounded by the complex integrated global supply chain for both vendors and customers. As the COVID-19 pandemic dissipates at varying times and rates in different regions around the world, there could be a prolonged negative impact on these global supply chains. Our ability to continue operations at specific facilities will be impacted by the interdependencies of the various participants of these global supply chains, which are largely beyond our direct control. A prolonged shut down of these global supply chains could have a material adverse effect on our business, results of operations, cash flows and financial condition.

7

If our suppliers have increased challenges with their workforce (including as a result of illness, absenteeism, reactions to health and safety or government requirements), facility closures, timely access to necessary components, materials and other supplies at reasonable prices, access to capital, and access to fundamental support services (such as shipping and transportation), they may be unable to provide the agreed-upon goods and services in a timely, compliant and cost-effective manner. We have incurred and may in the future incur additional costs and delays in our business resulting from the COVID-19 pandemic, including as a result of higher prices, schedule delays or the need to identify and develop alternative suppliers. In some instances, we may be unable to identify and develop alternative suppliers, incurring additional liabilities under our current contracts and hampering new ones. Our customers have experienced, and may continue to experience, disruptions in their operations and supply chains as a result of the COVID-19 pandemic, which can result in delayed, reduced, or canceled orders, or collection risks, and which may adversely affect our results of operations. Similarly, current, and future restrictions or disruptions of transportation, such as reduced availability of air transport, port closures or delays, and increased border controls, delays or closures, can also impact our ability to meet demand and could materially adversely affect us.

The spread of COVID-19 caused us to modify our business practices (including employee travel, employee work locations, cancellation of physical participation in meetings, events and conferences, and social distancing measures). To date, we eased many of these modifications. However, we may, in the future, reinstitute the same or similar changes or take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers, partners, vendors, and suppliers. Although we managed to continue most of our operations, the future course of the COVID-19 pandemic is uncertain and we cannot assure that this global pandemic, including its economic impact, will not have a material adverse impact on our business, financial position, results of operations and/or cash flows.

Basis of Consolidation:

The accompanying financial statements include the consolidated accounts of Digital Ally, its wholly-owned subsidiaries, Digital Ally International, Inc., Shield Products, LLC, Digital Ally Healthcare, LLC, TicketSmarter, Inc., Worldwide Reinsurance, Ltd., Digital Connect, Inc., Kustom 440, Inc., and its majority-owned subsidiary Nobility Healthcare, LLC. All intercompany balances and transactions have been eliminated during consolidation.

The Company formed Digital Ally International, Inc. during August 2009 to facilitate the export sales of its products. The Company formed Shield Products, LLC in May 2020 to facilitate the sales of its Shield™ line of disinfectant/cleanser products and ThermoVu® line of temperature monitoring equipment. The Company formed Nobility Healthcare, LLC in June 2021 to facilitate the operations of its revenue cycle management solutions and back-office services for healthcare organizations. Lastly, the Company formed TicketSmarter, Inc. upon its acquisition of Goody Tickets, LLC and TicketSmarter, LLC, to facilitate its global ticketing operations. The Company formed Worldwide Reinsurance Ltd., which is a captive insurance company domiciled in Bermuda. It will provide primarily liability insurance coverage to the Company for which insurance may not be currently available or economically feasible in today’s insurance marketplace. The Company formed Digital Connect, Inc. for travel and transportation purposes in 2022. The company formed Kustom 440, Inc. in 2022 to create unique entertainment experiences directly for consumers.

Fair Value of Financial Instruments:

The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and subordinated notes payable approximate fair value because of the short-term nature of these items.

Revenue Recognition:

The Company applies the provisions of Accounting Standards Codification (ASC) 606-10, Revenue from Contracts with Customers, and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to its customers in an amount reflecting the consideration to which it expects to be entitled. In order to achieve that core principle, the Company applies the following five-step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

The Company has two different revenue streams, product and service, represented through its three segments. The Company reports all revenues on a gross basis, other than service revenues from the Company’s ticketing and revenue cycle management segments. Revenues generated by all segments are reported net of sales taxes.

8

Video Solutions

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with the customer. In situations where sales are to a distributor, the Company had concluded its contracts are with the distributor as the Company holds a contract bearing enforceable rights and obligations only with the distributor. As part of its consideration for the contract, the Company evaluates certain factors including the customers’ ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. As the Company’s standard payment terms are less than one year, it has elected the practical expedient under ASC 606-10-32-18 to not assess whether a contract has a significant financing component. The Company allocates the transaction price to each distinct product based on its relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances. Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligations are satisfied), which typically occurs at shipment. Further in determining whether control has been transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer. Customers do not have a right to return the product other than for warranty reasons for which they would only receive repair services or replacement product. The Company has also elected the practical expedient under ASC 340-40-25-4 to expense commissions for product sales when incurred as the amortization period of the commission asset the Company would have otherwise recognized is less than one year.

Service and other revenue is comprised of revenues from extended warranties, repair services, cloud revenue and software revenue. Revenue is recognized upon shipment of the product and acceptance of the service or materials by the end customer for repair services. Revenue for extended warranty, cloud service or other software-based products is over the term of the contract warranty or service period. A time-elapsed method is used to measure progress because the Company transfers control evenly over the contractual period. Accordingly, the fixed consideration related to these revenues is generally recognized on a straight-line basis over the contract term, as long as the other revenue recognition criteria have been met.

The Company’s multiple performance obligations may include future in-car or body-worn camera devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price.

Revenue Cycle Management

The Company reports revenue cycle management revenues on a net basis, as its primary source of revenue is its end-to-end service fees which are generally determined as a percentage of the invoice amounts collected. These service fees are reported as revenue monthly upon completion of the Company’s performance obligation to provide the agreed upon service.

Ticketing

The Company reports ticketing revenue on a gross or net basis based on management’s assessment of whether the Company is acting as a principal or agent in the transaction. The determination is based upon the evaluation of control over the event ticket, including the right to sell the ticket, prior to its transfer to the ticket buyer.

The Company sells tickets held in inventory, which consists of one performance obligation, being to transfer control of an event ticket to the buyer upon confirmation of the order. The Company acts as the principal in these transactions, as the ticket is owned by the Company at the time of sale, therefore controlling the ticket prior to transferring to the customer. In these transactions, revenue is recorded on a gross basis based on the value of the ticket and is recognized when an order is confirmed. Payment is typically due upon delivery of the ticket.

The Company also acts as an intermediary between buyers and sellers through the online secondary marketplace. Revenues derived from this marketplace primarily consist of service fees from ticketing operations, and consists of one primary performance obligation, which is facilitating the transaction between the buyer and seller, being satisfied at the time the order has been confirmed. As the Company does not control the ticket prior to the transfer, the Company acts as an agent in these transactions. Revenue is recognized on a net basis, net of the amount due to the seller when an order is confirmed. The seller is then obligated to deliver the tickets to the buyer per the seller’s listing, and payment is due at the time of sale.

9

Other

Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied. During the three months ended June 30, 2022, the Company recognized revenue of $0.4 million related to its contract liabilities. Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract and are reported separately as current liabilities and non-current liabilities in the Consolidated Balance Sheets. Such amounts consist of extended warranty contracts, prepaid cloud services and prepaid installation services and are generally recognized as the respective performance obligations are satisfied. Total contract liabilities consist of the following:

SCHEDULE OF CONTRACT LIABILITIES

|  | December 31, 2021 |  |  | Additions/Reclass |  |  | Recognized Revenue |  |  | June 30, 2022 |
Contract liabilities, current |  | $ | 1,665,519 |  |  | $ | 611,938 |  |  | $ | 333,075 |  |  | $ | 1,944,382 |
Contract liabilities, non-current |  |  | 2,687,786 |  |  |  | 2,174,949 |  |  |  | 775,309 |  |  |  | 4,087,426 |
|  | $ | 4,353,305 |  |  | $ | 2,786,887 |  |  | $ | 1,108,384 |  |  | $ | 6,031,808 |

Sales returns and allowances aggregated $117,552 and $45,298 for the six months ended June 30, 2022 and year ended December 31, 2021, respectively. Obligations for estimated sales returns and allowances are recognized at the time of sales on an accrual basis. The accrual is determined based upon historical return rates adjusted for known changes in key variables affecting these return rates.

Use of Estimates:

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management utilizes various other estimates, including but not limited to, determining the estimated lives of long-lived assets, determining the potential impairment of long-lived assets, the fair value of warrants, options, the recognition of revenue, inventory valuation reserve, fair value of assets and liabilities acquired in a business combination, incremental borrowing rate on leases, the valuation allowance for deferred tax assets and other legal claims and contingencies. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period that they are determined to be necessary.

Cash and cash equivalents:

Cash and cash equivalents include funds on hand, in bank and short-term investments with original maturities of ninety (90) days or less.

SCHEDULE OF SHORT TERM INVESTMENTS

|  | June 30, 2022 |
|  | Adjusted Cost |  |  | Realized Gains |  |  | Realized Losses |  |  | Fair Value |
Demand deposits |  | $ | 5,841,857 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,841,857 |
Short-term investments with original maturities of 90 days or less (Level 1): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  |  | 7,612,389 |  |  |  | — |  |  |  | — |  |  |  | 7,612,389 |
|  | $ | 13,454,246 |  |  | $ | — |  |  | $ | — |  |  | $ | 13,454,246 |

10

|  | December 31, 2021 |
|  | Adjusted Cost |  |  | Unrealized Gains |  |  | Unrealized Losses |  |  | Fair Value |
Demand deposits |  | $ | 5,031,246 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,031,246 |
Short-term investments with original maturities of 90 days or less (Level 1): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  |  | 14,928,526 |  |  |  | — |  |  |  | — |  |  |  | 14,928,526 |
Mutual funds |  |  | 12,079,901 |  |  |  | — |  |  |  | (31,881 | ) |  |  | 12,048,020 |
|  | $ | 32,039,673 |  |  | $ | — |  |  | $ | (31,881 | ) |  | $ | 32,007,792 |

The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At June 30, 2022 and December 31, 2021, the uninsured balance amounted to $11,682,011 and $29,836,142, respectively.

Accounts Receivable:

Accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a weekly basis. The Company determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions.

Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than thirty (30) days beyond terms. No interest is charged on overdue trade receivables.

Goodwill and Other Intangibles:

Goodwill - In connection with acquisitions, the Company applies the provisions of ASC 805, Business Combinations, using the acquisition method of accounting. The excess purchase price over the fair value of net tangible assets and identifiable intangible assets acquired is recorded as goodwill. In accordance with ASC 350, Intangibles - Goodwill and Other, the Company assesses goodwill for impairment annually as of December 31, and more frequently if events and circumstances indicate that goodwill might be impaired.

Goodwill impairment testing is performed at the reporting unit level. Goodwill is assigned to reporting units at the date the goodwill is initially recorded. Once goodwill has been assigned to reporting units, it no longer retains its association with a particular acquisition, and all of the activities within a reporting unit, whether acquired or internally generated, are available to support the value of the goodwill.

Traditionally, goodwill impairment testing is a two-step process. Step one involves comparing the fair value of the reporting units to its carrying amount. If the carrying amount of a reporting unit is greater than zero and its fair value is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is greater than the fair value, the second step must be completed to measure the amount of impairment, if any. Step two involves calculating an implied fair value of goodwill. The Company has adopted ASU 2017-04 which simplifies subsequent goodwill measurement by eliminating step two from the goodwill impairment test. As a result, the Company compares the fair value of a reporting unit with its respective carrying value and recognized an impairment charge for the amount by which the carrying amount exceeded the reporting unit’s fair value.

The Company determines the fair value of its reporting units using an income approach. Under the income approach, the Company determined fair value based on estimated discounted future cash flows of each reporting unit. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates and EBITDA margins, discount rates and future market conditions, among others.

11

Long-lived and Other Intangible Assets - The Company periodically assesses potential impairments of its long-lived assets in accordance with the provisions of ASC 360, Accounting for the Impairment or Disposal of Long-lived Assets. An impairment review is performed whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. The Company groups its assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of the other assets and liabilities. The Company has determined that the lowest level for which identifiable cash flows are available is the operating segment level.

Factors considered by the Company include, but are not limited to, significant underperformance relative to historical or projected operating results; significant changes in the manner of use of the acquired assets or the strategy for the overall business; and significant negative industry or economic trends. When the carrying value of a long-lived asset may not be recoverable based upon the existence of one or more of the above indicators of impairment, the Company estimates the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future undiscounted cash flows and eventual disposition is less than the carrying amount of the asset, the Company recognizes an impairment loss. An impairment loss is reflected as the amount by which the carrying amount of the asset exceeds the fair value of the asset, based on the fair value if available, or discounted cash flows, if fair value is not available. The Company last assessed potential impairments of its long-lived assets as of June 30, 2022 and concluded that there was no impairment.

Intangible assets include deferred patent costs and license agreements. Legal expenses incurred in preparation of patent application have been deferred and will be amortized over the useful life of granted patents. Costs incurred in preparation of applications that are not granted will be charged to expense at that time. The Company has entered into several sublicense agreements under which it has been assigned the exclusive rights to certain licensed materials used in its products. These sublicense agreements generally require upfront payments to obtain the exclusive rights to such material. The Company capitalizes the upfront payments as intangible assets and amortizes such costs over their estimated useful life on a straight-line method.

Segment Reporting

The accounting guidance on Segment Reporting establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information of those segments to be presented in financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker (the Company’s Chief Executive Officer or “CODM”) in making decisions on how to allocate resources and assess performance. The Company’s three operating segments are Video Solutions, Revenue Cycle Management, and Ticketing, each of which has specific personnel responsible for that business and reports to the CODM. Corporate expenses capture the Company’s corporate administrative activities and are also to be reported in the segment information. The Company’s captive insurance subsidiary provides services to the Company’s other business segments and not to outside customers; however, that subsidiary had no activity in the three months ended June 30, 2022 and 2021. Therefore, its operations will be eliminated in consolidation, and it is not considered a separate business segment for financial reporting purposes.

Contingent Consideration

In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value through the consolidated statement of operations.

Repurchase and Cancellation of Shares

From time to time, the Company’s Board of Directors (the “Board”) may authorize share repurchases of common stock. Shares repurchased under Board authorizations are held in treasury for general corporate purposes and cancelled when it is determined appropriate by management. The Company accounts for repurchases of common stock under the cost method. Shares repurchased and cancelled during the period were recorded as a reduction to stockholders’ (deficit) equity. See further discussion of the Company’s share repurchase program in Note 15 –Stockholders’ Equity.

12

Non-Controlling Interests

Non-controlling interests in the Company’s Consolidated Financial Statements represents the interest in subsidiaries held by our venture partner. The venture partner holds a noncontrolling interests in the Company’s consolidated subsidiary Nobility Healthcare, LLC. Since the Company consolidates the financial statements of all wholly-owned and majority owned subsidiaries, the noncontrolling owners’ share of each subsidiary’s results of operations are deducted and reported as net income or loss attributable to noncontrolling interest in the Consolidated Statements of Operations.

New Accounting Standards

In 2020, FASB issued ASU No. 2020-06 to simplify the accounting for convertible debt instruments as the current accounting guidance was determined to be unnecessarily complex and difficult to navigate. The ASU primarily does three things: (1) The ASU eliminates the beneficial conversion feature model and the cash conversion model. The elimination of these models will result in more convertible instruments (convertible debt instruments or convertible preferred stock instruments) being reported as a single liability instrument. The ASU also makes targeted improvements to the related disclosures, (2) The ASU eliminates certain settlement conditions that are required to qualify for derivative scope exception which will allow for less equity contracts to be accounted for as a derivative and (3) The ASU aligns the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method and requiring share settlement be included in the calculation when the contract includes an option of cash or share settlement. ASU No. 2020-06 is effective for fiscal years beginning after December 15, 2021 with early adoption permitted for fiscal years beginning after December 15, 2020. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

In 2020, FASB issued ASU No. 2020-01 which represents a consensus of the Emerging Issues Task Force and it clarifies certain items related to ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU (1) clarifies that when an entity is either applying the equity method or upon discontinuing the equity method it should consider observable price changes in orderly transactions for the identical or a similar investment with the same issuer for valuing basis of the investment and (2) clarifies that when determining the accounting for certain forward contracts and purchased options an entity should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU No. 2020-01 is effective for fiscal years beginning after December 15, 2020 with early adoption permitted. The Company adopted this update for the quarter ended March 31, 2021. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - simplifying the accounting for income taxes (Topic 740), which is meant to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, Income Taxes. The amendment also improves consistent application and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

13

In August 2018, the FASB issued ASU No. 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40), or ASU 2018-15. ASU 2018-15 updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU 2018-15 are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations,

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - simplifying the accounting for income taxes (Topic 740), which is meant to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, Income Taxes. The amendment also improves consistent application and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in ASU 2019-12 are effective for public business entities for fiscal years beginning after Dec. 15, 2020. The adoption of this standard did not have a significant impact on the Company’s financial position and results of operations.

NOTE 2. INVENTORIES

Inventories consisted of the following at June 30, 2022 and December 31, 2021:

SCHEDULE OF INVENTORIES

|  | June 30, 2022 |  |  | December 31, 2021 |
Raw material and component parts– video solutions segment |  | $ | 4,083,713 |  |  | $ | 3,062,046 |
Work-in-process– video solutions segment |  |  | 153 |  |  |  | — |
Finished goods – video solutions segment |  |  | 7,866,087 |  |  |  | 8,410,307 |
Finished goods – ticketing segment |  |  | 1,178,468 |  |  |  | 2,102,272 |
Subtotal |  |  | 13,128,421 |  |  |  | 13,574,625 |
Reserve for excess and obsolete inventory– video solutions segment |  |  | (3,272,832 | ) |  |  | (3,353,458 | )
Reserve for excess and obsolete inventory – ticketing segment |  |  | (449,635 | ) |  |  | (561,631 | )
Total inventories |  | $ | 9,405,954 |  |  | $ | 9,659,536 |

Finished goods inventory includes units held by potential customers and sales agents for test and evaluation purposes. The cost of such units totaled $135,573 and $153,976 as of June 30, 2022 and December 31, 2021, respectively.

NOTE 3. DEBT OBLIGATIONS

Debt obligations is comprised of the following:

SUMMARY OF DEBT OBLIGATIONS

|  | June 30, 2022 |  |  | December 31, 2021 |
Economic injury disaster loan (EIDL) |  | $ | 150,000 |  |  | $ | 150,000 |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | 211,867 |  |  |  | 317,212 |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | 426,326 |  |  |  | 650,000 |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | 481,151 |  |  |  | — |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | — |  |  |  | — |
Debt obligations |  |  | 1,269,344 |  |  |  | 1,117,212 |
Less: current maturities of debt obligations |  |  | 514,664 |  |  |  | 389,934 |
Debt obligations, long-term |  | $ | 754,680 |  |  | $ | 727,278 |

14

Debt obligations mature as follows as of June 30, 2022:

SCHEDULE OF MATURITY OF DEBT OBLIGATIONS

|  | June 30, 2022 |
2022 (July 1, 2022 to December 31, 2022) |  | $ | 257,317 |
2023 |  |  | 514,722 |
2024 |  |  | 355,295 |
2025 |  |  | 3,412 |
2026 |  |  | 3,542 |
2027 and thereafter |  |  | 135,056 |
Total |  | $ | 1,269,344 |

2020 Small Business Administration Notes.

On May 4, 2020, the Company issued a promissory note in connection with the receipt of the Paycheck Protection Program (“PPP”) Loan of $1,418,900 (the “PPP Loan”) under the Small Business Administration’s (the “SBA”) PPP Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan had a two-year term and bore interest at a rate of 1.0% per annum. Monthly principal and interest payments were deferred for nine months after the date of disbursement and total $79,851 per month thereafter. The PPP Loan could have been prepaid at any time prior to maturity with no prepayment penalties. The promissory note contained events of default and other provisions customary for a loan of this type. The PPP Loan provided that it may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company used the majority of the PPP Loan amount for qualifying expenses. On December 10, 2020, the Company was fully forgiven of its $1,418,900 PPP Loan. Additionally, the Company was fully forgiven, during the three months ended June 30, 2021, of its $10,000 EIDL advance received with the PPP Loan.

On May 12, 2020, the Company received $150,000 in loan funding from the SBA under the EIDL program administered by the SBA, which program was expanded pursuant to the recently enacted CARES Act. The EIDL is evidenced by a secured promissory note, dated May 8, 2020, in the original principal amount of $150,000 with the SBA, the lender.

Under the terms of the note issued under the EIDL program, interest accrues on the outstanding principal at the rate of 3.75% per annum. The term of such note is thirty years, though it may be payable sooner upon an event of default under such note. Monthly principal and interest payments are deferred for twenty-four months after the date of disbursement and total $731 per month thereafter. Such note may be prepaid in part or in full, at any time, without penalty. The Company granted the secured party a continuing interest in and to any and all collateral, including but not limited to tangible and intangible personal property.

Contingent Consideration Promissory Notes

On June 30, 2021, Nobility Healthcare, a subsidiary of the Company, issued a contingent consideration promissory note (the “June Contingent Note”) in connection with a stock purchase agreement between Nobility Healthcare and a private company (the “June Seller”) of $350,000. The June Contingent Note has a three-year term and bears interest at a rate of 3.00% per annum. Quarterly principal and interest payments are deferred for six months and are due in equal quarterly installments on the seventh business day of each quarter. The principal amount of the June Contingent Note is subject to an earn-out adjustment, being the difference between $975,000 (the “June Projected Revenue”) and the cash basis revenue (the “June Measurement Period Revenue”) collected by the June Seller in its normal course of business from the clients existing on June 30, 2021, during the period from October 1, 2021 through September 30, 2022 (the “June Measurement Period”) measured on a quarterly basis and annualized as of the relevant period. If the June Measurement Period Revenue is less than the June Projected Revenue, such amount will be subtracted from the principal balance of this June Contingent Note on a dollar-for-dollar basis. If the June Measurement Period Revenue is more than the June Projected Revenue, such amount will be added to the principal balance of this June Contingent Note on a dollar-for-dollar basis. In no event will the principal balance of this June Contingent Note become a negative number. The maximum downward earn-out adjustment to the principal balance will be a reduction to zero. There are no limits to the increases to the principal balance of the June Contingent Note as a result of the earn-out adjustments.

15

The June Contingent Note is considered to be additional purchase price; therefore, the estimated fair value of the contingent liability is recorded as a liability at the acquisition date and the fair value is considered part of the consideration paid for the acquisition with subsequent changes in fair value recorded as a gain or loss in the Consolidated Statements of Operations. Management recorded the contingent consideration promissory note at its estimated fair value of $350,000 at the acquisition date. Total principal payments, since its inception, on this contingent consideration promissory note totaled $57,724. The estimated fair value of the June Contingent Note at June 30, 2022 is $211,868, representing an increase in its estimated fair value of $3,844 as compared to its estimated fair value as of March 31, 2022. Therefore, the Company recorded a loss of $3,844 in the Consolidated Statements of Operations for the three months ended June 30, 2022. The Company recorded a gain of $47,620 in the Consolidated Statements of Operations for the six months ended June 30, 2022.

On August 31, 2021, Nobility Healthcare issued another contingent consideration promissory note (the “August Contingent Payment Note”) in connection with a stock purchase agreement between Nobility Healthcare and a private company (the “August Sellers”) of $650,000. The August Contingent Payment Note has a three-year term and bears interest at a rate of 3.00% per annum. Quarterly principal and interest payments are deferred for six months and is due in equal quarterly installments on the seventh business day of each quarter. The principal amount of the August Contingent Payment Note is subject to an earn-out adjustment, being the difference between $3,000,000 (the “August Projected Revenue”) and the cash basis revenue (the “August Measurement Period Revenue”) collected by the August Sellers in its normal course of business from the clients existing on September 1, 2021, during the period from December 1, 2021 through November 30, 2022 (the “August Measurement Period”) measured on a quarterly basis and annualized as of the relevant period. If the August Measurement Period Revenue is less than the August Projected Revenue, such amount will be subtracted from the principal balance of this August Contingent Payment Note on a dollar-for-dollar basis. If the August Measurement Period Revenue is more than the August Projected Revenue, such amount will be added to the principal balance of this August Contingent Payment Note on a dollar-for-dollar basis. In no event will the principal balance of this August Contingent Payment Note become a negative number. The maximum downward earn-out adjustment to the principal balance will be a reduction to zero. There are no limits to the increases to the principal balance of the August Contingent Payment Note as a result of the earn-out adjustments.

The August Contingent Payment Note is considered to be additional purchase price, therefore the estimated fair value of the contingent liability is recorded as a liability at the acquisition date and the fair value is considered part of the consideration paid for the acquisition with subsequent changes in fair value recorded as a gain or loss in the Consolidated Statements of Operations. Management recorded the contingent consideration promissory note at its estimated fair value of $650,000 at the acquisition date. Principal payments, since its inception, on this contingent consideration promissory note totaled $159,098. The estimated fair value of the August Contingent Note at June 30, 2022 is $426,326, representing a decrease in its estimated fair value of $172,091 as compared to is estimated fair value as of March 31, 2022. Therefore, the Company recorded a gain of $172,091 in the Consolidated Statements of Operations for the three months ended June 30, 2022. The Company recorded a gain of $64,576 in the Consolidated Statements of Operations for the six months ended June 30, 2022.

On January 1, 2022, Nobility Healthcare issued another contingent consideration promissory note (the “January Contingent Payment Note”) in connection with a stock purchase agreement between Nobility Healthcare and a private company (the “January Sellers”) of $750,000. The January Contingent Payment Note has a two and a half year term and bears interest at a rate of 3.00% per annum. Quarterly principal and interest payments are deferred for seven months and is due in equal quarterly installments on the tenth business day of each quarter. The principal amount of the January Contingent Payment Note is subject to an earn-out adjustment, being the difference between $3,500,000 (the “January Projected Revenue”) and the cash basis revenue (the “January Measurement Period Revenue”) collected by the January Sellers in its normal course of business from the clients existing on January 1, 2022, during the period from April 1, 2022 through March 31, 2023 (the “January Measurement Period”) measured on a quarterly basis and annualized as of the relevant period. If the January Measurement Period Revenue is less than the January Projected Revenue, such amount will be subtracted from the principal balance of this January Contingent Payment Note on a dollar-for-dollar basis. If the January Measurement Period Revenue is more than the January Projected Revenue, such amount will be added to the principal balance of this January Contingent Payment Note on a dollar-for-dollar basis. In no event will the principal balance of this January Contingent Payment Note become a negative number. The maximum downward earn-out adjustment to the principal balance will be a reduction to zero. There are no limits to the increases to the principal balance of the January Contingent Payment Note as a result of the earn-out adjustments.

16

The January Contingent Payment Note is considered to be additional purchase price, therefore the estimated fair value of the contingent liability is recorded as a liability at the acquisition date and the fair value is considered part of the consideration paid for the acquisition. Management has recorded the contingent consideration promissory note at its estimated fair value of $750,000 at the acquisition date. The estimated fair value of the January Contingent Note at June 30, 2022 is $481,151, representing a decrease in its estimated fair value of $268,849 as compared to is estimated fair value as of March 31, 2022. Therefore, the Company recorded a gain of $268,849 in the Consolidated Statements of Operations for the three and six months ended June 30, 2022. There were no principal payments on this contingent consideration promissory note during the three months ended June 30, 2022.

On February 1, 2022, Nobility Healthcare issued another contingent consideration promissory note (the “February Contingent Payment Note”) in connection with an asset purchase agreement between Nobility Healthcare and a private company (the “February Sellers”) of $105,000. The February Contingent Payment Note has a three-year term and bears interest at a rate of 3.00% per annum. Quarterly principal and interest payments are deferred for seven months and are due in equal quarterly installments on the tenth business day of each quarter. The principal amount of the February Contingent Payment Note is subject to an earn-out adjustment, being the difference between $440,000 (the “February Projected Revenue”) and the cash basis revenue (the “February Measurement Period Revenue”) collected by the February Sellers in its normal course of business from the clients existing on February 1, 2022, during the period from May 1, 2022 through April 30, 2023 (the “February Measurement Period”) measured on a quarterly basis and annualized as of the relevant period. If the February Measurement Period Revenue is less than the February Projected Revenue, such amount will be subtracted from the principal balance of this February Contingent Payment Note on a dollar-for-dollar basis. If the February Measurement Period Revenue is more than the February Projected Revenue, such amount will be added to the principal balance of this February Contingent Payment Note on a dollar-for-dollar basis. In no event will the principal balance of this February Contingent Payment Note become a negative number. The maximum downward earn-out adjustment to the principal balance will be a reduction to zero. There are no limits to the increases to the principal balance of the February Contingent Payment Note as a result of the earn-out adjustments.

The February Contingent Payment Note is considered to be additional purchase price, therefore the estimated fair value of the contingent liability is recorded as a liability at the acquisition date and the fair value is considered part of the consideration paid for the acquisition. Management has recorded the contingent consideration promissory note at its estimated fair value of $105,000 at the acquisition date. The estimated fair value of the February Contingent Note at June 30, 2022 is $0, representing a reduction in its estimated fair value of $105,000 as compared to is estimated fair value as of March 31, 2022. Therefore, the Company recorded a gain of $105,000 in the Consolidated Statements of Operations for the three and six months ended June 30, 2022. There were no principal payments on this contingent consideration promissory note during the three months ended June 30, 2022.

NOTE 4. FAIR VALUE MEASUREMENT

In accordance with ASC Topic 820 — Fair Value Measurements and Disclosures (“ASC 820”), the Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets, liabilities or a group of assets or liabilities, such as a business.

ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

● | Level 1 — Quoted prices in active markets for identical assets and liabilities
● | Level 2 — Other significant observable inputs (including quoted prices in active markets for similar assets or liabilities)
● | Level 3 — Significant unobservable inputs (including the Company’s own assumptions in determining the fair value)

17

The following table represents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021:

SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS

|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
|  | June 30, 2022 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Warrant derivative liabilities |  | $ | — |  |  | $ | — |  |  | $ | 9,285,143 |  |  | $ | 9,285,143 |
Contingent consideration promissory notes |  |  | — |  |  |  | — |  |  |  | 1,119,344 |  |  |  | 1,119,344 |
Liabilities, fair value |  | $ | — |  |  | $ | — |  |  | $ | 10,404,487 |  |  | $ | 10,404,487 |

|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
|  | December 31, 2021 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Warrant derivative liabilities |  | $ | — |  |  | $ | — |  |  | $ | 14,846,932 |  |  | $ | 14,846,932 |
Contingent consideration promissory notes and contingent consideration earn-out agreement |  |  | — |  |  |  | — |  |  |  | 967,212 |  |  |  | 967,212 |
Liabilities, fair value |  | $ | — |  |  | $ | — |  |  | $ | 15,814,144 |  |  | $ | 15,814,144 |

The following table represents the change in Level 3 tier value measurements for the periods ended June 30, 2022:

SCHEDULE OF FAIR VALUE MEASUREMENTS CHANGE IN LEVEL 3 INPUTS

|  | Contingent Consideration Promissory Notes |  |  | Warrant Derivative Liabilities |
Balance, December 31, 2021 |  | $ | 967,212 |  |  | $ | 14,846,932 |
Issuance of contingent consideration promissory note - Revenue Cycle Management Segment Acquisition |  |  | 750,000 |  |  |  | — |
Issuance of contingent consideration promissory note - Revenue Cycle Management Segment Acquisition |  |  | 105,000 |  |  |  | — |
Principal payments on contingent consideration promissory notes – Revenue Cycle Management Acquisitions |  |  | (116,198 | ) |  |  | — |
Change in fair value of contingent consideration promissory notes - Revenue Cycle Management Acquisitions |  |  | 56,050 |  |  |  | — |
Change in fair value of warrant derivative liabilities |  |  | — |  |  |  | (148,171 | )
Balance, March 31, 2022 |  | $ | 1,762,064 |  |  | $ | 14,698,761 |
Principal payments on contingent consideration promissory notes – Revenue Cycle Management Acquisitions |  |  | (100,624 | ) |  |  | — |
Change in fair value of contingent consideration promissory notes - Revenue Cycle Management Acquisitions |  |  | (542,096 | ) |  |  | — |
Change in fair value of warrant derivative liabilities |  |  | — |  |  |  | (5,413,618 | )
Balance, June 30, 2022 |  | $ | 1,119,344 |  |  | $ | 9,285,143 |

18

NOTE 5. ACCRUED EXPENSES

Accrued expenses consisted of the following at June 30, 2022 and December 31, 2021:

SCHEDULE OF ACCRUED EXPENSES

|  | June 30, 2022 |  |  | December 31, 2021 |
Accrued warranty expense |  | $ | 16,389 |  |  | $ | 13,742 |
Accrued litigation costs |  |  | 247,984 |  |  |  | 250,000 |
Accrued sales commissions |  |  | 48,000 |  |  |  | 30,213 |
Accrued payroll and related fringes |  |  | 461,189 |  |  |  | 453,858 |
Accrued sales returns and allowances |  |  | 117,552 |  |  |  | 45,298 |
Accrued taxes |  |  | 104,506 |  |  |  | 180,486 |
Other |  |  | 135,117 |  |  |  | 202,401 |
Total accrued expenses |  | $ | 1,130,737 |  |  | $ | 1,175,998 |

Accrued warranty expense was comprised of the following for the six months ended June 30, 2022:

SCHEDULE OF ACCRUED WARRANTY EXPENSE

Beginning balance |  | $ | 13,742 |
Provision for warranty expense |  |  | 41,166 |
Charges applied to warranty reserve |  |  | (38,519 | )
Ending balance |  | $ | 16,389 |

NOTE 6. INCOME TAXES

The effective tax rate for the three months ended June 30, 2022 and 2021 varied from the expected statutory rate due to the Company continuing to provide a 100% valuation allowance on net deferred tax assets. The Company determined that it was appropriate to continue the full valuation allowance on net deferred tax assets as of June 30, 2022, primarily because of the Company’s history of operating losses.

The Company has incurred operating losses in recent years, and it continues to be in a three-year cumulative loss position at June 30, 2022. Accordingly, the Company determined there was not sufficient positive evidence regarding its potential for future profits to outweigh the negative evidence of our three-year cumulative loss position under the guidance provided in ASC 740. Therefore, it determined to continue to provide a 100% valuation allowance on its net deferred tax assets. The Company expects to continue to maintain a full valuation allowance until it determines that it can sustain a level of profitability that demonstrates its ability to realize these assets. To the extent the Company determines that the realization of some or all of these benefits is more likely than not based upon expected future taxable income, a portion or all of the valuation allowance will be reversed. The Company has available to it approximately $81.4 million (based on its December 31, 2021 tax return) in net operating loss carryforwards to offset future taxable income as of June 30, 2022.

NOTE 7. PREPAID EXPENSES

Prepaid expenses were the following at June 30, 2022 and December 31, 2021:

SCHEDULE OF PREPAID EXPENSE

|  | June 30, 2022 |  |  | December 31, 2021 |
Prepaid inventory |  | $ | 6,710,710 |  |  | $ | 6,546,100 |
Prepaid advertising |  |  | 657,831 |  |  |  | 2,455,527 |
Other |  |  | 542,894 |  |  |  | 727,155 |
Total prepaid expenses |  | $ | 7,911,435 |  |  | $ | 9,728,782 |

19

NOTE 8. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following at June 30, 2022 and December 31, 2021:

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT

|  | Estimated Useful Life |  |  | June 30, 2022 |  |  | December 31, 2021 |
Building |  |  | 30 years |  |  | $ | 4,909,478 |  |  | $ | 4,909,478 |
Land |  |  | — |  |  |  | 789,734 |  |  |  | 789,734 |
Office furniture, fixtures and equipment |  |  | 3-20 years |  |  |  | 2,013,281 |  |  |  | 493,652 |
Warehouse and production equipment |  |  | 3-5 years |  |  |  | 78,321 |  |  |  | 65,948 |
Demonstration and tradeshow equipment |  |  | 2-5 years |  |  |  | 131,838 |  |  |  | 82,337 |
Building improvements |  |  | 2-15 years |  |  |  | 1,253,937 |  |  |  | 911,940 |
Rental equipment |  |  | 1-3 years |  |  |  | 8,584 |  |  |  | 8,584 |
Total cost |  |  |  |  |  |  | 9,185,173 |  |  |  | 7,261,673 |
Less: accumulated depreciation and amortization |  |  |  |  |  |  | (727,974 | ) |  |  | (420,647 | )
Net property, plant and equipment |  |  |  |  |  | $ | 8,457,199 |  |  | $ | 6,841,026 |

Depreciation expense for the six months ended June 30, 2022 and June 30, 2021 was $307,328 and $95,346, respectively, and is included in general and administrative expenses.

NOTE 9. OPERATING LEASE

On May 13, 2020, the Company entered into an operating lease for new warehouse and office space, which the Company currently utilizes as one of its office, assembly and warehouse locations. The original lease agreement was amended on August 28, 2020 to correct the footage under lease and monthly payment amounts resulting from such correction. The lease terms, as amended, include no base rent for the first nine months and monthly payments ranging from $12,398 to $14,741 thereafter, with a termination date of December 2026. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to this location. The Company took possession of the leased facilities on June 15, 2020. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2022, was fifty-four months. The Company’s previous office and warehouse space lease expired in April 2020 and the Company paid holdover rent for the time period until it moved to and commenced occupying the new space on June 15, 2020.

The Company entered into an operating lease with a third party in October 2019 for copiers used for office and warehouse purposes. The terms of the lease include 48 monthly payments of $1,598 with a maturity date of October 2023. The Company has the option to purchase the equipment at maturity for its estimated fair market value at that point in time. The remaining lease term for the Company’s copier operating lease as of June 30, 2022, was sixteen months.

On June 30, 2021, the Company completed the acquisition of a private medical billing company, through its revenue cycle management segment. Upon completion of this acquisition, the Company became responsible for the operating lease for the seller’s office space. The lease terms include monthly payments ranging from $2,648 to $2,774, with a termination date of July 2024. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to this location. The Company took possession of the leased facilities on June 30, 2021. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2022, was twenty-five months.

On August 31, 2021, the Company completed the acquisition of a private medical billing company, through its revenue cycle management segment. Upon completion of this acquisition, the Company became responsible for the operating lease for the seller’s office space. The lease terms include monthly payments ranging from $11,579 to $11,811, with a termination date of March 2023. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to this location. The Company took possession of the leased facilities on September 1, 2021. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2022, was nine months.

20

On September 1, 2021, the Company completed the TicketSmarter Acquisition, in its ticketing segment. Upon completion of this acquisition, the Company became responsible for the operating lease for TicketSmarter Inc.’s office space. The lease terms include monthly payments ranging from $7,211 to $7,364, with a termination date of December 2022. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to this location. The Company took possession of the leased facilities on September 1, 2021. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2022 was six months.

On January 1, 2022, the Company completed the acquisition of a private medical billing company, through its revenue cycle management segment. Upon completion of this acquisition, the Company became responsible for the operating lease for the seller’s office space. The lease terms include monthly payments ranging from $4,233 to $4,626, with a termination date of June 2025. The Company is responsible for property taxes, utilities, insurance and its proportionate share of common area costs related to this location. The Company took possession of the leased facilities on January 1, 2022. The remaining lease term for the Company’s office and warehouse operating lease as of June 30, 2022, was thirty-six months.

Lease expense related to the office space and copier operating leases were recorded on a straight-line basis over their respective lease terms. Total lease expense under the six operating leases was approximately $119,230 and $274,302, during the three and six months ended June 30, 2022, respectively.

The weighted-average remaining lease term related to the Company’s lease liabilities as of June 30, 2022 was 3.5 years.

The discount rate implicit within the Company’s operating leases was not generally determinable and therefore the Company determined the discount rate based on its incremental borrowing rate on the information available at commencement date. As of commencement date, the operating lease liabilities reflect a weighted average discount rate of 8%.

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2022:

SCHEDULE OF OPERATING LEASES RIGHT OF USE ASSETS AND LIABILITIES

Assets: |  |  |
Operating lease right of use assets |  | $ | 951,928 |
Liabilities: |  |  |  |
Operating lease obligations-current portion |  | $ | 353,646 |
Operating lease obligations-less current portion |  |  | 666,477 |
Total operating lease obligations |  | $ | 1,020,123 |

Following are the minimum lease payments for each year and in total:

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS

Year ending December 31: |  |  |
2022 (July 1, to December 31, 2022) |  | $ | 250,285 |
2023 |  |  | 305,627 |
2024 |  |  | 245,761 |
2025 |  |  | 196,462 |
Thereafter |  |  | 175,113 |
Total undiscounted minimum future lease payments |  |  | 1,173,248 |
Imputed interest |  |  | (153,125 | )
Total operating lease liability |  | $ | 1,020,123 |

21

NOTE 10. GOODWILL AND OTHER INTANGIBLE ASSETS

Intangible assets consisted of the following at June 30, 2022 and December 31, 2021:

SCHEDULE OF INTANGIBLE ASSETS

|  | June 30, 2022 |  |  | December 31, 2021 |
|  | Gross value |  |  | Accumulated amortization |  |  | Net carrying value |  |  | Gross value |  |  | Accumulated amortization |  |  | Net carrying value |
Amortized intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses (video solutions segment) |  | $ | 194,286 |  |  | $ | 73,866 |  |  | $ | 120,420 |  |  | $ | 194,286 |  |  | $ | 65,578 |  |  | $ | 128,708 |
Patents and trademarks (video solutions segment) |  |  | 493,945 |  |  |  | 303,485 |  |  |  | 190,460 |  |  |  | 493,945 |  |  |  | 233,471 |  |  |  | 260,474 |
Sponsorship agreement network (ticketing segment) |  |  | 5,600,000 |  |  |  | 933,333 |  |  |  | 4,666,667 |  |  |  | 5,600,000 |  |  |  | 373,333 |  |  |  | 5,226,667 |
SEO content (ticketing segment) |  |  | 600,000 |  |  |  | 125,000 |  |  |  | 475,000 |  |  |  | 600,000 |  |  |  | 50,000 |  |  |  | 550,000 |
Personal seat licenses (ticketing segment) |  |  | 201,931 |  |  |  | 5,583 |  |  |  | 196,348 |  |  |  | 201,931 |  |  |  | 2,244 |  |  |  | 199,687 |
Client agreements (revenue cycle management segments) |  |  | 792,079 |  |  |  | — |  |  |  | 792,079 |  |  |  | — |  |  |  | — |  |  |  | — |
|  |  | 7,882,241 |  |  |  | 1,441,267 |  |  |  | 6,440,974 |  |  |  | 7,090,162 |  |  |  | 724,626 |  |  |  | 6,365,536 |
Indefinite life intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill (ticketing and revenue cycle management segments) |  |  | 11,574,468 |  |  |  | — |  |  |  | 11,574,468 |  |  |  | 9,931,547 |  |  |  | — |  |  |  | 9,931,547 |
Trade name (ticketing segment) |  |  | 600,000 |  |  |  | — |  |  |  | 600,000 |  |  |  | 600,000 |  |  |  | — |  |  |  | 600,000 |
Patents and trademarks pending (video solutions segment) |  |  | 60,027 |  |  |  | — |  |  |  | 60,027 |  |  |  | 5,430 |  |  |  | — |  |  |  | 5,430 |
Total |  | $ | 20,116,736 |  |  | $ | 1,441,267 |  |  | $ | 18,675,469 |  |  | $ | 17,627,139 |  |  | $ | 724,626 |  |  | $ | 16,902,513 |

Patents and trademarks pending will be amortized beginning at the time they are issued by the appropriate authorities. If issuance of the final patent or trademark is denied, then the amount deferred will be immediately charged to expense.

Amortization expense for the three months ended June 30, 2022 and 2021 was $358,944 and $27,483, respectively, and $716,910 and $50,114, for the six months ended June 30, 2022 and 2021, respectively. Estimated amortization for intangible assets with definite lives for the next five years ending December 31 and thereafter is as follows:

SCHEDULE OF ESTIMATED AMORTIZATION FOR INTANGIBLE ASSETS

Year ending December 31: |  |  |
2022 (July 1, to December 31, 2022) |  | $ | 813,792 |
2023 |  |  | 1,448,622 |
2024 |  |  | 1,398,065 |
2025 |  |  | 1,311,958 |
2026 and thereafter |  |  | 1,468,537 |
Total |  | $ | 6,440,974 |

22

NOTE 11. OTHER ASSETS

Other assets were the following at June 30, 2022 and December 31, 2021:

SCHEDULE OF OTHER ASSETS

|  | June 30, 2022 |  |  | December 31, 2021 |
Lease receivable |  | $ | 3,337,608 |  |  | $ | 1,921,021 |
Sponsorship network |  |  | 3,337,465 |  |  |  | 30,752 |
Other |  |  | 232,208 |  |  |  | 155,526 |
Total other assets |  | $ | 6,907,281 |  |  | $ | 2,107,299 |

NOTE 12. COMMITMENTS AND CONTINGENCIES

COVID-19 pandemic

The COVID-19 pandemic represents a fluid situation that presents a wide range of potential impacts of varying durations for different global geographies, including locations where we have offices, employees, customers, vendors and other suppliers and business partners.

Like most US-based businesses, the COVID-19 pandemic and efforts to mitigate the same began to have impacts on our business in March 2020. Since that time, the COVID-19 pandemic has dramatically impacted the global health and economic environment, including millions of confirmed cases, business slowdowns or shutdowns, labor shortages, supply chain challenges, changes in government spending and requirements, regulatory challenges, inflationary pressures and market volatility.

We operate within the complex integrated global supply chain for both vendors and customers. As the COVID-19 pandemic dissipates at varying times and rates in different regions around the world, there could be a prolonged negative impact on these global supply chains. Our ability to continue operations at specific facilities will be impacted by the interdependencies of the various participants of these global supply chains, which are largely beyond our direct control. A prolonged shut down of these global supply chains could have a material adverse effect on our business, results of operations, cash flows and financial condition.

If our suppliers have increased challenges with their workforce (including as a result of illness, absenteeism, reactions to health and safety or government requirements), facility closures, timely access to necessary components, materials and other supplies at reasonable prices, access to capital, and access to fundamental support services (such as shipping and transportation), they may be unable to provide the agreed-upon goods and services in a timely, compliant and cost-effective manner. We have incurred and may in the future incur additional costs and delays in our business resulting from the COVID-19 pandemic, including as a result of higher prices, schedule delays or the need to identify and develop alternative suppliers. In some instances, we may be unable to identify and develop alternative suppliers, incurring additional liabilities under our current contracts and hampering new ones. Our customers have experienced, and may continue to experience, disruptions in their operations and supply chains as a result of the COVID-19 pandemic, which can result in delayed, reduced, or canceled orders, or collection risks, and which may adversely affect our results of operations. Similarly, current, and future restrictions or disruptions of transportation, such as reduced availability of air transport, port closures or delays, and increased border controls, delays or closures, can also impact our ability to meet demand and could materially adversely affect us.

The spread of COVID-19 caused us to modify our business practices (including employee travel, employee work locations, cancellation of physical participation in meetings, events and conferences, and social distancing measures). To date, we have eased many of these modifications. However, we may in the future reinstitute the same or similar changes or take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers, partners, vendors, and suppliers. Although we managed to continue most of our operations, the future course of the COVID-19 pandemic is uncertain and we cannot assure that this global pandemic, including its economic impact, will not have a material adverse impact on our business, financial position, results of operations and/or cash flows.

Litigation

From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. It is our policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We re-evaluate and update accruals as matters progress over time.

23

On May 31, 2022, the Company filed a lawsuit against Culp McAuley, Inc. (“defendant”) in the United States District Court for the District of Kansas. The lawsuit arises from the defendant’s multiple breaches of its obligations to the Company. The Company seeks monetary damages and injunctive relief based on certain conduct by the defendant. On July 18, 2022, the defendant filed its Answer to the Company’s Verified Complaint and included Counterclaims alleging breach of contract and seeking monetary damages. On August 8, 2022, the Company filed its Reply and Affirmative Defenses to the Counterclaims by, among other things, denying the allegations and any and all liability. We have not concluded that a material loss related to the allegations is probable, nor have we accrued a liability related to these claims. Although we believe a loss could be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the potential damages given that the dispute is yet to enter the discovery process. We will continue to vigorously pursue these claims, and we continue to believe that we have valid grounds for recovery of the disputed deliverables. However, there can be no assurances as to the outcome of the dispute.

While the ultimate resolutions are unknown, based on the information currently available, we do not expect that this lawsuit will individually, or in the aggregate, have a material adverse effect to our results of operations, financial condition and cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

NOTE 13. STOCK-BASED COMPENSATION

The Company recorded pre-tax compensation expense related to the grant of stock options and restricted stock issued of $381,601 and $330,213 for the three months ended June 30, 2022 and 2021, and $776,350 and $656,378 for the six months ended June 30, 2022 and 2021, respectively.

As of June 30, 2022, the Company had adopted nine separate stock option and restricted stock plans: (i) the 2005 Stock Option and Restricted Stock Plan (the “2005 Plan”), (ii) the 2006 Stock Option and Restricted Stock Plan (the “2006 Plan”), (iii) the 2007 Stock Option and Restricted Stock Plan (the “2007 Plan”), (iv) the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), (v) the 2011 Stock Option and Restricted Stock Plan (the “2011 Plan”), (vi) the 2013 Stock Option and Restricted Stock Plan (the “2013 Plan”), (vii) the 2015 Stock Option and Restricted Stock Plan (the “2015 Plan”), (viii) the 2018 Stock Option and Restricted Stock Plan (the “2018 Plan”) and (ix) the 2020 Stock Option and Restricted Stock Plan (the “2020 Plan”). The 2005 Plan, 2006 Plan, 2007 Plan, 2008 Plan, 2011 Plan, 2013 Plan, 2015 Plan, 2018 Plan and 2020 Plan are referred to as the “Plans.”

These Plans permit the grant of stock options or restricted stock to the Company’s employees, non-employee directors and others for up to a total of 6,675,000 shares of common stock. The 2005 Plan terminated during 2015 with 21,553 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2005 Plan that remain unexercised and outstanding as of June 30, 2022 total 5,689. The 2006 Plan terminated during 2016 with 54,787 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2006 Plan that remain unexercised and outstanding as of June 30, 2022 total 10,625. The 2007 Plan terminated during 2017 with 94,651 shares not awarded or underlying options, which shares are now unavailable for issuance. There are no stock options granted under the 2007 Plan that remain unexercised and outstanding as of June 30, 2022. The 2008 Plan terminated during 2018 with 40,499 shares not awarded or underlying options, which shares are now unavailable for issuance. There were no stock options granted under the 2008 Plan that remain unexercised and outstanding as of June 30, 2022.

The Company believes that such awards better align the interests of our employees with those of its stockholders.

Stock option grants. The Board of Directors has granted stock options under the Plans. These option awards have been granted with an exercise price equal to the market price of the Company’s stock at the date of grant with such option awards generally vesting based on the completion of continuous service and having ten-year contractual terms. These option awards typically provide for accelerated vesting if there is a change in control (as defined in the Plans). The Company has registered all shares of common stock that are issuable under its Plans with the SEC. A total of 190,845 shares remained available for awards under the various Plans as of June 30, 2022.

24

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.

A summary of all stock option activity under the Plans for the six months ended June 30, 2022 is as follows:

SUMMARY OF STOCK OPTIONS OUTSTANDING

Options |  | Number of Shares |  |  | Weighted Average Exercise Price |
Outstanding at December 31, 2021 |  |  | 1,086,063 |  |  | $ | 2.37 |
Granted |  |  | 25,000 |  |  |  | 0.98 |
Exercised |  |  | — |  |  |  | — |
Forfeited |  |  | (23,750 | ) |  |  | (4.33 | )
Outstanding at June 30, 2022 |  |  | 1,087,313 |  |  | $ | 2.30 |
Exercisable at June 30, 2022 |  |  | 999,813 |  |  | $ | 2.36 |

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. The total estimated grant date fair value stock options issued during the six months ended June 30, 2022 was $22,768. Following are certain estimates and assumptions utilized as of the issuance date to determine the grant-date fair value of the stock options issued during 2022:

SCHEDULE OF FAIR VALUE OF STOCK OPTIONS ASSUMPTION

Volatility – range |  |  | 111.67 | %
Risk-free rate |  |  | 1.8 | %
Contractual term |  |  | 10.0 years |
Exercise price |  | $ | 0.98 |

The Plans allow for the cashless exercise of stock options. This provision allows the option holder to surrender/cancel options with an intrinsic value equivalent to the purchase/exercise price of other options exercised. There were no shares surrendered pursuant to cashless exercises during the six months ended June 30, 2022 and 2021.

The aggregate intrinsic value of options outstanding was $-0- and $-0-, at June 30, 2022 and December 31, 2021, respectively. The aggregate intrinsic value of options exercisable was $-0- and $-0-, at June 30, 2022 and December 31, 2021, respectively.

As of June 30, 2022, the unrecognized portion of stock compensation expense on all existing stock options was $-0-.

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s option plans as of June 30, 2022:

SCHEDULE OF SHARES AUTHORIZED UNDER STOCK OPTION PLANS BY EXERCISE PRICE RANGE

|  |  | Outstanding options |  | Exercisable options
Exercise price range |  |  | Number of options |  |  | Weighted average remaining contractual life |  | Number of options |  |  | Weighted average remaining contractual life
$ | 0.01 to $2.49 |  |  |  | 740,000 |  |  | 8.1 years |  |  | 652,500 |  |  | 8.0 years
$ | 2.50 to $3.49 |  |  |  | 310,313 |  |  | 5.8 years |  |  | 310,313 |  |  | 5.8 years
$ | 3.50 to $4.49 |  |  |  | 37,000 |  |  | 3.3 years |  |  | 37,000 |  |  | 3.3 years
|  |  |  |  | 1,087,313 |  |  | 7.3 years |  |  | 999,813 |  |  | 7.1 years

25

Restricted stock grants. The Board of Directors has granted restricted stock awards under the Plans. Restricted stock awards are valued on the date of grant and have no purchase price for the recipient. Restricted stock awards typically vest over one to five years corresponding to anniversaries of the grant date. Under the Plans, unvested shares of restricted stock awards may be forfeited upon the termination of service to or employment with the Company, depending upon the circumstances of termination. Except for restrictions placed on the transferability of restricted stock, holders of unvested restricted stock have full stockholder’s rights, including voting rights and the right to receive cash dividends.

A summary of all restricted stock activity under the Plans for the six months ended June 30, 2022 is as follows:

SUMMARY OF RESTRICTED STOCK ACTIVITY

|  | Number of Restricted shares |  |  | Weighted average grant date fair value |
Nonvested balance, December 31, 2021 |  |  | 1,057,375 |  |  | $ | 1.87 |
Granted |  |  | 715,000 |  |  |  | 1.07 |
Vested |  |  | (463,375 | ) |  |  | (1.89 | )
Forfeited |  |  | (65,000 | ) |  |  | (1.06 | )
Nonvested balance, June 30, 2022 |  |  | 1,244,000 |  |  | $ | 1.45 |

The Company estimated the fair market value of these restricted stock grants based on the closing market price on the date of grant. As of June 30, 2022, there were $880,299 of total unrecognized compensation costs related to all remaining non-vested restricted stock grants, which will be amortized over the next fifty-five months in accordance with their respective vesting scale.

The nonvested balance of restricted stock vests as follows:

SCHEDULE OF NON-VESTED BALANCE OF RESTRICTED STOCK

Years ended |  | Number of shares |
2022 (July 1, 2022 through December 31, 2022) |  |  | 119,500 |
2023 |  |  | 663,000 |
2024 |  |  | 279,000 |
2025 |  |  | 80,000 |
2026 |  |  | 72,500 |
2027 |  |  | 30,000 |

NOTE 14. COMMON STOCK PURCHASE WARRANTS

The Company has issued common stock purchase warrants in conjunction with various debt and equity issuances. The warrants are either immediately exercisable or have a delayed initial exercise date, no more than six months from their respective issue date and allow the holders to purchase up to 25,674,931 shares of common stock at $2.60 to $3.75 per share as of June 30, 2022. The warrants expire from August 21, 2022 through September 18, 2026 and under certain circumstances allow for cashless exercise.

On January 14, 2021 and February 1, 2021, the Company issued warrants to purchase a total of 42,550,000 shares of common stock. The warrants issued on January 14, 2021 consist of (i) pre-funded warrants to purchase up to 7,200,000 shares of common stock and (ii) common stock purchase warrants to purchase up to an aggregate of 10,000,000 shares of common stock. The warrants issued on February 1, 2021 consist of (i) pre-funded warrants to purchase up to 11,050,000 shares of common stock and (ii) common stock purchase warrants (“February Warrants”) to purchase up to an aggregate of 14,300,000 shares of common stock. The warrant terms provide for net cash settlement outside the control of the Company under certain circumstances in the event of tender offers. As such, the Company is required to treat these warrants as derivative liabilities which are valued at their estimated fair value at their issuance date and at each reporting date with any subsequent changes reported in the consolidated statements of operations as the change in fair value of warrant derivative liabilities. Furthermore, the Company re-values the fair value of warrant derivative liability as of the date the warrant is exercised with the resulting warrant derivative liability transitioned to change in fair value of warrant derivative liabilities through the consolidated statement of operations.

26

On August 19, 2021, the Company entered into a Warrant Exchange Agreement (the “Exchange Agreement”) with certain investors cancelling February Warrants exercisable for an aggregate of 7,681,540 shares of common stock in consideration for its issuance of new warrants (the “Exchange Warrants”) to such investors, exercisable for an aggregate of up to 7,681,540 shares of common stock. The Company also issued warrants (the “Replacement Original Warrants”) replacing the February Warrants for the remaining shares of common stock exercisable thereunder, representing an aggregate of 6,618,460 shares of common stock, and extended the expiration date of the February Warrants to September 18, 2026. The Exchange Warrants provide for an initial exercise price of $3.25 per share, subject to customary adjustments thereunder, and are immediately exercisable upon issuance for cash and on a cashless basis. On the date of the exchange, the Company calculated the fair value, using the Black-Scholes method, of the cancelled February Warrants and the newly issued Exchange Warrants, the difference in fair value measurement of the respective warrants was attributed to warrant modification expense in the consolidated statement of operations.

On the date of the exchange, the cancelled February Warrants and Exchange Warrants were valued at $11,818,644 and $12,114,424 using the original and modified expiry date of the warrants, respectively, using the Black-Scholes method. The difference of $295,780 was accordingly recorded as a warrant modification expense in the consolidated statement of operations during 2021.

SCHEDULE OF WARRANT MODIFICATION

|  | Original terms at August 19, 2021 |  |  | Modified terms at August 19, 2021 |
Volatility - range |  |  | 109.3 | % |  |  | 104.7 | %
Risk-free rate |  |  | 0.78 | % |  |  | 0.78 | %
Dividend |  |  | 0 | % |  |  | 0 | %
Remaining contractual term |  |  | 4.5 years |  |  |  | 5.1 years |
Exercise price |  | $ | 3.25 |  |  | $ | 3.25 |
Common stock issuable under the warrants |  |  | 14,300,000 |  |  |  | 14,300,000 |

Fluctuations in the Company’s stock price is a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in higher fair value measurement. A 10% change in pricing inputs and changes in volatilities and correlation factors would not result in a material change in our Level 3 fair value.

The Company has utilized the following assumptions in its Black-Scholes option valuation model to calculate the estimated fair value of the warrant derivative liabilities as of their date of issuance and as of June 30, 2022:

SCHEDULE OF FAIR VALUE OF THE WARRANT DERIVATIVE LIABILITIES

|  | Issuance date assumptions |  |  | June 30, 2022 assumptions |
Volatility - range |  |  | 106.6 – 166.6 | % |  |  | 104.7 | %
Risk-free rate |  |  | 0.08 - 0.49 | % |  |  | 3.01 | %
Dividend |  |  | 0 | % |  |  | 0 | %
Remaining contractual term |  |  | 0.01 - 5 years |  |  |  | 3.5 – 4.2 years |
Exercise price |  | $ | 2.80 - 3.25 |  |  | $ | 3.25 |
Common stock issuable under the warrants |  |  | 42,550,000 |  |  |  | 24,300,000 |

27

The following table summarizes information about shares issuable under warrants outstanding during the six months ended June 30, 2022:

SUMMARY OF WARRANT ACTIVITY

|  | Warrants |  |  | Weighted average exercise price |
Vested Balance, January 1, 2022 |  |  | 26,008,598 |  |  | $ | 3.24 |
Granted |  |  | — |  |  |  | — |
Exercised |  |  | — |  |  |  | — |
Forfeited/cancelled |  |  | (333,667 | ) |  |  | 3.51 |
Vested Balance, June 30, 2022 |  |  | 25,674,931 |  |  | $ | 3.24 |

The total intrinsic value of all outstanding warrants aggregated $-0- as of June 30, 2022, and the weighted average remaining term is 45 months.

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable warrants to purchase shares of common stock as of June 30, 2022:

SUMMARY OF RANGE OF EXERCISE PRICES AND WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF WARRANTS

|  |  |  |  | Outstanding and exercisable warrants |
| Exercise price |  |  |  | Number of warrants |  |  |  | Weighted average remaining contractual life |
$ | 2.60 |  |  |  | 465,712 |  |  |  | 1.1 years |
$ | 3.00 |  |  |  | 316,800 |  |  |  | 0.8 years |
$ | 3.25 |  |  |  | 24,300,000 |  |  |  | 3.9 years |
$ | 3.36 |  |  |  | 566,666 |  |  |  | 0.7 years |
$ | 3.75 |  |  |  | 25,753 |  |  |  | 0.1 years |
|  |  |  |  | 25,674,931 |  |  |  | 3.8 years |

NOTE 15. STOCKHOLDERS’ EQUITY

Cancellation of Restricted Stock

During the six months ended June 30, 2022, the Company cancelled 65,000 restricted shares of common stock due to forfeiture reasons.

Stock Repurchase Program

On December 6, 2021, the board of directors of the Company authorized the repurchase of up to $10.0 million of the Company’s outstanding common stock under the specified terms of a share repurchase program (the “Program”). During the three months ended June 30, 2022, the Company repurchased 1,849,952 shares of its common stock for $1,962,755, in accordance with the Program. Furthermore, during the six months ended June 30, 2022, the Company repurchased 3,725,986 shares of its common stock for $4,026,523, in accordance with the Program.

SCHEDULE OF STOCK REPURCHASE

Period |  | Total Number of Shares Purchased |  |  | Average Price Paid per Shares |  |  | Total Number of Shares Purchased as Part of Publicly Announced Program |  |  | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program |
December 2021 |  |  | 1,734,838 |  |  | $ | 1.14 |  |  |  | 1,734,838 |  |  |  | — |
January 2022 |  |  | 697,093 |  |  |  | 1.11 |  |  |  | 697,093 |  |  |  | — |
February 2022 |  |  | 692,984 |  |  |  | 1.12 |  |  |  | 692,984 |  |  |  | — |
March 2022 |  |  | 485,957 |  |  |  | 1.06 |  |  |  | 485,957 |  |  |  | — |
April 2022 |  |  | 595,476 |  |  |  | 1.14 |  |  |  | 595,476 |  |  |  | — |
May 2022 |  |  | 716,911 |  |  |  | 1.08 |  |  |  | 716,911 |  |  |  | — |
June 2022 |  |  | 537,565 |  |  |  | 0.96 |  |  |  | 537,565 |  |  |  | — |
Total all plans |  |  | 5,460,824 |  |  | $ | 1.10 |  |  |  | 5,460,824 |  |  | $ | 3,998,398 |

28

On June 30, 2022, the board of directors of the Company elected to terminate the Program, effective immediately. The Program began in December 2021, with the Company purchasing a total of 5,460,824 shares at a cost of $6,001,602 through June 30, 2022.

Noncontrolling Interests

The Company owns a 51% equity interest in its consolidated subsidiary, Nobility Healthcare. As a result, the noncontrolling shareholders or minority interest is allocated 49% of the income/loss of Nobility Healthcare which is reflected in the statement of (income) loss as “net (income) loss attributable to noncontrolling interests of consolidated subsidiary”. We reported net income attributable to noncontrolling interests of consolidated subsidiary of $383,326 and $-0- for the three months ended June 30, 2022 and 2021, and $285,232 and $-0- for the six months ended June 30, 2022 and 2021, respectively.

NOTE 16. NET EARNINGS (LOSS) PER SHARE

The calculation of the weighted average number of shares outstanding and loss per share outstanding for the three and six months ended June 30, 2022 and 2021 are as follows:

SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING AND LOSS PER SHARE OUTSTANDING

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Numerator for basic and diluted income per share – Net income (loss) attributable to common stockholders |  | $ | (1,065,513 | ) |  | $ | (5,382,487 | ) |  | $ | (7,665,662 | ) |  | $ | 16,339,371 |
Denominator for basic loss per share – weighted average shares outstanding |  |  | 48,657,440 |  |  |  | 51,513,691 |  |  |  | 49,787,562 |  |  |  | 48,177,399 |
Dilutive effect of shares issuable under stock options and warrants outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Denominator for diluted loss per share – adjusted weighted average shares outstanding |  |  | 48,657,440 |  |  |  | 51,513,691 |  |  |  | 49,787,562 |  |  |  | 48,177,399 |
Net loss per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.02 | ) |  | $ | (0.10 | ) |  | $ | (0.15 | ) |  | $ | 0.34 |
Diluted |  | $ | (0.02 | ) |  | $ | (0.10 | ) |  | $ | (0.15 | ) |  | $ | 0.34 |

Basic income (loss) per share is based upon the weighted average number of common shares outstanding during the period. For the three and six months ended June 30, 2022 and 2021, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options and warrants were antidilutive, and, therefore, not included in the computation of diluted income (loss) per share.

29

NOTE 17. DIGITAL ALLY HEALTHCARE VENTURE

On June 4, 2021, Digital Ally Healthcare, a wholly-owned subsidiary of the Company, entered into a venture with Nobility LLC (“Nobility”), an eight-year-old revenue cycle management (“RCM”) company servicing the medical industry, to form Nobility Healthcare, LLC (“Nobility Healthcare”). Digital Ally Healthcare is capitalizing the venture with $13.5 million to support the venture’s business strategy to make acquisitions of RCM companies. Digital Ally Healthcare owns 51% of the venture that entitles it to 51% of the distributable cash as defined in the venture’s operating agreement plus a cumulative preferred return of 10% per annum on its invested capital. Nobility will receive a management fee and 49% of the distributable cash, subordinated to Digital Ally Healthcare’s preferred return. The venture comprises the Company’s revenue cycle management segment.

On June 30, 2021, the Company’s revenue cycle management segment completed the acquisition of a private medical billing company (the “Healthcare Acquisition”). In accordance with the stock purchase agreement, the Company’s revenue cycle management segment agreed to a non-refundable initial payment (the “Initial Payment Amount”) of $850,000. In addition to the Initial Payment Amount, the Company’s revenue cycle management segment agreed to issue a promissory note to the stockholders of the Healthcare Acquisition in the principal amount of $350,000 that is subject to an earn-out adjustment. Management’s estimate of the fair value of this contingent promissory note at December 31, 2021 is $317,212. The gain associated with the adjustment in the estimated fair value of this contingent promissory note is recorded as a gain in the Consolidated Statements of Operations for the year ended December 31, 2021. Lastly, the Company’s revenue cycle management segment agreed to pay $162,552 representing the principal and accrued interest balance due under a promissory note issued to the selling shareholders prior to the acquisition closing date. The Company’s revenue cycle management segment anticipates the estimated fair value of the contingent promissory note to be paid in full and, therefore, the total aggregate purchase price was determined to be approximately $1,376,509. Total acquisition related costs aggregated $164,630, which was expensed as incurred. Subsequent to the acquisition date, the Company received further information regarding the purchased assets and assumed liabilities. As a result, the initial allocation of the purchase price was adjusted by increasing accounts receivable by $75,000 with a corresponding reduction of goodwill during the year ended December 31, 2021.

The Company accounts for business combinations using the acquisition method and that the Company has early adopted the amendments of Regulation S-X dated May 21, 2020 and has concluded that this acquisition was not significant. Accordingly, the presentation of the assets acquired, historical financial statements under Rule 3-05 and related pro forma information under Article 8 of Regulation S-X, respectively, are not required to be presented. Under the acquisition method, the purchase price of the Healthcare Acquisition has been allocated to the acquired tangible and identifiable intangible assets and assumed liabilities based on their estimated fair values at the time of the Healthcare Acquisition. This allocation involves a number of assumptions, estimates, and judgments that could materially affect the timing or amounts recognized in our financial statements. Our assumptions and estimates are based upon information obtained from the management of the Company’s revenue cycle management segment. The acquisition was structured as stock purchase, therefore the excess purchase price over the fair value of net tangible assets acquired was recorded as goodwill, which will not be amortized for income tax filing purposes. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date.

The purchase price of the Healthcare Acquisition was allocated to the tangible assets, and assumed liabilities based on their preliminary estimated fair values at the time of the Healthcare Acquisition. The Company retained the services of an independent valuation firm to determine the fair value of these identifiable intangible assets. The Company will continue to evaluate the fair value of the identified intangible assets. The preliminary and final estimated fair value of assets acquired, and liabilities assumed in the Healthcare Acquisition were as follows:

SCHEDULE OF PRELIMINARY FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ACQUISITION

|  | Purchase price allocation |
Description |  | Preliminary as allocated June 30, 2021 |  |  | Final as allocated June 30, 2022 |
Assets acquired: |  |  |  |  |  |  |  |
Tangible assets acquired, consisting of acquired cash, accounts receivable and right of use asset |  | $ | 174,351 |  |  | $ | 174,351 |
Intangible assets acquired – Client Agreements |  | $ | 174,351 |  |  | $ | 174,351 |
Intangible assets acquired – client agreements |  |  | — |  |  |  | 457,079 |
Goodwill |  |  | 1,125,000 |  |  |  | 667,921 |
Liabilities assumed consisting of a promissory note issued by the selling shareholders which was paid off at closing, net of lease liability assumed |  |  | 77,158 |  |  |  | 77,158 |
Liabilities assumed pursuant to stock purchase agreement |  |  | 77,158 |  |  |  | 77,158 |
Net assets acquired and liabilities assumed |  | $ | 1,376,509 |  |  | $ | 1,376,509 |
Consideration: |  |  |  |  |  |  |  |
Cash paid at Healthcare Acquisition date |  | $ | 1,026,509 |  |  | $ | 1,026,509 |
Contingent consideration earn-out agreement |  |  | 350,000 |  |  |  | 350,000 |
Total Healthcare Acquisition purchase price |  | $ | 1,376,509 |  |  | $ | 1,376,509 |

30

Definite-lived intangible assets consist of client agreements and are amortized on a straight-line basis over their ten-year estimated useful life. See Note 10. Goodwill and Other Intangible Assets.

For the period from the date of the Healthcare Acquisition to June 30, 2022, the Company adjusted its preliminary fair value estimates and estimated useful lives based upon information obtained through June 30, 2022, which resulted in adjustments to the preliminary allocation of the purchase price. These adjustments primarily related to estimated identifiable intangible asset fair values of client agreements and goodwill.

During the measurement period (which is the period required to obtain all necessary information that existed at the acquisition date, or to conclude that such information is unavailable, not to exceed one year), additional assets or liabilities may be recognized, or there could be changes to the amounts of assets or liabilities previously recognized on a preliminary basis, if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of these assets or liabilities as of that date. The change in fair value of the contingent consideration is more fully described in Note 3, “Debt Obligations”.

On August 31, 2021, the Company’s revenue cycle management segment completed the acquisition of another private medical billing company (the “Medical Billing Acquisition”). In accordance with the stock purchase agreement, Nobility Healthcare agreed to a non-refundable initial payment (the “Initial Payment Amount”) of $2,270,000. In addition to the Initial Payment Amount, the Company’s revenue cycle management segment agreed to issue a contingent promissory note to the stockholders of the Medical Billing Acquisition in the principal amount of $650,000 that is subject to an earn-out adjustment. The Company’s revenue cycle management segment anticipates the estimated fair value of the contingent promissory note to be paid in full, therefore, the total aggregate purchase price was determined to be approximately $2,920,000. Total acquisition related costs aggregated $5,602, which was expensed as incurred.

The Company accounts for business combinations using the acquisition method and that the Company has early adopted the amendments of Regulation S-X dated May 21, 2020 and has concluded that this acquisition was not significant. Accordingly, the presentation of the assets acquired, historical financial statements under Rule 3-05 and related pro forma information under Article 11 of Regulation S-X, respectively, are not required to be presented. Under the acquisition method, the purchase price of the Medical Billing Acquisition has been allocated to the acquired tangible and identifiable intangible assets and assumed liabilities based on their estimated fair values at the time of the Medical Billing Acquisition. This allocation involves a number of assumptions, estimates, and judgments that could materially affect the timing or amounts recognized in our financial statements. The acquisition was structured as stock purchase, therefore the excess purchase price over the fair value of net tangible assets acquired was recorded as goodwill, which will not be amortized for income tax filing purposes. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date.

The purchase price of the Medical Billing Acquisition was allocated to the tangible assets, and assumed liabilities based on their preliminary estimated fair values at the time of the Medical Billing Acquisition. The Company expects to retain the services of an independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on August 31, 2021. The preliminary estimated fair value of assets acquired, and liabilities assumed in the Medical Billing Acquisition were as follows:

SCHEDULE OF PRELIMINARY FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ACQUISITION

Description |  | Amount |
Assets acquired: |  |  |  |
Tangible assets acquired |  | $ | 401,547 |
Goodwill |  |  | 2,920,000 |
Liabilities assumed pursuant to stock purchase agreement |  |  | (401,547 | )
Total assets acquired and liabilities assumed |  | $ | 2,920,000 |
Consideration: |  |  |  |
Cash paid at acquisition date |  | $ | 2,270,000 |
Contingent consideration promissory note |  |  | 650,000 |
Total acquisition purchase price |  | $ | 2,920,000 |

31

During the measurement period (which is the period required to obtain all necessary information that existed at the acquisition date, or to conclude that such information is unavailable, not to exceed one year), additional assets or liabilities may be recognized, or there could be changes to the amounts of assets or liabilities previously recognized on a preliminary basis, if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of these assets or liabilities as of that date. The change in fair value of the contingent consideration is more fully described in Note 3, “Debt Obligations”.

On January 1, 2022, the Company’s revenue cycle management segment completed the acquisition of another private medical billing company (the “Medical Billing Acquisition”). In accordance with the stock purchase agreement, Nobility Healthcare agreed to a non-refundable initial payment (the “Initial Payment Amount”) of $1,153,626. In addition to the Initial Payment Amount, the Company’s revenue cycle management segment agreed to issue a contingent promissory note to the stockholders of the Medical Billing Acquisition in the principal amount of $750,000 that is subject to an earn-out adjustment. The Company’s revenue cycle management segment anticipates the estimated fair value of the contingent promissory note to be paid in full, therefore, the total aggregate purchase price was determined to be approximately $1,903,626. Total acquisition related costs aggregated $7,996, which was expensed as incurred.

The Company accounts for business combinations using the acquisition method and that the Company has early adopted the amendments of Regulation S-X dated May 21, 2020 and has concluded that this acquisition was not significant. Accordingly, the presentation of the assets acquired, historical financial statements under Rule 3-05 and related pro forma information under Article 11 of Regulation S-X, respectively, are not required to be presented. Under the acquisition method, the purchase price of the Medical Billing Acquisition has been allocated to the acquired tangible and identifiable intangible assets and assumed liabilities based on their estimated fair values at the time of the Medical Billing Acquisition. This allocation involves a number of assumptions, estimates, and judgments that could materially affect the timing or amounts recognized in our financial statements. The acquisition was structured as stock purchase, therefore the excess purchase price over the fair value of net tangible assets acquired was recorded as goodwill, which will not be amortized for income tax filing purposes. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date.

The purchase price of the Medical Billing Acquisition was allocated to the tangible assets, and assumed liabilities based on their preliminary estimated fair values at the time of the Medical Billing Acquisition. The Company expects to retain the services of an independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on January 1, 2022. The preliminary estimated fair value of assets acquired, and liabilities assumed in the Medical Billing Acquisition were as follows:

SCHEDULE OF PRELIMINARY FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ACQUISITION

Description |  | Amount |
Assets acquired: |  |  |  |
Tangible assets acquired |  | $ | 190,631 |
Goodwill |  |  | 2,100,000 |
Liabilities assumed pursuant to stock purchase agreement |  |  | (387,005 | )
Total assets acquired and liabilities assumed |  | $ | 1,903,626 |
Consideration: |  |  |  |
Cash paid at acquisition date |  | $ | 1,153,626 |
Contingent consideration promissory note |  |  | 750,000 |
Total acquisition purchase price |  | $ | 1,903,626 |

During the measurement period (which is the period required to obtain all necessary information that existed at the acquisition date, or to conclude that such information is unavailable, not to exceed one year), additional assets or liabilities may be recognized, or there could be changes to the amounts of assets or liabilities previously recognized on a preliminary basis, if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of these assets or liabilities as of that date. The change in fair value of the contingent consideration is more fully described in Note 3, “Debt Obligations”.

32

On February 1, 2022, the Company’s revenue cycle management segment completed an asset acquisition from another private medical billing company (the “Medical Billing Asset Acquisition”). In accordance with the asset purchase agreement, Nobility Healthcare agreed to a non-refundable initial payment (the “Initial Payment Amount”) of $230,000. In addition to the Initial Payment Amount, the Company’s revenue cycle management segment agreed to issue a contingent promissory note to the stockholders of the Medical Billing Asset Acquisition in the principal amount of $105,000 that is subject to an earn-out adjustment. The Company’s revenue cycle management segment anticipates the estimated fair value of the contingent promissory note to be paid in full, therefore, the total aggregate purchase price was determined to be approximately $335,000. Total acquisition related costs aggregated $10,322, which was expensed as incurred.

In accordance with ASC 805, “Business Combinations”, the acquisition method of accounting is used, and recognition of the assets acquired is at fair value as of the acquisition dates. All acquisition costs were expensed as incurred. The consideration paid has been allocated to the assets acquired based on their estimated fair values at the acquisition date. The estimate of fair values for the intangible assets acquired were agreed to by both buyer and seller. The estimated fair value of intangible assets acquired in the Medical Billing Asset Acquisition were as follows:

SCHEDULE OF PRELIMINARY FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ACQUISITION

Description |  | Amount |
Assets acquired: |  |  |  |
Intangible assets acquired – client agreements |  | $ | 335,000 |
Total assets acquired and liabilities assumed |  | $ | 335,000 |
Consideration: |  |  |  |
Cash paid at acquisition date |  | $ | 230,000 |
Contingent consideration promissory note |  |  | 105,000 |
Total acquisition purchase price |  | $ | 335,000 |

Definite-lived intangible assets consist of client agreements and are amortized on a straight-line basis over their ten-year estimated useful life. See Note 10. Goodwill and Other Intangible Assets.

The change in fair value of the contingent consideration is more fully described in Note 3, “Debt Obligations” and will be estimated on a quarterly basis.

NOTE 18. TICKETSMARTER ACQUISITION

On September 1, 2021, Digital Ally, Inc. formed TicketSmarter, Inc. (“TicketSmarter”), through which the Company completed the acquisition of Goody Tickets, LLC, a Kansas limited liability company (“Goody Tickets”) and TicketSmarter, LLC, a Kansas limited liability company (“TicketSmarter LLC”) (such acquisitions, collectively, the “TicketSmarter Acquisition”). TicketSmarter, Inc. comprises the Company’s ticketing business segment. In accordance with the stock purchase agreement, the Company agreed to an initial payment (the “Initial Payment Amount”) of $9,403,600 through a combination of cash and common stock. In addition to the Initial Payment Amount, the Company agreed to issue an earn-out agreement to the stockholders of Goody Tickets and TicketSmarter LLC in the contingent amount of $4,244,400 that is subject to an earn-out adjustment based on actual EBITDA achieved in 2021, of which the Company gave a fair value of $3,700,000 on the date of acquisition. However, following the completion of 2021, it was determined that the actual EBITDA threshold for any earn-out adjustment to be paid was not met. Thus, in accordance with U.S. GAAP, the fair value of the contingent earn-out is reduced to zero, and the associated gain related to this revaluation is recorded in our Consolidated Statements of Operations for the year ended December 31, 2021. Lastly, included in the agreement, the Company agreed to place $500,000 in escrow, subject to a working capital adjustment based on actual working capital amounts on the acquisition date as defined in the agreement. This amount was subject to disbursement 45 days following the close of the acquisition. The parties completed the working capital adjustment resulting in the Company retaining $297,726 of the escrow amount with the $202,274 released to the sellers. The total acquisition related costs aggregated $40,625, which was expensed as incurred.

33

The Company accounts for business combinations using the acquisition method and that the Company has early adopted the amendments of Regulation S-X dated May 21, 2020 and has concluded that this acquisition was not significant. Accordingly, the presentation of the assets acquired, historical financial statements under Rule 3-05 and related pro forma information under Article 11 of Regulation S-X, respectively, are not required to be presented. Under the acquisition method, the purchase price of the TicketSmarter Acquisition has been allocated to Goody Tickets’ and TicketSmarter LLC’s acquired tangible and identifiable intangible assets and assumed liabilities based on their estimated fair values at the time of the TicketSmarter Acquisition. This allocation involves a number of assumptions, estimates, and judgments that could materially affect the timing or amounts recognized in our financial statements. The TicketSmarter Acquisition was structured as a stock purchase; however the parties agreed to coordinate the election to invoke IRS Section 338(h)(10) relative to this transaction for tax purposes. Therefore, the excess purchase price over the fair value of net tangible assets acquired was recorded as goodwill, which will be amortized over 15 years for income tax filing purposes. Likewise, the other acquired assets were stepped up to fair value and is deductible for income tax purposes. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date.

The purchase price of the TicketSmarter Acquisition was allocated to Goody Tickets’ and TicketSmarter LLC’s tangible assets, goodwill, identifiable intangible assets, and assumed liabilities based on their preliminary estimated fair values at the time of the TicketSmarter Acquisition. The Company retained the services of an independent valuation firm to determine the fair value of these identifiable intangible assets. The Company will continue to evaluate the fair value of the identified intangible assets. The preliminary estimated fair value of assets acquired, and liabilities assumed in the TicketSmarter Acquisition were as follows:

SCHEDULE OF PRELIMINARY FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED ACQUISITION

|  | Preliminary purchase price allocation |
|  | As allocated |  |  | As allocated |
Description |  | September 30, 2021 |  |  | December 31, 2021 |
Assets acquired: |  |  |  |  |  |  |  |
Tangible assets acquired, including $51,432 of cash acquired |  | $ | 7,139,930 |  |  | $ | 5,748,291 |
Identifiable intangible assets acquired |  |  | — |  |  |  | 6,800,000 |
Goodwill |  |  | 11,839,308 |  |  |  | 5,886,547 |
Liabilities assumed |  |  | (5,128,964 | ) |  |  | (5,128,964 | )
Net assets acquired and liabilities assumed |  | $ | 13,850,274 |  |  | $ | 13,305,874 |
Consideration: |  |  |  |  |  |  |  |
Cash paid at TicketSmarter Acquisition date |  | $ | 8,413,240 |  |  | $ | 8,413,240 |
Common stock issued as consideration for TicketSmarter Acquisition at date of acquisition |  |  | 990,360 |  |  |  | 990,360 |
Contingent consideration earn-out agreement |  |  | 4,244,400 |  |  |  | 3,700,000 |
Cash paid at closing to escrow amount |  |  | 500,000 |  |  |  | 500,000 |
Cash retained from escrow amount pursuant to settlement of working capital target |  |  | (297,726 | ) |  |  | (297,726 | )
Total TicketSmarter Acquisition purchase price |  | $ | 13,850,274 |  |  | $ | 13,305,874 |

34

The following table sets forth the components of identifiable intangible assets acquired and their estimated useful lives in years as of the date of acquisition:

SCHEDULE OF COMPONENTS OF IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND ESTIMATED USEFUL LIVES

|  | Cost |  |  | Amortization through June 30, 2022 |  |  | Estimated useful life
Identifiable intangible assets: |  |  |  |  |  |  |  |  |  |
Trademarks |  | $ | 600,000 |  |  | $ | — |  |  | indefinite
Sponsorship agreement network |  |  | 5,600,000 |  |  |  | 933,333 |  |  | 5 years
Search engine optimization/content |  |  | 600,000 |  |  |  | 125,000 |  |  | 4 years
|  | $ | 6,800,000 |  |  | $ | 1,058,333 |  |  |

For the period from the date of the TicketSmarter Acquisition to December 31, 2021, the Company adjusted its preliminary fair value estimates and estimated useful lives based upon information obtained through December 31, 2021, which resulted in adjustments to the preliminary allocation of the purchase price. These adjustments primarily related to estimated identifiable intangible asset fair values (primarily related to the sponsorship agreement network), the estimated fair value of the contingent earn-out agreement liability and goodwill. There were no adjustments to the allocation of the purchase price during the three and six months ended June 30, 2022.

During the measurement period (which is the period required to obtain all necessary information that existed at the acquisition date, or to conclude that such information is unavailable, not to exceed one year), additional assets or liabilities may be recognized, or there could be changes to the amounts of assets or liabilities previously recognized on a preliminary basis, if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of these assets or liabilities as of that date. The change in fair value of the contingent consideration is more fully described in Note 3, “Debt Obligations”.

NOTE 19. SEGMENT DATA

The accounting guidance on Segment Reporting establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information of those segments to be presented in financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker (the Company’s Chief Executive Officer or “CODM”) in making decisions on how to allocate resources and assess performance. The Company’s three operating segments are Video Solutions, Revenue Cycle Management, and Ticketing, each of which has specific personnel responsible for that business and reports to the CODM. Corporate expenses capture the Company’s corporate administrative activities, and are also to be reported in the segment information. The Company’s captive insurance subsidiary provides services to the Company’s other business segments and not to outside customers. Therefore, its operations are eliminated in consolidation and it is not considered a separate business segment for financial reporting purposes.

The Video Solutions Segment encompasses our law, commercial, and shield divisions. This segment includes both service and product revenues through our subscription models offering cloud and warranty solutions, and hardware sales for video and health safety solutions. The Revenue Cycle Management Segment provides working capital and back-office services to a variety of healthcare organizations throughout the country, as a monthly service fee. The Ticketing Segment acts as an intermediary between ticket buyers and sellers within our secondary ticketing platform, ticketsmarter.com, and we also acquire tickets from primary sellers to then sell through various platforms.

The Company’s corporate administration activities are reported in the corporate line item. These activities primarily include expense related to certain corporate officers and support staff, certain accounting staff, expense related to the Company’s Board of Directors, stock option expense for options granted to corporate administration employees, certain consulting expenses, investor relations activities, and a portion of the Company’s legal, auditing and professional fee expenses. Corporate identifiable assets primarily consist of cash, invested cash (if any), refundable income taxes (if any), and deferred income taxes.

35

Summarized financial information for the Company’s reportable business segments is provided for the indicated periods and as of June 30, 2022, and June 30, 2021:

SCHEDULE OF SEGMENT REPORTING

|  | 2022 |  |  | 2021 |  |  |  | 1 |  |  |  | 2 |
|  | Three months ended June 30, |  |  | Six months ended June 30,
|  | 2022 |  |  | 2021 |  |  | 2022 |  | 2021
Net Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | 2,049,756 |  |  | $ | 2,493,671 |  |  | $ | 4,059,805 |  |  | $ | 5,029,501 |
Revenue Cycle Management |  |  | 2,120,738 |  |  |  | — |  |  |  | 4,024,695 |  |  |  | — |
Ticketing |  |  | 5,180,963 |  |  |  | — |  |  |  | 11,561,738 |  |  |  | — |
Total Net Revenues |  | $ | 9,351,457 |  |  | $ | 2,493,671 |  |  | $ | 19,646,238 |  |  | $ | 5,029,501 |
Gross Profit: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | 759,010 |  |  | $ | 1,260,800 |  |  | $ | 1,027,440 |  |  | $ | 2,072,683 |
Revenue Cycle Management |  |  | 957,263 |  |  |  | — |  |  |  | 1,654,432 |  |  |  | — |
Ticketing |  |  | 2,805 |  |  |  | — |  |  |  | 976,824 |  |  |  | — |
Total Gross Profit |  | $ | 1,719,078 |  |  | $ | 1,260,800 |  |  | $ | 3,658,696 |  |  | $ | 2,072,683 |
Operating Income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | (1,130,749 | ) |  | $ | (296,601 | ) |  | $ | (2,846,004 | ) |  | $ | (979,520 | )
Revenue Cycle Management |  |  | 247,301 |  |  |  | — |  |  |  | 118,783 |  |  |  | — |
Ticketing |  |  | (2,320,694 | ) |  |  | — |  |  |  | (3,766,541 | ) |  |  | — |
Corporate |  |  | (3,457,110 | ) |  |  | (2,320,283 | ) |  |  | (6,970,828 | ) |  |  | (4,503,058 | )
Total Operating Income (Loss) |  | $ | (6,661,252 | ) |  | $ | (2,616,884 | ) |  | $ | (13,464,590 | ) |  | $ | (5,482,578 | )
Depreciation and Amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | 209,442 |  |  | $ | 87,830 |  |  | $ | 385,516 |  |  | $ | 145,459 |
Revenue Cycle Management |  |  | 319,175 |  |  |  | — |  |  |  | 638,358 |  |  |  | — |
Ticketing |  |  | 218 |  |  |  | — |  |  |  | 364 |  |  |  | — |
Total Depreciation and Amortization |  | $ | 528,835 |  |  | $ | 87,830 |  |  | $ | 1,024,238 |  |  | $ | 145,459 |

|  | June 30, 2022 |  |  | December 31, 2021 |
Assets (net of eliminations): |  |  |  |  |  |  |  |
Video Solutions |  | $ | 35,219,240 |  |  | $ | 25,983,348 |
Revenue Cycle Management |  |  | 1,678,775 |  |  |  | 934,095 |
Ticketing |  |  | 10,097,319 |  |  |  | 12,260,780 |
Corporate |  |  | 23,733,487 |  |  |  | 43,810,974 |
Total Identifiable Assets |  | $ | 70,728,821 |  |  | $ | 82,989,197 |

The segments recorded noncash items affecting the gross profit and operating income (loss) through the established inventory reserves based on estimates of excess and/or obsolete current and non-current inventory. The Company recorded a reserve for excess and obsolete inventory in the video solutions segment of $3,272,831 and a reserve for the ticketing segment of $449,635.

The segment net revenues reported above represent sales to external customers. Segment gross profit represents net revenues less cost of revenues. Segment operating income, which is used in management’s evaluation of segment performance, represents net revenues, less cost of revenues, less all operating expenses. Identifiable assets are those assets used by each segment in its operations. Corporate assets primarily consist of cash, property, plant and equipment, accounts receivable, inventories, and other assets.

NOTE 20. RELATED PARTY TRANSACTIONS

Transactions with Managing Member of Nobility Healthcare

On January 27, 2022, the Board of Directors appointed Christian J. Hoffmann, III as a member of the Board, effective immediately. Mr. Hoffmann is a principal owner and manager of Nobility, LLC which is currently the managing member of our consolidated subsidiary Nobility Healthcare, LLC.

Nobility, LLC is currently the managing member of Nobility Healthcare, LLC. The Company has advanced a total of $158,384 in the form of a working capital loan to Nobility, LLC in order to fund capital expenditures necessary for the initial growth of the joint venture during 2021. The outstanding balance of the working capital loan was $138,384 as of June 30, 2022 and the Company anticipates full repayment of this advance during the year ended December 31, 2022. During the six months ended June 30, 2022, the Company paid distributions to the noncontrolling in consolidated subsidiary totaling $15,692.

On August 1, 2022, Mr. Hoffmann resigned as a member of the Board, effective immediately. He remains as a principal owner and manager of Nobility, LLC which is currently the managing member of our consolidated subsidiary Nobility Healthcare, LLC.

NOTE 21. SUBSEQUENT EVENTS

Notice of Delisting

On July 7, 2022, Digital Ally, Inc., a Nevada Corporation (the “Company”), received a written notification (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), because the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), was below $1.00 per share for the previous thirty (30) consecutive business days. The Notice has no immediate effect on the listing of the Common Stock, which will continue to trade uninterrupted on the Nasdaq Capital Market under the ticker “DGLY.”

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted 180 calendar days from the date of the Notice, or until January 3, 2023 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. If at any time during the Compliance Period, the bid price of the Common Stock closes at or above $1.00 per share for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company with written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed.

In the event the Company does not regain compliance with the Minimum Bid Price Requirement by January 3, 2023, the Company may be eligible for an additional 180-calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice to Nasdaq of its intent to regain compliance with such requirement during such second compliance period.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting from the Nasdaq Capital Market.

Resignation of a Member of Board of Directors

On August 1, 2022, Mr. Hoffmann resigned as a member of the Board, effective immediately. He remains as a principal owner and manager of Nobility, LLC which is currently the managing member of our consolidated subsidiary Nobility Healthcare, LLC.

*************************************

36

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation.

This quarterly report on Form 10-Q (the “Report”) of Digital Ally, Inc. (the “Company”, “we”, “us”, or “our”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “feel,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based largely on our expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond our control. Therefore, actual results could differ materially from the forward-looking statements contained in this document, and readers are cautioned not to place undue reliance on such forward-looking statements.

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. A variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this document will, in fact, transpire or prove to be accurate.

Factors that could cause or contribute to our actual results differing materially from those discussed herein or for our stock price to be adversely affected include, but are not limited to: (1) our losses in recent years, including during fiscal 2020 and 2019; (2) economic and other risks for our business from the effects of the COVID-19 pandemic, including the impacts on our law-enforcement and commercial customers, suppliers and employees and on our ability to raise capital as required; (3) our ability to increase revenues, increase our margins and return to consistent profitability in the current economic and competitive environment; (4) our operation in developing markets and uncertainty as to market acceptance of our technology and new products; (5) the availability of funding from federal, state and local governments to facilitate the budgets of law enforcement agencies, including the timing, amount and restrictions on such funding; (6) our ability to maintain or expand our share of the market for our products in the domestic and international markets in which we compete, including increasing our international revenues; (7) our ability to produce our products in a cost-effective manner; (8) competition from larger, more established companies with far greater economic and human resources; (9) our ability to attract and retain quality employees; (10) risks related to dealing with governmental entities as customers; (11) our expenditure of significant resources in anticipation of sales due to our lengthy sales cycle and the potential to receive no revenue in return; (12) characterization of our market by new products and rapid technological change; (13) our dependence on sales of our EVO-HD, DVM-800, DVM-250 and FirstVU products; (14) that stockholders may lose all or part of their investment if we are unable to compete in our markets and return to profitability; (15) defects in our products that could impair our ability to sell our products or could result in litigation and other significant costs; (16) our dependence on a few manufacturers and suppliers for components of our products and our dependence on domestic and foreign manufacturers for certain of our products; (17) our ability to protect technology through patents and to protect our proprietary technology and information, such as trade secrets, through other similar means; (18) our ability to generate more recurring cloud and service revenues; (19) risks related to our license arrangements; (20) the fluctuation of our operation results from quarter to quarter; (21) sufficient voting power by coalitions of a few of our larger stockholders, including directors and officers, to make corporate governance decisions that could have a significant effect on us and the other stockholders; (22) the issuance or sale of substantial amounts of our common stock, or the perception that such sales may occur in the future, which may have a depressive effect on the market price of our securities; (23) potential dilution from the issuance of common stock underlying outstanding options and warrants; (24) our additional securities available for issuance, which, if issued, could adversely affect the rights of the holders of our common stock; (25) the volatility of our stock price due to a number of factors, including, but not limited to, a relatively limited public float; (26) our ability to integrate and realize the anticipated benefits from acquisitions; (27) our ability to maintain the listing of our common stock on the Nasdaq Capital Market.

37

Current Trends and Recent Developments for the Company

Segment Overview

Video Solutions Operating Segment – Within our video solutions operating segment we supply technology-based products utilizing our portable digital video and audio recording capabilities for the law enforcement and security industries and for the commercial fleet and mass transit markets. We have the ability to integrate electronic, radio, computer, mechanical, and multi-media technologies to create positive solutions to our customers’ requests. Our products include: the EVO-HD, DVM-800 and DVM-800 Lite, which are in-car digital video systems for law enforcement and commercial markets; the FirstVu body-worn camera line, consisting of the FirstVu Pro, FirstVu II, and the FirstVu HD; our patented and revolutionary VuLink product which integrates our body-worn cameras with our in-car systems by providing hands-free automatic activation for both law enforcement and commercial markets; the FLT-250, DVM-250, and DVM-250 Plus, which are our commercial line of digital video mirrors that serve as “event recorders” for the commercial fleet and mass transit markets; and FleetVu and VuLink, which are our cloud-based evidence management systems. We further diversified and broadened our product offerings in 2020, by introducing two new lines of branded products: (1) the ThermoVu® which is a line of self-contained temperature monitoring stations that provides alerts and controls facility access when an individual’s temperature exceeds a pre-set threshold and (2) our Shield™ disinfectants and cleansers which are for use against viruses and bacteria.

Our video solutions segment revenue encompasses video recording products and services for our law enforcement and commercial customers and the sale of Shield disinfectant and personal protective products. This segment generates revenues through our subscription models offering cloud and warranty solutions, and hardware sales for video and personal protective safety products and solutions. Revenues for product sales are recognized upon delivery of the product, and revenues from our cloud and warranty subscription plans are deferred over the term of the subscription, typically 3 or 5 years.

Revenue Cycle Management Operating Segment - We have recently entered the revenue cycle management business late in the second quarter of 2021 with the formation of our wholly owned subsidiary, Digital Ally Healthcare, Inc. and its majority-owned subsidiary Nobility Healthcare. Nobility Healthcare completed its first acquisition on June 30, 2021, when it acquired a private medical billing company, and a second acquisition on August 31, 2021 upon the completion of its acquisition of another private medical billing company, along with two more acquisitions completed during the three months ended March 31, 2022, in which we assist in providing working capital and back-office services to healthcare organizations throughout the country. Our assistance consists of insurance and benefit verification, medical treatment documentation and coding, and collections. Through our expertise and experience in this field, we aim to maximize our customers’ service revenues collected, leading to substantial improvements in their operating margins and cash flows.

Our revenue cycle management segment consists of our medical billing subsidiaries. Revenues of this segment are recognized after we perform the obligations of our revenue cycle management services. Our revenue cycle management services are services, performed and charged monthly, generally based on a contractual percentage of total customer collections, for which we recognize our net service fees.

38

Ticketing Operating Segment - We have also recently entered into live entertainment and events ticketing services through the formation of our wholly owned subsidiary, TicketSmarter and its completed acquisitions of Goody Tickets, LLC and TicketSmarter, LLC, on September 1, 2021. TicketSmarter provides ticket sales, partnerships, and mainly, ticket resale services through its online ticketing marketplace for live events, TicketSmarter.com. TicketSmarter offers tickets for over 125,000 live events through its platform, for a wide range of events, including concerts, sporting events, theatres, and performing arts, throughout the country.

Our ticketing operating segment consists of ticketing services provided through TicketSmarter and its online platform, TicketSmarter.com. Revenues of this segment include ticketing service charges generally determined as a percentage of the face value of the underlying ticket and ticket sales from our ticket inventory which are recognized when the underlying tickets are sold. Ticketing direct expenses include the cost of tickets purchased for resale by the Company and held as inventory, credit card fees, ticketing platform expenses, website maintenance fees, along with other administrative costs.

Results of Operations

Summarized financial information for the Company’s reportable business segments is provided for the indicated periods and as of June 30, 2022, and June 30, 2021:

|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | 2,049,756 |  |  | $ | 2,493,671 |  |  | $ | 4,059,805 |  |  | $ | 5,029,501 |
Revenue Cycle Management |  |  | 2,120,738 |  |  |  | — |  |  |  | 4,024,695 |  |  |  | — |
Ticketing |  |  | 5,180,963 |  |  |  | — |  |  |  | 11,561,738 |  |  |  | — |
Total Net Revenues |  | $ | 9,351,457 |  |  | $ | 2,493,671 |  |  | $ | 19,646,238 |  |  | $ | 5,029,501 |
Gross Profit: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | 759,010 |  |  | $ | 1,260,800 |  |  | $ | 1,027,440 |  |  | $ | 2,072,683 |
Revenue Cycle Management |  |  | 957,263 |  |  |  | — |  |  |  | 1,654,432 |  |  |  | — |
Ticketing |  |  | 2,805 |  |  |  | — |  |  |  | 976,824 |  |  |  | — |
Total Gross Profit |  | $ | 1,719,078 |  |  | $ | 1,260,800 |  |  | $ | 3,658,696 |  |  | $ | 2,072,683 |
Operating Income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | (1,130,749 | ) |  | $ | (296,601 | ) |  | $ | (2,846,004 | ) |  | $ | (979,520 | )
Revenue Cycle Management |  |  | 247,301 |  |  |  | — |  |  |  | 118,783 |  |  |  | — |
Ticketing |  |  | (2,320,694 | ) |  |  | — |  |  |  | (3,766,541 | ) |  |  | — |
Corporate |  |  | (3,457,110 | ) |  |  | (2,320,283 | ) |  |  | (6,970,828 | ) |  |  | (4,503,058 | )
Total Operating Income (Loss) |  | $ | (6,661,252 | ) |  | $ | (2,616,884 | ) |  | $ | (13,464,590 | ) |  | $ | (5,482,578 | )
Depreciation and Amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Video Solutions |  | $ | 209,442 |  |  | $ | 87,830 |  |  | $ | 385,516 |  |  | $ | 145,459 |
Revenue Cycle Management |  |  | 319,175 |  |  |  | — |  |  |  | 638,358 |  |  |  | — |
Ticketing |  |  | 218 |  |  |  | — |  |  |  | 364 |  |  |  | — |
Total Depreciation and Amortization |  | $ | 528,835 |  |  | $ | 87,830 |  |  | $ | 1,024,238 |  |  | $ | 145,459 |

|  | June 30, 2022 |  |  | December 31, 2021 |
Assets (net of eliminations): |  |  |  |  |  |  |  |
Video Solutions |  | $ | 35,219,240 |  |  | $ | 25,983,348 |
Revenue Cycle Management |  |  | 1,678,775 |  |  |  | 934,095 |
Ticketing |  |  | 10,097,319 |  |  |  | 12,260,780 |
Corporate |  |  | 23,733,487 |  |  |  | 43,810,974 |
Total Identifiable Assets |  | $ | 70,728,821 |  |  | $ | 82,989,197 |

39

Segment net revenues reported above represent only sales to external customers. Segment gross profit represents net revenues less cost of revenues. Segment operating income (loss), which is used in management’s evaluation of segment performance, represents net revenues, less cost of revenues, less all operating expenses. Identifiable assets are those assets used by each segment in its operations. Corporate assets primarily consist of cash, property, plant and equipment, accounts receivable, inventories, and other assets.

Consolidated Results of Operations

We experienced operating losses for the first half of 2022 and all quarters during 2021. The following is a summary of our recent operating results on a quarterly basis:

|  | For the Three Months Ended: |
|  | June 30, 2022 |  |  | March 31, 2022 |  |  | December 31, 2021 |  |  | September 30, 2021 |  |  | June 30, 2021 |
Total revenue |  | $ | 9,351,457 |  |  | $ | 10,294,781 |  |  | $ | 11,744,112 |  |  | $ | 4,639,822 |  |  | $ | 2,493,671 |
Gross profit |  |  | 1,719,078 |  |  |  | 1,939,619 |  |  |  | 2,190,523 |  |  |  | 1,400,570 |  |  |  | 1,260,800 |
Gross profit margin % |  |  | 18.4 | % |  |  | 18.8 | % |  |  | 18.7 | % |  |  | 30.2 | % |  |  | 50.6 | %
Total selling, general and administrative expenses |  |  | 8,380,330 |  |  |  | 8,742,957 |  |  |  | 7,869,883 |  |  |  | 4,999,543 |  |  |  | 3,877,684 |
Operating income (loss) |  |  | (6,661,252 | ) |  |  | (6,803,338 | ) |  |  | (5,679,360 | ) |  |  | (3,598,973 | ) |  |  | (2,616,884 | )
Operating income (loss) % |  |  | (71.2 | )% |  |  | (66.1 | )% |  |  | (48.4 | )% |  |  | (77.6 | )% |  |  | (104.9 | )%
Net income (loss) attributable to common stockholders |  | $ | (1,065,513 | ) |  | $ | (6,698,242 | ) |  | $ | 1,122,791 |  |  | $ | 8,068,799 |  |  | $ | (5,382,487 | )

Our business is subject to substantial fluctuations on a quarterly basis as reflected in the significant variations in revenues and operating results in the above table. These variations result from various factors, including but not limited to: (1) the timing of large individual orders; (2) the traction gained by products, such as the recently released FirstVu Pro, FirstVu II, FLT-250, EVO HD, the ThermoVu™ and the Shield™ lines; (3) production, quality and other supply chain issues affecting our cost of goods sold; (4) unusual increases in operating expenses, such as the timing of trade shows and stock-based and bonus compensation; (5) the timing of patent infringement litigation settlements (6) ongoing patent and other litigation and related expenses respecting outstanding lawsuits; (7) the impact of COVID-19 on the economy and our businesses; and (8) the completion of corporate acquisitions. We reported a net loss of $1,065,513 on revenues of $9,351,457 for the second quarter 2022.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet debt, nor did we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that may have a material current or future effect on financial conditions, changes in the financial conditions, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenue or expenses other than the following:

We are a party to operating leases and license agreements that represent commitments for future payments (described in Note 9, “Operating Leases,” to our condensed consolidated financial statements) and we have issued purchase orders in the ordinary course of business that represent commitments to future payments for goods and services.

40

For the Three Months Ended June 30, 2022 and 2021

Results of Operations

Summarized immediately below and discussed in more detail in the subsequent subsections is an analysis of our operating results for the three months ended June 30, 2022 and 2021, represented as a percentage of total revenues for each such quarter:

|  | Three Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Revenue |  |  | 100 | % |  |  | 100 | %
Cost of revenue |  |  | 82 | % |  |  | 49 | %
Gross profit |  |  | 18 | % |  |  | 51 | %
Selling, general and administrative expenses: |  |  |  |  |  |  |  |
Research and development expense |  |  | 6 | % |  |  | 18 | %
Selling, advertising and promotional expense |  |  | 30 | % |  |  | 35 | %
General and administrative expense |  |  | 54 | % |  |  | 102 | %
Total selling, general and administrative expenses |  |  | 90 | % |  |  | 156 | %
Operating loss |  |  | (71 | )% |  |  | (105 | )%
Change in fair value of short-term investments |  |  | — | % |  |  | — | %
Change in fair value of contingent consideration promissory notes |  |  | 6 | % |  |  | — | %
Change in fair value of derivative liabilities |  |  | 58 | % |  |  | (115 | )%
Other income and interest income (expense), net |  |  | — | % |  |  | 4 | %
Income (loss) before income tax benefit |  |  | (7 | )% |  |  | (216 | )%
Income tax (provision) |  |  | — | % |  |  | — | %
Net income/(loss) |  |  | (7 | )% |  |  | (216 | )%
Net loss attributable to noncontrolling interests of consolidated subsidiary |  |  | (4 | )% |  |  | — | %
Net income (loss) attributable to common stockholders |  |  | (11 | )% |  |  | (216 | )%
Net income/(loss) per share information: |  |  |  |  |  |  |  |
Basic |  | $ | (0.02 | ) |  | $ | (0.10 | )
Diluted |  | $ | (0.02 | ) |  | $ | (0.10 | )

Revenues

Revenues by Type and by Operating Segment

Our operating segments generate two types of revenues:

Product revenues primarily include video operating segment hardware sales of in-car and body-worn cameras, along with sales of our ThermoVuTM units, disinfectants, and personal protective equipment. Additionally, product revenues also include the sale of tickets by our ticketing operating segment that have been purchased or received through our sponsorships and partnerships and held in inventory by our ticketing segment until their sale.

41

Service and other revenues consist of cloud and warranty services revenues from our subscription plan and storage offerings of our video solutions segment. Our ticketing operating segments’ secondary ticketing marketplace revenues are included in service revenue. We recognize service revenue from sales generated through its secondary ticketing marketplace as we collect net services fees on secondary ticketing marketplace transactions. Lastly, our revenue cycle management segment revenues are included in the service revenues for services provided to medical providers throughout the country.

Our video operating segment sells our products and services to customers in the following manner:

| ● | Sales to domestic customers are made directly to the end customer (typically a law enforcement agency or a commercial customer) through our sales force, comprised of our employees. Revenue is recorded when the product is shipped to the end customer.
| ● | Sales to international customers are made through independent distributors who purchase products from us at a wholesale price and sell to the end user (typically law enforcement agencies or a commercial customer) at a retail price. The distributor retains the margin as its compensation for its role in the transaction. The distributor generally maintains product inventory, customer receivables and all related risks and rewards of ownership. Revenue is recorded when the product is shipped to the distributor consistent with the terms of the distribution agreement.
| ● | Repair parts and services for domestic and international customers are generally handled by our inside customer service employees. Revenue is recognized upon shipment of the repair parts and acceptance of the service or materials by the end customer.

Our revenue cycle management operating segment sells its services to customers in the following manner:

| ● | Our revenue cycle management operating segment generates service revenues through relationships with medium to large healthcare organizations, in which the underlying service revenue is recognized upon execution of services. Service revenues are generally determined as a percentage of the amount of medical billings collected by the customer.

Our ticketing operating segment sells our products and services to customers in the following manner:

| ● | Our ticketing operating segment generates product revenues from the sale of tickets directly to consumers for a particular event that the ticketing operating segment has previously purchased and held in inventory for ultimate resale to the end consumer. Service sales through TicketSmarter are driven largely in part by the usage of the TicketSmarter.com marketplace by buyers and sellers, in which the Company collects service fees for each transaction completed through this platform.

We may discount our prices on specific orders based upon the size of the order, the specific customer and the competitive landscape.

The Omicron variant of COVID-19 and nationwide inflationary concerns had an impact on all of our operating segment revenue streams for the three months ended June 30, 2022. In particular, it had a negative impact generally on our video solutions operating segment legacy products and, specifically, our commercial event recorder hardware (DVM-250 Plus) and in-car hardware for law enforcement (DVM-800) during the quarter. Ticketing operating segment revenues also continue to be negatively impacted due to the continued public caution surrounding the COVID-19 pandemic and the impacts of inflation on consumer’s discretionary spending.

42

Product revenues by operating segment is as follows:

|  | Three Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Product Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 1,404,242 |  |  | $ | 1,719,332 |
Revenue Cycle Management |  |  | — |  |  |  | — |
Ticketing |  |  | 805,939 |  |  |  | — |
Total Product Revenues |  | $ | 2,210,181 |  |  | $ | 1,719,332 |

Product revenues for the three months ended June 30, 2022 and 2021 were $2,210,181 and $1,719,332 respectively, an increase of $490,849 (29%), due to the following factors:

| ● | Revenues generated by the new ticketing operating segment began with the Company’s September 2021 acquisition of TicketSmarter. The new ticketing operating segment generated $805,939 in product revenues for the three months ended June 30, 2022, compared to $-0- for the three months ended June 30, 2021. This product revenue relates to the resale of tickets purchased for live events, including sporting events, concerts, and theatre, then sold through various platforms to customers.

| ● | The Company’s video segment operating segment generated revenues totaling $1,404,242 during the three months ended June 30, 2022 compared to $1,719,332 for the three months ended June 30, 2021 due to slowing sales of our ThermoVuTM product lines related to our COVID-19 response. The Company launched two product lines in direct response to the increased safety precautions that organizations and individuals are taking due to the COVID-19 pandemic. ThermoVu™ was launched as a non-contact temperature-screening instrument that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined parameters. ThermoVu™ has optional features such as facial recognition to improve facility security by restricting access based on temperature and/or facial recognition reasons. ThermoVu™ provides an instant pass/fail audible tone with its temperature display and controls access to facilities based on such results. ThermoVuTM has been applied in schools, dental offices, hospitals, office buildings, and other public venues. The Company also launched its Shield™ disinfectant/sanitizer product lines to fulfill demand by current customers and others for a disinfectant and sanitizer that is less harsh than many of the traditional products now widely distributed. The Shield™ Cleanser product line contains a cleanser with no harsh chemicals or fumes. The Company is beginning to experience decreased demand for these product lines as the COVID-19 pandemic begins to subside.
| ● | In general, our video solutions operating segment has experienced decreased demand on its product revenues due to price-cutting and competitive actions by our competitors, adverse marketplace effects related to our patent litigation proceedings and our recent financial condition. We introduced our new body-worn cameras, the FirstVu Pro and FirstVu II, in the fourth quarter of 2021, and we have begun to see increased traction with these products in the first and second quarters of 2022. The Company hopes the interest throughout the marketplace continues to grow for these new products as the market is able to review and test these new products.
| ● | Our video solutions operating segment management has been focusing on migrating customers, and in particular commercial customers, from a hardware sale to a service fee model. Therefore, we expect a reduction in commercial hardware sales (principally DVM-250’s, FLT-250’s, and our body-worn camera line) as we convert these customers to a service model under which we provide the hardware as part of a recurring monthly service fee. In that respect, we introduced a monthly subscription agreement plan for our body worn cameras and related equipment during the second quarter of 2020 that allowed law enforcement agencies to pay a monthly service fee to obtain body worn cameras without incurring a significant upfront capital outlay. This program has continued to gain traction, resulting in decreased product revenues and increased service revenues. We expect this program to continue to gain momentum, resulting in recurring revenues over a span of three to five years.

Service and other revenues by operating segment is as follows:

|  | Three Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Service and Other Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 645,514 |  |  | $ | 774,339 |
Revenue Cycle Management |  |  | 2,120,738 |  |  |  | — |
Ticketing |  |  | 4,375,024 |  |  |  | — |
Total Service and Other Revenues |  | $ | 7,141,276 |  |  | $ | 774,339 |

Service and other revenues for the three months ended June 30, 2022 and 2021 were $7,141,276 and $774,339, respectively, an increase of $6,366,937 (822%), due to the following factors:

| ● | Cloud revenues generated by the video solutions operating segment were $365,599 and $247,085 for the three months ended June 30, 2022 and 2021, respectively, an increase of $118,514 (48%). We have experienced increased interest in our cloud solutions for law enforcement primarily due to the deployment of our cloud-based EVO-HD in-car system and our next generation body-worn camera products, which contributed to our increased cloud revenues in the three months ended June 30, 2022. We expect this trend to continue throughout 2022 as the migration from local storage to cloud storage continues in our customer base.

43

| ● | Video solutions operating segment revenues from extended warranty services were $163,639 and $232,614 for the three months ended June 30, 2022 and 2021, respectively, a decrease of $68,975 (30%). However, the continued effects from the COVID-19 pandemic have adversely affected our sales of DVM-800 hardware systems resulting in a decrease in their sales in the three months ended June 30, 2022 compared to the same period in 2021.
| ● | Our new ticketing operating segment generated service revenues totaling $4,375,024 and $-0- for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,375,024 (100%). The Company completed the acquisitions of Goody Tickets, LLC and TicketSmarter, LLC on September 1, 2021, thus resulting in the new revenue stream for the Company. TicketSmarter collects fees on transactions administered through the TicketSmarter.com platform for the buying and selling of tickets for live events throughout the country. We expect our ticketing operating segment to continue to present a strong revenue outlook moving forward.
| ● | Our new revenue cycle management operating segment generated service revenues totaling $2,120,739 and $-0- for the three months ended June 30, 2022 and 2021, respectively, an increase of $2,120,739 (100%). Our revenue cycle management operating segment has completed four acquisitions since formation in June of 2021, thus resulting in the new service revenue stream added in the three months ended June 30, 2022. Our revenue cycle management operating segment provides revenue cycle management solutions and back-office services to healthcare organizations throughout the country. We expect our revenue cycle management segment to continue to present a strong revenue outlook moving forward.

Total revenues for the three months ended June 30, 2022 and 2021 were $9,351,458 and $2,493,671, respectively, an increase of $6,857,786 (275%), due to the reasons noted above.

Cost of Product Revenue

Overall cost of product revenue sold for the three months ended June 30, 2022, and 2021 was $2,070,476 and $1,017,659, respectively, an increase of $1,052,817 (103%). Overall cost of goods sold for products as a percentage of product revenues for the three months ended June 30, 2022, and 2021 were 93.7% and 59.2%, respectively. Cost of products sold by operating segment is as follows:

|  | Three Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Cost of Product Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 1,029,403 |  |  | $ | 1,017,659 |
Revenue Cycle Management |  |  | — |  |  |  | — |
Ticketing |  |  | 1,041,073 |  |  |  | — |
Total Cost of Product Revenues |  | $ | 2,070,476 |  |  | $ | 1,017,659 |

The decrease in cost of goods sold for our video solutions segment products is directly correlated with the decrease in product sales for the three months ended June 30, 2022 compared to the three months ended June 30, 2021. In addition, the video solutions segment recorded valuation allowances for its older product lines and a portion of its Shield products during the second quarter of 2022, directly increasing cost of goods sold for the period. Cost of product sold as a percentage of product revenues for the video solutions segment increased to 73.3% for the three months ended June 30, 2022 as compared to 59.2% for the three months ended June 30, 2021.

The increase in ticketing operating segment cost of product sold is due to the acquisition of TicketSmarter in the third quarter of 2021, resulting in an increase to cost of product revenue of $1,041,073 for the three months ended June 30, 2022, compared to $-0- for the three months ended June 30, 2021. Cost of product sold as a percentage of product revenues for the ticketing solutions was 129.2% for the three months ended June 30, 2022. The Ticketing Segment recorded an allowance for unsold and under-market tickets during the first quarter of 2022 due to event cancellations and restrictions imposed on the size and type of gatherings related to the Omicron variant.

44

We recorded $3,722,467 and $3,915,089 in reserves for obsolete and excess inventories at June 30, 2022 and December 31, 2021, respectively. Total raw materials and component parts were $4,083,713 and $3,062,046 at June 30, 2022 and December 31, 2021, respectively, an increase of $1,021,667 (33%). Finished goods balances were $9,044,555 and $10,512,577 at June 30, 2022 and December 31, 2021, respectively, a decrease of $1,468,022 (14%) which was attributable to a decrease in finished goods from our newly acquired ticketing segment. The small decrease in the inventory reserve is primarily due to the reduction in finished goods and movement of excess inventory. We believe the reserves are appropriate given our inventory levels as of June 30, 2022.

Cost of Service Revenue

Overall cost of service revenue sold for the three months ended June 30, 2022, and 2021 was $5,561,903 and $215,212, respectively, an increase of $5,346,691 (2,484%). Overall cost of goods sold for services as a percentage of service revenues for the three months ended June 30, 2022, and 2021 were 77.9% and 27.8%, respectively. Cost of service revenues by operating segment is as follows:

|  | Three Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Cost of Service Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 261,363 |  |  | $ | 215,212 |
Revenue Cycle Management |  |  | 1,163,476 |  |  |  | — |
Ticketing |  |  | 4,137,084 |  |  |  | — |
Total Cost of Service Revenues |  | $ | 5,561,903 |  |  | $ | 215,212 |

The increase in cost of service revenues for our video solutions segment is commensurate with the increase in service revenues in the three months ended June 30, 2022 compared to the three months ended June 30, 2021. Cost of service revenues as a percentage of service revenues for the video solutions segment increased to 40.5% for the three months ended June 30, 2022 as compared to 27.8% for the three months ended June 30, 2021.

The increase in revenue cycle management operating segment cost of service revenue is due to the four acquisitions of medical billing companies completed since June 2021. Cost of service revenues as a percentage of service revenues for the revenue cycle management operating segment was 54.9% for the three months ended June 30, 2022.

The increase in ticketing operating segment cost of service revenues is due to the 2021 acquisition of TicketSmarter, resulting in an increase to cost of service revenue of $4,137,084 for the three months ended June 30, 2022, compared to $-0- for the three months ended June 30, 2021. Cost of service revenues as a percentage of service revenues for the ticketing segment was 94.6% for the three months ended June 30, 2022.

Gross Profit

Overall gross profit for the three months ended June 30, 2022 and 2021 was $1,719,078 and $1,260,800, respectively, an increase of $458,278 (36.3%). Gross profit by operating segment was as follows:

|  |  | Three Months Ended June 30, |
|  |  | 2022 |  |  |  | 2021 |
Gross Profit: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 759,010 |  |  | $ | 1,260,800 |
Revenue Cycle Management |  |  | 957,263 |  |  |  | — |
Ticketing |  |  | 2,805 |  |  |  | — |
Total Gross Profit |  | $ | 1,719,078 |  |  | $ | 1,260,800 |

The overall increase is attributable to the large overall increase in revenues for the three months ended June 30, 2022 and an increase in the overall cost of sales as a percentage of overall revenues to 81.6% for the three months ended June 30, 2022 from 49.4% for the three months ended June 30, 2021. Our goal is to improve our margins over the longer term based on the expected margins generated by our new recent revenue cycle management and ticketing operating segments together with our video solutions operating segment and its expected margins from our EVO-HD, DVM-800, VuLink, FirstVu Pro, FirstVu II, FirstVu HD, ThermoVuTM, ShieldTM disinfectants and our cloud evidence storage and management offering, provided that they gain traction in the marketplace and subject to a normalizing economy in the wake of the COVID-19 pandemic and current inflationary concerns. In addition, if revenues from the video solutions segment increase, we will seek to further improve our margins from this segment through expansion and increased efficiency utilizing fixed manufacturing overhead components. We plan to continue our initiative to more efficient management of our supply chain through outsourcing production, quantity purchases and more effective purchasing practices.

45

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $8,380,330 and $3,877,684 for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,502,646 (116.1%). The increase was primarily attributable to the recent acquisitions completed in the third quarter of 2021. Our selling, general and administrative expenses as a percentage of sales decreased to 90% for the three months ended June 30, 2022 compared to 156% in the same period in 2021. The significant components of selling, general and administrative expenses are as follows:

|  | Three months ended June 30, |
|  | 2022 |  |  | 2021 |
Research and development expense |  | $ | 540,222 |  |  | $ | 460,999 |
Selling, advertising and promotional expense |  |  | 2,763,045 |  |  |  | 870,183 |
General and administrative expense |  |  | 5,077,063 |  |  |  | 2,546,502 |
Total |  | $ | 8,380,330 |  |  | $ | 3,877,684 |

Research and development expense. We continue to focus on bringing new products to market, including updates and improvements to current products. Our research and development expenses totaled $540,222 and $460,999 for the three months ended June 30, 2022 and 2021, respectively, an increase of $79,223 (17.2%). Most of our engineers are dedicated to research and development activities for new products, primarily the new generation of body-worn cameras, EVO-HD and non-mirror based DVM-250 that can be located in multiple places in a vehicle. We expect our research and development activities will continue to trend higher in future quarters as we continue to expand our product offerings based on our new body-worn camera and EVO-HD product platform and as we outsource more development projects. We consider our research and development capabilities and new product focus to be a competitive advantage and intend to continue to invest in this area on a prudent basis and consistent with our financial resources.

Selling, advertising and promotional expenses. Selling, advertising and promotional expense totaled $2,763,045 and $870,183 for the three months ended June 30, 2022 and 2021, respectively, an increase of $1,892,862 (217.5%). Promotional and advertising expenses represent the primary component of these costs and totaled $2,361,235 during the three months ended June 30, 2022, compared to $373,968 during the three months ended June 30, 2021, an increase of $1,987,267 (531.4%). The increase is primarily attributable to the 2022 sponsorship of NASCAR and IndyCar. Additionally, TicketSmarter remains active in sponsorship and advertising. TicketSmarter accounted for $1,394,622 of the total promotional and advertising expense for the three months ended June 30, 2022.

General and administrative expense. General and administrative expenses totaled $5,077,063 and $2,546,502 for the three months ended June 30, 2022 and 2021, respectively, an increase of $2,530,561 (99.4%). The increase in general and administrative expenses in the three months ended June 30, 2022 compared to the same period in 2021 is primarily attributable to an increase in administrative salaries, as payroll continues to increase with the new acquisition completed by the Company’s healthcare venture during the first half of 2022. General and administrative expense also increased due to a substantial increase in depreciation and amortization, rent expenses, and legal and professional expenses for the three months ended June 30, 2022 compared to the same period in 2021, as a result of the numerous acquisitions completed by the Company that were not relevant to the same period in 2021.

46

Operating Loss

For the reasons stated above, our operating loss was $6,661,252 and $2,616,884 for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,044,368 (154.5%). Operating loss as a percentage of revenues improved to 71% in the three months ended June 30, 2022 from 105% in the same period in 2021.

Interest Income

Interest income increased to $32,233 for the three months ended June 30, 2022, from $90,774 in the same period of 2021, which reflects our change cash and cash equivalent levels in the second quarter of 2022 compared to the second quarter of 2021. The Company held significant cash and cash equivalents throughout the second quarter of 2021, allowing a full three months of interest income due to the two completed registered direct offerings in the first quarter of 2021 which yielded net proceeds of approximately $66.4 million.

Interest Expense

We incurred interest expense of $8,501 and $1,365 during the three months ended June 30, 2022 and 2021, respectively. The increase is attributable to the contingent earn-out notes associated with the four Nobility Healthcare acquisitions, currently at a total balance of $1,119,344 for the four notes, with interest rates of 3.00% per annum.

Change in Fair Value of Short-Term Investments

We recognized a loss on change in fair value of short-term investments totaling $-0- and $1,590 during the three months ended June 30, 2022 and 2021, respectively. Such short-term investments are included in cash and cash equivalents as they contain original maturities of ninety (90) days or less.

Change in Fair Value of Contingent Consideration Promissory Notes

During the three months ended June 30, 2022, The Company recognized a gain on the change in fair value of contingent consideration promissory notes of $542,096 and $-0- during the three months ended June 30, 2022 and 2021, respectively. This is in connection with the four acquisitions made by our revenue cycle management segment.

Change in Fair Value of Derivative Liabilities

During the first quarter of 2021, the Company issued detachable warrants to purchase a total of 42,500,000 shares of Common Stock in association with the two registered direct offerings previously described. The underlying warrant agreement terms provide for net cash settlement outside the control of the Company in the event of tender offers under certain circumstances. As such, the Company is required to treat these warrants as derivative liabilities which are valued at their estimated fair value at their issuance date and at each reporting date with any subsequent changes reported in the condensed consolidated statement of operations as the change in fair value of warrant derivative liabilities. The change in fair value of the warrant derivative liabilities from March 31, 2022, to June 30, 2022, totaled $5,413,618 which was recognized as a gain in the second quarter of 2022. The Company determined the fair value of such warrants as of March 31, 2022, and as of June 30, 2022, to be $14,698,761 and $9,285,143, respectively.

Loss before Income Tax Benefit

As a result of the above results of operations, we reported a loss before income tax benefit of $682,187 and $5,382,487 for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,700,300 (87.3%).

Income Tax Benefit

We did not record an income tax expense related to our income for the three months ended June 30, 2022 due to our overall net operating loss carryforwards available. We have further determined to continue providing a full valuation reserve on our net deferred tax assets as of June 30, 2022. We had approximately $81.4 million of net operating loss carryforwards and $1.8 million of research and development tax credit carryforwards as of June 30, 2022 available to offset future net taxable income.

47

Net Loss

As a result of the above results of operations, we reported a net loss of $682,187 and $5,382,487 for the three months ended June 30, 2022 and 2021, respectively, an increase of $4,700,300 (87.3%).

Net Income Attributable to Noncontrolling Interests of Consolidated Subsidiary

The Company owns a 51% equity interest in its consolidated subsidiary, Nobility Healthcare. As a result, the noncontrolling shareholders or minority interest is allocated 49% of the income of Nobility Healthcare which is reflected in the statement of income as “net income attributable to noncontrolling interests of consolidated subsidiary”. We reported net income attributable to noncontrolling interests of consolidated subsidiary of $383,326 and $-0- for the three months ended June 30, 2022 and 2021, respectively.

Net Loss Attributable to Common Stockholders

As a result of the above, we reported a net loss attributable to common stockholders of $1,065,513 and $5,382,487 for the years three months June 30, 2022 and 2021, respectively, an increase of $4,316,974 (80.2%).

Basic and Diluted Loss per Share

The basic and diluted loss per share was $0.02 and $0.10 for the three months ended June 30, 2022 and 2021, respectively. Basic loss per share is based upon the weighted average number of common shares outstanding during the period. For the three months ended June 30, 2022 and 2021, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options and warrants were antidilutive, and, therefore, not included in the computation of diluted loss per share.

For the Six Months Ended June 30, 2022 and 2021

Results of Operations

Summarized immediately below and discussed in more detail in the subsequent subsections is an analysis of our operating results for the six months ended June 30, 2022 and 2021, represented as a percentage of total revenues for each such quarter:

|  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Revenue |  |  | 100 | % |  |  | 100 | %
Cost of revenue |  |  | 81 | % |  |  | 59 | %
Gross profit |  |  | 19 | % |  |  | 41 | %
Selling, general and administrative expenses: |  |  |  |  |  |  |  |
Research and development expense |  |  | 5 | % |  |  | 18 | %
Selling, advertising and promotional expense |  |  | 28 | % |  |  | 29 | %
General and administrative expense |  |  | 54 | % |  |  | 103 | %
Total selling, general and administrative expenses |  |  | 87 | % |  |  | 150 | %
Operating loss |  |  | (69 | )% |  |  | (109 | )%
Change in fair value of contingent consideration promissory notes |  |  | 2 | % |  |  | — | %
Change in fair value of derivative liabilities |  |  | 28 | % |  |  | 431 | %
Other income and interest income (expense), net |  |  | 1 | % |  |  | 3 | %
Income (loss) before income tax benefit |  |  | (38 | )% |  |  | 325 | %
Income tax (provision) |  |  | — | % |  |  | — | %
Net income/(loss) |  |  | (38 | )% |  |  | 325 | %
Net loss attributable to noncontrolling interests of consolidated subsidiary |  |  | (1 | )% |  |  | — | %
Net income (loss) attributable to common stockholders |  |  | (39 | )% |  |  | 325 | %
Net income/(loss) per share information: |  |  |  |  |  |  |  |
Basic |  | $ | (0.15 | ) |  | $ | 0.34 |
Diluted |  | $ | (0.15 | ) |  | $ | 0.34 |

48

Product revenues by operating segment is as follows:

|  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Product Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 2,740,472 |  |  | $ | 3,631,910 |
Revenue Cycle Management |  |  | — |  |  |  | — |
Ticketing |  |  | 1,879,769 |  |  |  | — |
Total Product Revenues |  | $ | 4,620,241 |  |  | $ | 3,631,910 |

Product revenues for the six months ended June 30, 2022 and 2021 were $4,620,241 and $3,631,910 respectively, an increase of $988,331 (27%), due to the following factors:

| ● | Revenues generated by the new ticketing operating segment began with the Company’s September 2021 acquisition of TicketSmarter. The new ticketing operating segment generated $1,879,769 in product revenues for the six months ended June 30, 2022, compared to $-0- for the six months ended June 30, 2021. This product revenue relates to the resale of tickets purchased for live events, including sporting events, concerts, and theatre, then sold through various platforms to customers.

| ● | The Company’s video segment operating segment generated revenues totaling $2,740,472 during the six months ended June 30, 2022 compared to $3,631,910 for the six months ended June 30, 2021 due to slowing sales of our ThermoVuTM product lines related to our COVID-19 response. The Company launched two product lines in direct response to the increased safety precautions that organizations and individuals are taking due to the COVID-19 pandemic. ThermoVu™ was launched as a non-contact temperature-screening instrument that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined parameters. ThermoVu™ has optional features such as facial recognition to improve facility security by restricting access based on temperature and/or facial recognition reasons. ThermoVu™ provides an instant pass/fail audible tone with its temperature display and controls access to facilities based on such results. ThermoVuTM has been applied in schools, dental office, hospitals, office buildings, and other public venues. The Company also launched its Shield™ disinfectant/sanitizer product lines to fulfill demand by current customers and others for a disinfectant and sanitizer that is less harsh than many of the traditional products now widely distributed. The Shield™ Cleanser product line contains a cleanser with no harsh chemicals or fumes. The Company is beginning to experience decreased demand on these product lines as the COVID-19 pandemic begins to subside.
| ● | In general, our video solutions operating segment has experienced decreased demand on its product revenues due to price-cutting and competitive actions by our competitors, adverse marketplace effects related to our patent litigation proceedings and our recent financial condition. We introduced our new body-worn cameras, the FirstVu Pro and FirstVu II, in the fourth quarter of 2021, and we have begun to see increased traction with these products in the first six months of 2022. The Company hopes the interest throughout the marketplace continues to grow for these new products as the market is able to review and test these new products.

49

| ● | Our video solutions operating segment management has been focusing on migrating customers, and in particular commercial customers, from a hardware sale to a service fee model. Therefore, we expect a reduction in commercial hardware sales (principally DVM-250’s, FLT-250’s, and our body-worn camera line) as we convert these customers to a service model under which we provide the hardware as part of a recurring monthly service fee. In that respect, we introduced a monthly subscription agreement plan for our body worn cameras and related equipment during the second quarter of 2020 that allowed law enforcement agencies to pay a monthly service fee to obtain body worn cameras without incurring a significant upfront capital outlay. This program has continued to gain traction, resulting in decreased product revenues and increased service revenues. We expect this program to continue to gain momentum, resulting in recurring revenues over a span of three to five years.

Service and other revenues by operating segment is as follows:

|  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Service and Other Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 1,319,333 |  |  | $ | 1,397,591 |
Revenue Cycle Management |  |  | 4,024,695 |  |  |  | — |
Ticketing |  |  | 9,681,969 |  |  |  | — |
Total Service and Other Revenues |  | $ | 15,025,997 |  |  | $ | 1,397,591 |

Service and other revenues for the six months ended June 30, 2022 and 2021 were $15,025,997 and $1,397,591, respectively, an increase of $13,628,406 (975%), due to the following factors:

| ● | Cloud revenues generated by the video solutions operating segment were $627,874 and $488,738 for the six months ended June 30, 2022 and 2021, respectively, an increase of $139,136 (28.5%). We have experienced increased interest in our cloud solutions for law enforcement primarily due to the deployment of our cloud-based EVO-HD in-car system and our next generation body-worn camera products, which contributed to our increased cloud revenues in the six months ended June 30, 2022. We expect this trend to continue throughout 2022 as the migration from local storage to cloud storage continues in our customer base.
| ● | Video solutions operating segment revenues from extended warranty services were $363,130 and $487,307 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $124,177 (25.5%). However, the continued effects from the COVID-19 pandemic have adversely affected our sales of DVM-800 hardware systems resulting in a decrease in their sales in the six months ended June 30, 2022 compared to the same period in 2021.
| ● | Our new ticketing operating segment generated service revenues totaling $9,681,969 and $-0- for the six months ended June 30, 2022 and 2021, respectively, an increase of $9,681,969 (100%). The Company completed the acquisitions of Goody Tickets, LLC and TicketSmarter, LLC on September 1, 2021, thus resulting in the new revenue stream for the Company. TicketSmarter collects fees on transactions administered through the TicketSmarter.com platform for the buying and selling of tickets for live events throughout the country. We expect our ticketing operating segment to continue to present a strong revenue outlook moving forward.
| ● | Our new revenue cycle management operating segment generated service revenues totaling $4,024,695 and $-0- for the six months ended June 30, 2022 and 2021, respectively, an increase of $4,024,695 (100%). Our revenue cycle management operating segment has completed four acquisitions since formation in June of 2021, thus resulting in the new service revenue stream added in the six months ended June 30, 2022. Our revenue cycle management operating segment provides revenue cycle management solutions and back-office services to healthcare organizations throughout the country. We expect our revenue cycle management segment to continue to present a strong revenue outlook moving forward.

Total revenues for the six months ended June 30, 2022 and 2021 were $19,646,238 and $5,029,501, respectively, an increase of $14,616,737 (291%), due to the reasons noted above.

Cost of Product Revenue

Overall cost of product revenue sold for the six months ended June 30, 2022, and 2021 was $4,892,527 and $2,578,969, respectively, an increase of $2,313,558 (89.7%). Overall cost of goods sold for products as a percentage of product revenues for the six months ended June 30, 2022, and 2021 were 105.8% and 71.0%, respectively. Cost of products sold by operating segment is as follows:

|  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Cost of Product Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 2,507,118 |  |  | $ | 2,578,969 |
Revenue Cycle Management |  |  | — |  |  |  | — |
Ticketing |  |  | 2,385,409 |  |  |  | — |
Total Cost of Product Revenues |  | $ | 4,892,527 |  |  | $ | 2,578,969 |

50

The decrease in cost of goods sold for our video solutions segment products is directly correlated with the decrease in product sales for the six months ended June 30, 2022 compared to the six months ended June 30, 2021. In addition, the video solutions segment recorded valuation allowances for its older product lines and a portion of its Shield products during the first six months of 2022, directly increasing cost of goods sold for the period. Cost of product sold as a percentage of product revenues for the video solutions segment increased to 91.5% for the six months ended June 30, 2022 as compared to 71.0% for the six months ended June 30, 2021.

The increase in ticketing operating segment cost of product sold is due to the acquisition of TicketSmarter in the third quarter of 2021, resulting in an increase to cost of product revenue of $2,385,409 for the six months ended June 30, 2022, compared to $-0- for the six months ended June 30, 2021. Cost of product sold as a percentage of product revenues for the ticketing solutions was 126.9% for the six months ended June 30, 2022. The Ticketing Segment recorded an allowance for unsold and under-market tickets during the first quarter 2022 due to event cancellations and restrictions imposed on the size and type of gatherings related to the Omicron variant.

We recorded $3,722,467 and $3,915,089 in reserves for obsolete and excess inventories at June 30, 2022 and December 31, 2021, respectively. Total raw materials and component parts were $4,083,713 and $3,062,046 at June 30, 2022 and December 31, 2021, respectively, an increase of $1,021,667 (33%). Finished goods balances were $9,044,555 and $10,512,577 at June 30, 2022 and December 31, 2021, respectively, a decrease of $1,468,022 (14%) which was attributable to a decrease in finished goods from our newly acquired ticketing segment. The small decrease in the inventory reserve is primarily due to the reduction in finished goods and movement of excess inventory. We believe the reserves are appropriate given our inventory levels as of June 30, 2022.

Cost of Service Revenue

Overall cost of service revenue sold for the six months ended June 30, 2022, and 2021 was $11,095,015 and $377,849, respectively, an increase of $10,717,166 (2,836%). Overall cost of goods sold for services as a percentage of service revenues for the six months ended June 30, 2022, and 2021 were 73.8% and 27.0%, respectively. Cost of service revenues by operating segment is as follows:

|  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Cost of Service Revenues: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 525,247 |  |  | $ | 377,849 |
Revenue Cycle Management |  |  | 2,370,263 |  |  |  | — |
Ticketing |  |  | 8,199,505 |  |  |  | — |
Total Cost of Service Revenues |  | $ | 11,095,015 |  |  | $ | 377,849 |

The increase in cost of service revenues for our video solutions segment is commensurate with the increase in service revenues in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. Cost of service revenues as a percentage of service revenues for the video solutions segment increased to 39.8% for the six months ended June 30, 2022 as compared to 27.0% for the six months ended June 30, 2021.

The increase in revenue cycle management operating segment cost of service revenue is due to the four acquisitions of medical billing companies completed since June 2021. Cost of service revenues as a percentage of service revenues for the revenue cycle management operating segment was 58.9% for the six months ended June 30, 2022.

51

The increase in ticketing operating segment cost of service revenues is the due to the 2021 acquisition of TicketSmarter, resulting in an increase to cost of service revenue of $8,199,505 for the six months ended June 30, 2022, compared to $-0- for the six months ended June 30, 2021. Cost of service revenues as a percentage of service revenues for the ticketing segment was 84.7% for the six months ended June 30, 2022.

Gross Profit

Overall gross profit for the six months ended June 30, 2022 and 2021 was $3,658,696 and $2,072,683, respectively, an increase of $1,586,013 (76.5%). Gross profit by operating segment was as follows:

|  |  | Six Months Ended June 30, |
|  |  | 2022 |  |  |  | 2021 |
Gross Profit: |  |  |  |  |  |  |  |
Video Solutions |  | $ | 1,027,440 |  |  | $ | 2,072,683 |
Revenue Cycle Management |  |  | 1,654,432 |  |  |  | — |
Ticketing |  |  | 976,824 |  |  |  | — |
Total Gross Profit |  | $ | 3,658,696 |  |  | $ | 2,072,683 |

The overall increase is attributable to the large overall increase in revenues for the six months ended June 30, 2022 and an increase in the overall cost of sales as a percentage of overall revenues to 81.4% for the six months ended June 30, 2022 from 58.8% for the six months ended June 30, 2021. Our goal is to improve our margins over the longer term based on the expected margins generated by our new recent revenue cycle management and ticketing operating segments together with our video solutions operating segment and its expected margins from our EVO-HD, DVM-800, VuLink, FirstVu Pro, FirstVu II, FirstVu HD, ThermoVuTM, ShieldTM disinfectants and our cloud evidence storage and management offering, provided that they gain traction in the marketplace and subject to a normalizing economy in the wake of the COVID-19 pandemic and current inflationary concerns. In addition, if revenues from the video solutions segment increase, we will seek to further improve our margins from this segment through expansion and increased efficiency utilizing fixed manufacturing overhead components. We plan to continue our initiative to more efficient management of our supply chain through outsourcing production, quantity purchases and more effective purchasing practices.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $17,123,286 and $7,555,261 for the six months ended June 30, 2022 and 2021, respectively, an increase of $9,568,025 (126.6%). The increase was primarily attributable to the recent acquisitions completed in the third quarter of 2021. Our selling, general and administrative expenses as a percentage of sales decreased to 87% for the six months ended June 30, 2022 compared to 150% in the same period in 2021. The significant components of selling, general and administrative expenses are as follows:

|  | Six months ended June 30, |
|  | 2022 |  |  | 2021 |
Research and development expense |  | $ | 1,038,222 |  |  | $ | 909,964 |
Selling, advertising and promotional expense |  |  | 5,542,448 |  |  |  | 1,466,938 |
General and administrative expense |  |  | 10,542,616 |  |  |  | 5,178,359 |
Total |  | $ | 17,123,286 |  |  | $ | 7,555,261 |

Research and development expense. We continue to focus on bringing new products to market, including updates and improvements to current products. Our research and development expenses totaled $1,038,222 and $909,964 for the six months ended June 30, 2022 and 2021, respectively, an increase of $128,258 (14.1%). Most of our engineers are dedicated to research and development activities for new products, primarily the new generation of body-worn cameras, EVO-HD and non-mirror based DVM-250 that can be located in multiple places in a vehicle. We expect our research and development activities will continue to trend higher in future quarters as we continue to expand our product offerings based on our new body-worn camera and EVO-HD product platform and as we outsource more development projects. We consider our research and development capabilities and new product focus to be a competitive advantage and intend to continue to invest in this area on a prudent basis and consistent with our financial resources.

52

Selling, advertising and promotional expenses. Selling, advertising and promotional expense totaled $5,542,448 and $1,466,938 for the six months ended June 30, 2022 and 2021, respectively, an increase of $4,075,510 (277.8%). Promotional and advertising expenses represent the primary component of these costs and totaled $4,750,298 during the six months ended June 30, 2022, compared to $571,171 during the six months ended June 30, 2021, an increase of $4,179,127 (731.7%). The increase is primarily attributable to the 2022 sponsorship of NASCAR and IndyCar. Additionally, TicketSmarter remains in sponsorship and advertising. TicketSmarter accounted for $2,852,888 of the total promotional and advertising expense for the six months ended June 30, 2022.

General and administrative expense. General and administrative expenses totaled $10,542,616 and $5,178,359 for the six months ended June 30, 2022 and 2021, respectively, an increase of $5,364,258 (103.6%). The increase in general and administrative expenses in the six months ended June 30, 2022 compared to the same period in 2021 is primarily attributable to an increase in administrative salaries, as payroll continues to increase with the new acquisition completed by the Company’s healthcare venture during the first half of 2022. General and administrative expense also increased due to a substantial increase in depreciation and amortization, rent expenses, and legal and professional expenses for the six months ended June 30, 2022 compared to the same period in 2021, as a result of the numerous acquisitions completed by the Company that were not relevant to the same period in 2021.

Operating Loss

For the reasons stated above, our operating loss was $13,464,590 and $5,482,578 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $7,982,012 (145.6%). Operating loss as a percentage of revenues improved to 69% in the six months ended June 30, 2022 from 109% in the same period in 2021.

Interest Income

Interest income decreased to $103,595 for the six months ended June 30, 2022, from $132,461 in the same period of 2021, which reflects our change in cash and cash equivalent levels in the second quarter of 2022 compared to the second quarter of 2021. The Company held significant cash and cash equivalents throughout the second quarter of 2021, allowing a full six months of interest income due to the two completed registered direct offerings in the first quarter of 2021 which yielded net proceeds of approximately $66.4 million.

Interest Expense

We incurred interest expense of $25,511 and $2,793 during the six months ended June 30, 2022 and 2021, respectively. The increase is attributable to the contingent earn-out notes associated with the four Nobility Healthcare acquisitions, currently at a total balance of $1,119,344 for the four notes, with interest rates of 3.00% per annum.

Change in Fair Value of Short-Term Investments

We recognized a loss on change in fair value of short-term investments totaling $84,818 and $6,554 during the six months ended June 30, 2022 and 2021, respectively. Such short-term investments are included in cash and cash equivalents as they contain original maturities of ninety (90) days or less.

Change in Fair Value of Contingent Consideration Promissory Notes

During the six months ended June 30, 2022, The Company recognized a gain on the change in fair value of contingent consideration promissory notes of $486,046 and $-0- during the six months ended June 30, 2022 and 2021, respectively. This is in connection with the four acquisitions made by our revenue cycle management segment.

53

Change in Fair Value of Derivative Liabilities

During the first quarter of 2021, the Company issued detachable warrants to purchase a total of 42,500,000 shares of Common Stock in association with the two registered direct offerings previously described. The underlying warrant agreement terms provide for net cash settlement outside the control of the Company in the event of tender offers under certain circumstances. As such, the Company is required to treat these warrants as derivative liabilities which are valued at their estimated fair value at their issuance date and at each reporting date with any subsequent changes reported in the condensed consolidated statement of operations as the change in fair value of warrant derivative liabilities. The change in fair value of the warrant derivative liabilities from December 31, 2021, to June 30, 2022, totaled $5,561,789 which was recognized as a gain in the second quarter of 2022. The Company determined the fair value of such warrants as of December 31, 2021, and as of June 30, 2022, to be $14,846,932 and $9,285,143, respectively.

Income/(Loss) before Income Tax Benefit

As a result of the above results of operations, we reported an income/(loss) before income tax benefit of ($7,380,430) and $16,339,371 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $23,719,802 (145.2%).

Income Tax Benefit

We did not record an income tax expense related to our income for the six months ended June 30, 2022 due to our overall net operating loss carryforwards available. We have further determined to continue providing a full valuation reserve on our net deferred tax assets as of June 30, 2022. We had approximately $81.4 million of net operating loss carryforwards and $1.8 million of research and development tax credit carryforwards as of June 30, 2022 available to offset future net taxable income.

Net Income/(Loss)

As a result of the above results of operations, we reported a net income/(loss) of $(7,380,430) and $16,339,371 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $23,719,802 (145.2%).

Net Income Attributable to Noncontrolling Interests of Consolidated Subsidiary

The Company owns a 51% equity interest in its consolidated subsidiary, Nobility Healthcare. As a result, the noncontrolling shareholders or minority interest is allocated 49% of the income of Nobility Healthcare which is reflected in the statement of income as “net income attributable to noncontrolling interests of consolidated subsidiary”. We reported net income attributable to noncontrolling interests of consolidated subsidiary of $285,232 and $-0- for the six months ended June 30, 2022 and 2021, respectively.

Net Income/(Loss) Attributable to Common Stockholders

As a result of the above, we reported a net income/(loss) attributable to common stockholders of ($7,665,662) and $16,339,371 for the years six months June 30, 2022 and 2021, respectively, a decrease of $24,005,033 (146.9%).

Basic and Diluted Income/(Loss) per Share

The basic and diluted loss per share was ($0.15) and $0.34 for the six months ended June 30, 2022 and 2021, respectively. Basic loss per share is based upon the weighted average number of common shares outstanding during the period. For the six months ended June 30, 2022 and 2021, all shares issuable upon conversion of convertible debt and the exercise of outstanding stock options and warrants were antidilutive, and, therefore, not included in the computation of diluted loss per share.

54

Liquidity and Capital Resources

Overall:

Management’s Liquidity Plan. The Company has historically raised capital in the form of equity and debt instruments from private and public sources to supplement its needs for funds to support its business operational and strategic plans. In recent years the Company has accessed the public and private capital markets to raise funding through the issuance of debt and equity. In that regard, the Company had raised net proceeds of approximately $66.4 million in registered direct offerings of common stock, pre-funded warrants and warrants during 2021. Furthermore, the Company’s only remaining interest-bearing debt at June 30, 2022 is $150,000 remaining due on the promissory notes under the SBA’s PPP and EIDL programs, along with the four acquired private medical billing companies’ contingent consideration promissory notes, as more fully described in Note 3, “Debt Obligations”. We believe that the net proceeds from the registered direct offerings will be sufficient to fund our operations during the remainder of 2022 and management believes that it now has adequate liquidity for the foreseeable future from the 2021 registered direct offerings. However, should those funds not be sufficient, the Company will explore numerous equity and debt instruments to obtain sufficient funds needed to support its business operations.

Management believes that it has adequate funding to support its business operations for the foreseeable future as a result of the funds raised through these offerings.

Cash, cash equivalents: As of June 30, 2022, we had cash and cash equivalents with an aggregate balance of $13,454,246, a decrease from a balance of $32,007,792 at December 31, 2021. Summarized immediately below and discussed in more detail in the subsequent subsections are the main elements of the $18,553,546 net decrease in cash during the six months ended June 30, 2022:

| ● | Operating activities: | $10,932,515 of net cash used in operating activities. Net cash used in operating activities was $10,932,515 and $6,149,773 for the six months ended June 30, 2022 and 2021, respectively, an increase of $4,782,742. The decrease is attributable to the net loss incurred for the first six months of 2022, the non-cash gain attributable to the change in value of the warrant derivative liability, and the usage of cash to increase accounts receivable, prepaid expenses, and other operating assets during the six months ended June 30, 2022 compared to the same period in 2021.
| ● | Investing activities: | $3,361,994 of net cash used in investing activities. Cash used in investing activities was $3,361,994 and $6,506,407 for the six months ended June 30, 2022 and 2021, respectively. During the six months ended June 30, 2022, we made capital expenditures for: (i) building improvements of the newly purchased office and warehouse building, and transportation assets; (ii) patent applications on our proprietary technology utilized in our new products and included in intangible assets; and (iii) the closing of a business and asset acquisition.
| ● | Financing activities: | $4,259,037 of net cash used in financing activities. Cash used in financing activities was $4,259,037 and cash provided by financing activities was $66,570,600 for the six months ended June 30, 2022 and 2021, respectively. During the first six months of 2022, the Company repurchased its common stock on the open market pursuant to the stock repurchase plan, and made principal payments on contingent consideration promissory notes. During 2021, we raised substantial funds through the completion of two registered direct offerings of our common stock.

55

Commitments:

We had $13,454,245 of cash and cash equivalents and net positive working capital $15,733,652 as of June 30, 2022. Accounts receivable and other receivables balances represented $4,965,309 of our net working capital at June 30, 2022. We believe we will be able to collect our outstanding receivables on a timely basis and reduce the overall level during the balance of 2022, which could provide positive cash flow to support our operations during 2022. Inventory represents $9,405,954 of our net working capital at June 30, 2022, and finished goods represented $9,044,555 of total inventory at June 30, 2022. We are actively managing the level of inventory and our goal is to reduce such level during the balance of 2022 by our sales activities, the increase of which should provide additional cash flow to help support our operations during 2022.

Capital Expenditures:

We had the following material commitments for capital expenditures at June 30, 2022:

Stock Repurchase Program - On December 6, 2021, the board of directors of the Company authorized the repurchase of up to $10.0 million of the Company’s outstanding common stock under the specified terms of a share repurchase program (the “Program”). During the three months ended June 30, 2022, the Company repurchased 1,849,952 shares of its common stock for $1,962,755, in accordance with the Program. Furthermore, during the six months ended June 30, 2022, the Company repurchased 3,725,986 shares of its common stock for $4,026,523, in accordance with the Program.

On June 30, 2022, the board of directors of the Company elected to terminate the Program, effective immediately. The Program began in December 2021, with the Company purchasing a total of 5,460,824 shares at a cost of $6,001,602 through June 30, 2022.

Lease commitments. Total lease expense under the six operating leases was approximately $119,230 and $274,302, during the three and six months ended June 30, 2022, respectively. The following sets forth the operating lease right of use assets and liabilities as of June 30, 2022:

The following sets forth the operating lease right of use assets and liabilities as of June 30, 2022:

Assets: |  |  |
Operating lease right of use assets |  | $ | 951,928 |
Liabilities: |  |  |  |
Operating lease obligations-current portion |  | $ | 353,646 |
Operating lease obligations-less current portion |  |  | 666,477 |
Total operating lease obligations |  | $ | 1,020,123 |

Following are the minimum lease payments for each year and in total:

Year ending December 31: |  |  |
2022 (July 1, to December 31, 2022) |  | $ | 250,285 |
2023 |  |  | 305,627 |
2024 |  |  | 245,761 |
2025 |  |  | 196,462 |
Thereafter |  |  | 175,113 |
Total undiscounted minimum future lease payments |  |  | 1,173,248 |
Imputed interest |  |  | (153,125 | )
Total operating lease liability |  | $ | 1,020,123 |

Debt obligations – Outstanding debt obligations comprises the following:

|  | June 30, 2022 |  |  | December 31, 2021 |
Economic injury disaster loan (EIDL) |  | $ | 150,000 |  |  | $ | 150,000 |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | 211,867 |  |  |  | 317,212 |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | 426,326 |  |  |  | 650,000 |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | 481,151 |  |  |  | — |
Contingent consideration promissory note – Nobility Healthcare Division Acquisition |  |  | — |  |  |  | — |
Debt obligations |  |  | 1,269,344 |  |  |  | 1,117,212 |
Less: current maturities of debt obligations |  |  | 514,664 |  |  |  | 389,934 |
Debt obligations, long-term |  | $ | 754,680 |  |  | $ | 727,278 |

56

Debt obligations mature as follows as of June 30, 2022:

|  | June 30, 2022 |
2022 (July 1, 2022 to December 31, 2022) |  | $ | 257,317 |
2023 |  |  | 514,722 |
2024 |  |  | 355,295 |
2025 |  |  | 3,412 |
2026 |  |  | 3,542 |
2027 and thereafter |  |  | 135,0564 |
Total |  | $ | 1,269,344 |

Critical Accounting Estimates

Our significant accounting policies are summarized in Note 1, “Nature of Business and Summary of Significant Accounting Policies,” to our consolidated financial statements. While the selection and application of any accounting policy may involve some level of subjective judgments and estimates, we believe the following accounting policies and estimates are the most critical to our financial statements, potentially involve the most subjective judgments in their selection and application, and are the most susceptible to uncertainties and changing conditions:

| ● | Revenue Recognition / Allowance for Doubtful Accounts;
| ● | Allowance for Excess and Obsolete Inventory;
| ● | Goodwill and other intangible assets;
| ● | Warranty Reserves;
| ● | Fair value of warrant derivative liabilities;
| ● | Stock-based Compensation Expense;
| ● | Fair value of warrants;
| ● | Fair value of assets and liabilities acquired in business combinations; and
| ● | Accounting for Income Taxes.

57

Revenue Recognition / Allowances for Doubtful Accounts. Revenue is recognized for the shipment of products or delivery of service when all five of the following conditions are met:

| (i) | Identify the contract with the customer;
| (ii) | Identify the performance obligations in the contract;
| (iii) | Determine the transaction price;
| (iv) | Allocate the transaction price to the performance obligations in the contract; and
| (v) | Recognize revenue when a performance obligation is satisfied.

We consider the terms and conditions of the contract and our customary business practices in identifying our contracts under ASC 606. We determine we have a contract when the customer order is approved, we can identify each party’s rights regarding the services to be transferred, we can identify the payment terms for the services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. At contract inception we evaluate whether the contract includes more than one performance obligation. We apply judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, credit and financial information pertaining to the customer.

Performance obligations promised in a contract are identified based on the services and the products that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services and the products is separately identifiable from other promises in the contract. Our performance obligations consist of (i) products, (ii) professional services, and (iii) extended warranties.

The transaction price is determined based on the consideration to which we expect to be entitled in exchange for transferring services to the customer. Variable consideration is included in the transaction price if, in our judgment it is probable that a significant future reversal of cumulative revenue under the contract will not occur. None of our contracts contain a significant financing component.

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on the relative standalone selling price (“SSP”).

Revenue for our video solutions segment is recognized at the time the related performance obligation is satisfied by transferring the control of the promised service to a customer. Revenue is recognized when control of the service is transferred to the customer, in an amount that reflects the consideration that we expect to receive in exchange for our services. We generate all our revenue from contracts with customers.

Revenue for our revenue cycle management segment is recorded on a net basis, as its primary source of revenue is its end-to-end service fees. These service fees are reported as revenue monthly upon completion of our performance obligation to provide the agreed upon services.

Revenue for our ticketing segment is recorded on a gross or net basis based on management’s assessment of whether we are acting as a principal or agent in the transaction. The determination is based upon the evaluation of control over the event ticket, including the right to sell the ticket, prior to its transfer to the ticket buyer.

We sell our tickets held in inventory, which consists of one performance obligation, being to transfer control of an event ticket to the buyer upon confirmation of the order. We act as the principal in these transactions as we own the ticket at the time of sale, therefore we control the ticket prior to transferring to the customer. In these transactions, revenue is recorded on a gross basis based on the value of the ticket and is recognized when an order is confirmed. Payment is typically due upon delivery of the ticket.

58

We also act as an intermediary between buyers and sellers through the online secondary marketplace. Revenues derived from this marketplace primarily consist of service fees from ticketing operations, and consists of one primary performance obligation, which is facilitating the transaction between the buyer and seller, being satisfied at the time the order has been confirmed. As we do not control the ticket prior to the transfer, we act as an agent in these transactions. Revenue is recognized on a net basis, net of the amount due to the seller when an order is confirmed. The seller is then obligated to deliver the tickets to the buyer per the seller’s listing. Payment is due at the time of sale.

We review all significant, unusual, or nonstandard shipments of product or delivery of services as a routine part of our accounting and financial reporting process to determine compliance with these requirements. Extended warranties are offered on selected products, and when a customer purchases an extended warranty, the associated proceeds are treated as contract liability and recognized over the term of the extended warranty.

For our video solutions segment, our principal customers are state, local, and federal law enforcement agencies, which historically have been low risks for uncollectible accounts. However, we have commercial customers and international distributors that present a greater risk for uncollectible accounts than such law enforcement customers and we consider a specific reserve for bad debts based on their individual circumstances. Our historical bad debts have been negligible, with less than $258,000 charged off as uncollectible on cumulative revenues of $248.0 million since we commenced deliveries during 2006.

For our ticketing segment, our customers are mainly online visitors that pay at the time of the transaction, and we collect the service fees charged with the transaction, thus leading to minimal risk for uncollectible accounts, to which we then consider a specific reserve for bad debts based on their individual circumstances. As we continue to learn more about the collectability related to this recent acquisition, we will track historical bad debts and continue to assess appropriate reserves.

For our revenue cycle management segment, our customers are mainly medium to large healthcare organizations that are charged monthly upon the execution of our services. Being these customers are healthcare organizations with minimal risk for uncollectible accounts, we consider a specific reserve for bad debts based on their individual circumstances. As we continue to learn more about the collectability related to this recently added segment, we will track historical bad debts and continue to assess appropriate reserves.

Allowance for Excess and Obsolete Inventory. We record valuation reserves on our inventory for estimated excess or obsolete inventory items. The amount of the reserve is equal to the difference between the cost of the inventory and the estimated market value based upon assumptions about future demand and market conditions. On a quarterly basis, management performs an analysis of the underlying inventory to identify reserves needed for excess and obsolescence. Management uses its best judgment to estimate appropriate reserves based on this analysis. In addition, we adjust the carrying value of inventory if the current market value of that inventory is below its cost.

Inventories consisted of the following at June 30, 2022 and December 31, 2021:

|  | June 30, 2022 |  |  | December 31, 2021 |
Raw material and component parts– video solutions segment |  | $ | 4,083,713 |  |  | $ | 3,062,046 |
Work-in-process– video solutions segment |  |  | 153 |  |  |  | — |
Finished goods – video solutions segment |  |  | 7,866,087 |  |  |  | 8,410,307 |
Finished goods – ticketing segment |  |  | 1,178,468 |  |  |  | 2,102,272 |
Subtotal |  |  | 13,128,421 |  |  |  | 13,574,625 |
Reserve for excess and obsolete inventory– video solutions segment |  |  | (3,272,832 | ) |  |  | (3,353,458 | )
Reserve for excess and obsolete inventory – ticketing segment |  |  | (449,635 | ) |  |  | (561,631 | )
Total inventories |  | $ | 9,405,954 |  |  | $ | 9,659,536 |

59

We balance the need to maintain strategic inventory levels to ensure competitive delivery performance to our customers against the risk of inventory obsolescence due to changing technology and customer requirements. As reflected above, our inventory reserves represented 28.4% of the gross inventory balance at June 30, 2022, compared to 28.8% of the gross inventory balance at December 31, 2021. We had $3,722,467 and $3,915,089 in reserves for obsolete and excess inventories at June 30, 2022 and December 31, 2021, respectively. Total raw materials and component parts were $4,083,713 and $3,062,046 at June 30, 2022 and December 31, 2021, respectively, an increase of $1,021,667 (33.4%). Finished goods balances were $9,044,555 and $10,512,579 at June 30, 2022 and December 31, 2021, respectively, a decrease of $1,468,024 (14.0%). The decrease in finished goods was primarily attributable to a reduction in ticketing inventory of $923,804 at June 30, 2022 compared to December 31, 2021. The slight decrease in the inventory reserve is primarily due to the reduction in finished goods that had a reserve placed on them prior to sale. The remaining reserve for inventory obsolescence is generally provided for the level of component parts of the older versions of our printed circuit boards and the phase out of our DVM-750, DVM-500 Plus and LaserAlly legacy products. Additionally, the Company determined a reasonable reserve for inventory held at the ticket operating segment, in which some inventory items sell below cost or go unsold, thus having to be fully written-off following the event date. We believe the reserves are appropriate given our inventory levels at June 30, 2022.

If actual future demand or market conditions are less favorable than those projected by management or there are significant engineering changes to our products that are not anticipated and appropriately managed, additional inventory write-downs may be required in excess of the inventory reserves already established.

Goodwill and other intangible assets. When we acquire a business, we determine the fair value of the assets acquired and liabilities assumed on the date of acquisition, which may include a significant amount of intangible assets such as customer relationships, software and content, as well as goodwill. When determining the fair values of the acquired intangible assets, we consider, among other factors, analyses of historical financial performance and an estimate of the future performance of the acquired business. The fair values of the acquired intangible assets are primarily calculated using an income approach that relies on discounted cash flows. This method starts with a forecast of the expected future net cash flows for the asset and then adjusts the forecast to present value by applying a discount rate that reflects the risk factors associated with the cash flow streams. We consider this approach to be the most appropriate valuation technique because the inherent value of an acquired intangible asset is its ability to generate future income. In a typical acquisition, we engage a third-party valuation expert to assist us with the fair value analyses for acquired intangible assets.

Determining the fair values of acquired intangible assets requires us to exercise significant judgment. We select reasonable estimates and assumptions based on evaluating a number of factors, including, but not limited to, marketplace participants, consumer awareness and brand history. Additionally, there are significant judgments inherent in discounted cash flows such as estimating the amount and timing of projected future cash flows, the selection of discount rates, hypothetical royalty rates and contributory asset capital charges. Specifically, the selected discount rates are intended to reflect the risk inherent in the projected future cash flows generated by the underlying acquired intangible assets.

Determining an acquired intangible asset’s useful life also requires significant judgment and is based on evaluating a number of factors, including, but not limited to, the expected use of the asset, historical client retention rates, consumer awareness and trade name history, as well as any contractual provisions that could limit or extend an asset’s useful life.

The Company’s goodwill is evaluated in accordance with FASB ASC Topic 350, which requires goodwill to be assessed for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. In addition, an impairment evaluation of our amortizable intangible assets may also be performed if events or circumstances indicate potential impairment. Among the factors that could trigger an impairment review are current operating results that do not align with our annual plan or historical performance; changes in our strategic plans or the use of our assets; restructuring changes or other changes in our business segments; competitive pressures and changes in the general economy or in the markets in which we operate; and a significant decline in our stock price and our market capitalization relative to our net book value.

When performing our annual assessment of the recoverability of goodwill, we initially perform a qualitative analysis evaluating whether any events or circumstances occurred or exist that provide evidence that it is more likely than not that the fair value of any of our reporting units is less than the related carrying amount. If we do not believe that it is more likely than not that the fair value of any of our reporting units is less than the related carrying amount, then no quantitative impairment test is performed. However, if the results of our qualitative assessment indicate that it is more likely than not that the fair value of a reporting unit is less than its respective carrying amount, then we perform a two-step quantitative impairment test.

60

Evaluating the recoverability of goodwill requires judgments and assumptions regarding future trends and events. As a result, both the precision and reliability of our estimates are subject to uncertainty. Among the factors that we consider in our qualitative assessment are general economic conditions and the competitive environment; actual and projected reporting unit financial performance; forward-looking business measurements; and external market assessments. To determine the fair values of our reporting units for a quantitative analysis, we typically utilize detailed financial projections, which include significant variables, such as projected rates of revenue growth, profitability and cash flows, as well as assumptions regarding discount rates, the Company’s weighted average cost of capital and other data.

Our most recent annual impairment test of goodwill was a qualitative analysis conducted as of December 31, 2021 that indicated no impairment. Subsequent to completing our 2021 annual impairment test, no events or changes in circumstances were noted that required an interim goodwill impairment test. Note 1 — Nature of Business and Summary of Significant Accounting Policies and Note 10 — Goodwill and Other Intangible Assets in the Notes to Consolidated Financial Statements provide additional information regarding the Company’s goodwill and other intangible assets.

Warranty Reserves. We generally provide up to a two-year parts and labor standard warranty on our products to our customers. Provisions for estimated expenses related to product warranties are made at the time products are sold. These estimates are established using historical information on the nature, frequency, and average cost of claims. We actively study trends of claims and take action to improve product quality and minimize claims. Our warranty reserves were decreased to $10,582 as of June 30, 2022 compared to $13,742 as of December 31, 2021 as we began to slow our warranty exposures through the roll-off of DVM-750 and DVM-800 units from warranty coverage. Standard warranty exposure on the DVM-800 and DVM-250plus are the responsibility of the contract manufacturers which reduced our overall warranty exposure as these are very popular products in our line. There is a risk that we will have higher warranty claim frequency rates and average cost of claims than our history has indicated on our legacy mirror products on our new products for which we have limited experience. Actual experience could differ from the amounts estimated requiring adjustments to these liabilities in future periods.

Warrant derivative liabilities. On January 14, 2021 and February 1, 2021, the Company issued warrants to purchase a total of 42,550,000 shares of Common Stock. The warrant terms provide for net cash settlement outside the control of the Company under certain circumstances in the event of tender offers. As such, the Company is required to treat these warrants as derivative liabilities which are valued at their estimated fair value at their issuance date and at each reporting date with any subsequent changes reported in the consolidated statements of operations as the change in fair value of warrant derivative liabilities. Furthermore, the Company revalues the fair value of warrant derivative liability as of the date the warrant is exercised with the resulting warrant derivative liability transitioned to equity.

The Company has utilized the following assumptions in its Black-Scholes option valuation model to calculate the estimated fair value of the warrant derivative liabilities as of their date of issuance and as of June 30, 2022:

|  | Issuance date assumptions |  |  | June 30, 2022 assumptions |
Volatility - range |  |  | 106.6 – 166.6 | % |  |  | 104.7 | %
Risk-free rate |  |  | 0.08 – 0.49 | % |  |  | 3.01 | %
Dividend |  |  | 0 | % |  |  | 0 | %
Remaining contractual term |  |  | 0.01 – 5 years |  |  |  | 3.5 – 4.2 years |
Exercise price |  | $ | 2.80 - 3.25 |  |  | $ | 3.25 |
Common stock issuable under the warrants |  |  | 42,550,000 |  |  |  | 24,300,000 |

Stock-based Compensation Expense. We grant stock options to our employees and directors and such benefits provided are share-based payment awards which require us to make significant estimates related to determining the value of our share-based compensation. Our expected stock-price volatility assumption is based on historical volatilities of the underlying stock that are obtained from public data sources and there were 25,000 stock options granted during the six months ended June 30, 2022.

61

If factors change and we develop different assumptions in future periods, the compensation expense that we record in the future may differ significantly from what we have recorded in the current period. There is a high degree of subjectivity involved when using option pricing models to estimate share-based compensation. Changes in the subjective input assumptions can materially affect our estimates of fair values of our share-based compensation. Certain share-based payment awards, such as employee stock options, may expire worthless or otherwise result in zero intrinsic value compared to the fair values originally estimated on the grant date and reported in our financial statements. Alternatively, values may be realized from these instruments that are significantly in excess of the fair values originally estimated on the grant date and reported in our financial statements. Although the fair value of employee share-based awards is determined using an established option pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction. In addition, we account for forfeitures as they occur.

Accounting for Income Taxes. Accounting for income taxes requires significant estimates and judgments on the part of management. Such estimates and judgments include, but are not limited to, the effective tax rate anticipated to apply to tax differences that are expected to reverse in the future, the sufficiency of taxable income in future periods to realize the benefits of net deferred tax assets and net operating losses currently recorded and the likelihood that tax positions taken in tax returns will be sustained on audit.

As required by authoritative guidance, we record deferred tax assets or liabilities based on differences between financial reporting and tax bases of assets and liabilities using currently enacted rates that will be in effect when the differences are expected to reverse. Authoritative guidance also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that all or some portion of the deferred tax asset will not be realized. As of June 30, 2022, we have fully reserved all of our deferred tax assets. Based on a review of our deferred tax assets and recent operating performance, we determined that our valuation allowance should be decreased by $7,615,000 to a balance of $16,980,000 to fully reserve our deferred tax assets at December 31, 2021. We determined that it was appropriate to continue to provide a full valuation reserve on our net deferred tax assets as of June 30, 2022, because of the overall net operating loss carryforwards available. We expect to continue to maintain a full valuation allowance until we determine that we can sustain a level of profitability that demonstrates our ability to realize these assets. To the extent we determine that the realization of some or all of these benefits is more likely than not based upon expected future taxable income, a portion or all of the valuation allowance will be reversed. Such a reversal would be recorded as an income tax benefit and, for some portion related to deductions for stock option exercises, an increase in shareholders’ equity.

As required by authoritative guidance, we have performed a comprehensive review of our portfolio of uncertain tax positions in accordance with recognition standards established by the FASB, an uncertain tax position represents our expected treatment of a tax position taken in a filed tax return or planned to be taken in a future tax return, that has not been reflected in measuring income tax expense for financial reporting purposes. We have no recorded liability as of June 30, 2022 representing uncertain tax positions.

We have generated substantial deferred income tax assets related to our operations primarily from the charge to compensation expense taken for stock options, certain tax credit carryforwards and net operating loss carryforwards. For us to realize the income tax benefit of these assets, we must generate sufficient taxable income in future periods when such deductions are allowed for income tax purposes. In some cases where deferred taxes were the result of compensation expense recognized on stock options, our ability to realize the income tax benefit of these assets is also dependent on our share price increasing to a point where these options have intrinsic value at least equal to the grant date fair value and are exercised. In assessing whether a valuation allowance is needed in connection with our deferred income tax assets, we have evaluated our ability to generate sufficient taxable income in future periods to utilize the benefit of the deferred income tax assets. We continue to evaluate our ability to use recorded deferred income tax asset balances. If we fail to generate taxable income for financial reporting in future years, no additional tax benefit would be recognized for those losses, since we will not have accumulated enough positive evidence to support our ability to utilize net operating loss carryforwards in the future. Therefore, we may be required to increase our valuation allowance in future periods should our assumptions regarding the generation of future taxable income not be realized.

62

Inflation and Seasonality

As inflation in the United States and abroad has increased and become more prominent, inflationary pressures adversely affected all of the Company’s reporting segments’ gross margins during the first six months of fiscal year 2022, and are expected to persist for the remainder of fiscal year 2022 and beyond. We do not believe that our Video Solutions and Revenue Cycle Management segments business is seasonal in nature; however, the Ticketing Segment is expected to generate higher revenues during the second half of the calendar year than in the first half due to the increased sporting events throughout the country during the second half of the calendar year in comparison to the first half.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not Applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures, as such terms are defined in Rules 13a-15(e) under the Exchange Act. The Company, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of such disclosure controls and procedures for this Report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2022 to provide reasonable assurance that material information required to be disclosed by the Company in this Report was recorded, processed, summarized and communicated to the Company’s management as appropriate and within the time periods specified in SEC rules and forms.

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the Company’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

The information regarding certain legal proceedings in which we are involved as set forth in Note 11 – Commitments and Contingencies of the Notes to the Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report on Form 10-Q) is incorporated by reference into this Item 1.

In addition to such legal proceedings, we are faced with or involved in various other claims and legal proceedings arising in the normal course of our businesses. At this time, we do not believe any material losses under such other claims and proceedings to be probable. While the ultimate outcome of such claims or legal proceedings cannot be predicted with certainty, it is in the opinion of management, after consultation with legal counsel, that the final outcome in such proceedings, in the aggregate, would not have a material adverse effect on our consolidated financial condition, results of operations or cash flows.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information required by this Item.

63

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Purchases of Equity Securities by the Issuer

On December 6, 2021, the board of directors of the Company announced the repurchase of up to $10.0 million of the Company’s outstanding common stock under the specified terms of a share repurchase program (the “Program”). During the three months ended June 30, 2022, the Company repurchased 1,849,952 shares of its common stock for $1,962,755, in accordance with the Program. Furthermore, during the six months ended June 30, 2022, the Company repurchased 3,725,986 shares of its common stock for $4,026,523, in accordance with the Program.

Period |  | Total Number of Shares Purchased |  |  | Average Price Paid per Shares |  |  | Total Number of Shares Purchased as Part of Publicly Announced Program |  |  | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program |
December 2021 |  |  | 1,734,838 |  |  | $ | 1.14 |  |  |  | 1,734,838 |  |  |  | — |
January 2022 |  |  | 697,093 |  |  |  | 1.11 |  |  |  | 697,093 |  |  |  | — |
February 2022 |  |  | 692,984 |  |  |  | 1.12 |  |  |  | 692,984 |  |  |  | — |
March 2022 |  |  | 485,957 |  |  |  | 1.06 |  |  |  | 485,957 |  |  |  | — |
April 2022 |  |  | 595,476 |  |  |  | 1.14 |  |  |  | 595,476 |  |  |  | — |
May 2022 |  |  | 716,911 |  |  |  | 1.08 |  |  |  | 716,911 |  |  |  | — |
June 2022 |  |  | 537,565 |  |  |  | 0.96 |  |  |  | 537,565 |  |  |  | — |
Total all plans |  |  | 5,460,824 |  |  | $ | 1.10 |  |  |  | 5,460,824 |  |  | $ | 3,998,398 |

On June 30, 2022, the board of directors of the Company elected to terminate the Program, effective immediately. The Program began in December 2021, with the Company purchasing a total of 5,460,824 shares at a cost of $6,001,602 through June 30, 2022.

Item 3. Defaults upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Not applicable.

Item 6. Exhibits.

(a) Exhibits.

| 31.1 | Certificate of Stanton E. Ross pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as amended.
| 31.2 | Certificate of Thomas J. Heckman pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as amended.
| 32.1 | Certificate of Stanton E. Ross pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.
| 32.2 | Certificate of Thomas J. Heckman pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended.
| 101.INS | Inline XBRL Instance Document
| 101.SCH | Inline XBRL Schema Document
| 101.CAL | Inline XBRL Calculation Linkbase Document
| 101.DEF | Inline XBRL Definition Linkbase Document
| 101.LAB | Inline XBRL Label Linkbase Document
| 101.PRE | Inline XBRL Presentation Linkbase Document
| 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

64

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 15, 2022

| DIGITAL ALLY, INC.
| By: | /s/ Stanton E. Ross
| Name: | Stanton E. Ross
| Title: | President and Chief Executive Officer
| By: | /s/ Thomas J. Heckman
| Name: | Thomas J. Heckman
| Title: | Chief Financial Officer, Secretary and Treasurer (Principal Financial and Accounting Officer)

65